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ABSTRACT
This thesis explores the pathophysiological mechanisms underlying the 
myeloproliferative disease, Polycythaemia Vera (PV). PV is characterised by clonal 
red cell expansion with a tendency for leukaemic transformation. This study focusses 
on primary erythroid progenitor cells derived from 27 PV patients and 49 control 
subjects with non-clonal red cell expansion or normal red cell mass providing insight 
into survival, signal transduction & the molecular signature of these cells. The 
erythropoietin independent colonies (EECs) characteristic of PV were detected in 
93% PV, the V617F Jak2 mutation was present in 93% PV and marked upregulation 
of PRV 1 mRNA which can be associated with PV was found in 89% PV. None of the 
control subjects showed these features. PV erythroid progenitors showed increased 
proliferation with relative resistance to cytokine deprivation when 14 PV samples 
were compared with 10 controls. Apoptosis was not found to be increased in PV.
In over 40 experiments PV erythroid progenitors showed aberrant signalling with 
constitutive and stimulated increases in activation of the PI3K, MAPK and Jak/STAT 
pathways. Activation of each pathway was reduced with specific small molecule 
inhibitors. Use of PI3K & Jak2 inhibitors caused comparable reduction between PV & 
control samples in 40 erythroid colony assays and 20 survival experiments using 
erythroid progenitors. However, there was some evidence to suggest that the Jak2 
inhibitors used were less effective in PV with homozygous expression of V617F Jak2. 
EECs from PV samples were, however, greatly reduced with inhibitors. RNA from 14 
erythroid progenitor samples including 6 PV were hybridised onto Affymetrix 
GeneChip microarrays. There was segregation of signature between subject groups. 
The array data was validated by real-time quantitative PCR and this technique was 
further used to show that 2/4 genes identified as upregulated in PV were not Jak2 
dependent but that the well recognised Jak/STAT target, Pim-1 was.
ACKNOWLEDGEMENTS
The Leukaemia Research Fund generously supported work towards this PhD thesis 
for a 3 year period. I am indebted to them for this sponsorship.
The work presented in this thesis was prepared under the close clinical and laboratory 
supervision of Professor Asim Khwaja with Dr. Rosemary Gale providing 
considerable scientific support.
Several other members of the Academic Department of Haematology at UCL 
contributed to this work including Dr. Victoria Grandage, Dr. Simon Thomas, Dr. 
Adam Mead, Dr. Marc Mansour, Mr. Arnold Pizzey, Dr. Mike Watts & Professor 
David Linch.
The clinical basis for this thesis would not have been possible without the work of the 
staff involved in the Polycythaemia Clinic at UCH including the phlebotomy 
performed by the day-care nurses and the secretarial contribution of Ysabel Howard. I 
am also indebted to my patients, not only for their clinical histories and blood, but 
also for being a constant source of inspiration.
I am, as ever, immensely grateful for the practical support, encouragement & love of 
my family & friends and in particular, my mother, Laila, my sister, Kari, my husband, 




CHAPTER 1 -  INTRODUCTION.............................................................................17
1.1 Normal Haematopoiesis........................................................................................ 17
Figure 1 [1] : Normal Haematopoiesis......................................................... 18
1.2 Background to polycythaemia.....................................................................19
1.2.1 Polycythaemia Vera as a clinical syndrome within the group of 
myeloproliferative disorders...............................................................................19
Figure 2[1]: Polycythaemia Vera Study Group [PVSG] and World Health 
Organization [WHO] diagnostic criteria for Polycythaemia Vera...........21
1.3 Signal Transduction in tumour cells & erythroid progenitors............... 26
1.3.1 Basic haematopoietic signalling.........................................................26
Figure 3[1]: Schematic representation of the JAK2 gene showing the
position of the V617F mutation..................................................................... 27
Figure 4[1]: Schematic representation of signal transduction via JAK2..28
1.3.2 Erythropoietin, stem cell factor & erythroid signalling pathways 30
1.4 Erythroblast proliferation & survival........................................................ 32
1.4.1 Aberrant proliferation in Polycythaemia Vera............................... 32
1.4.2 The effects of JAK2 inhibition on erythropoiesis............................ 33
1.5 Gene expression in erythroid progenitors................................................. 36
1.5.1 Gene expression studies in Polycythaemia Vera............................. 36
CHAPTER 2 -  METHODS....................................................................................... 38
2.1 The Polycythaemia Clinic........................................................................... 38
2.1.1 Clinical profiling...................................................................................38
2.1.2 Routine laboratory profiling............................................................... 38
2.1.3 Venesection procedure........................................................................ 39
2.2 Processing and liquid culture of primary haematopoietic cells..............40
Figure 1[2]: Flow chart for initial processing of primary cells.................. 40
2.2.1 Sources and initial storage of primary haematopoietic cells 40
2.2.2 Manual separation of cells from peripheral blood.......................... 41
2.2.3 Purification & storage of neutrophils from peripheral blood........ 42
2.2.4 Liquid culture of mononuclear cells promoting erythroid
differentiation.......................................................................................................43
2.2.5 Negative selection of mononuclear cells & subsequent culture...... 44
2.2.6 Erythroid differentiation of CD34+ rich samples.............................45
2.2.7 Evaluation of samples by morphological analysis............................45
2.2.8 Evaluation of samples by immunopbenotyping................................45
2.3.1 Standard colony system....................................................................... 46
2.3.2 Erythropoietin independent colonies (EECs)....................................46
2.3.3 Colonies with added inhibitors & cytokines...................................... 46
2.4 DNA & RNA. extraction & processing.......................................................48
2.4.1 DNA extraction chloroform technique............................................... 48
2.4.2 RNA extraction chloroform technique............................................... 48
2.4.3 Reverse transcriptase polymerase chain reaction (RT PCR)......... 49
2.4.4 Semi>quantitative analysis of transcripts of PRVl and other genes 
49
2.4.5 Screening for Chuvash polycythaemia............................................... 50
2.4.6 Screening for V617F Jak 2 mutation................................................. 50
2.4.7 Quantitative RQ-PCR by the SYBR Green technique.................... 51
2.5 Tumour cell lines.......................................................................................... 53
2.5.1 Cytokine dependent cell lines.............................................................. 53
2.5.2 Cytokine independent cell lines.......................................................... 53
2.6 Western blotting........................................................................................... 54
2.6.1 Starvation, Pre-inhibition & stimulation of cells..............................54
2.6.2 Protein lysates........................................................................................55
2.6.3 Sodium dodecyl sulphate -  polyacrylamide gel electrophoresis
(SDS-PAGE) & nitrocellulose transfer.............................................................55
2.6.4 Primary antibodies & incubation....................................................... 56
2.6.5 Secondary antibodies & chemiluminescent analysis....................... 57
2.6.6 Densitometry.........................................................................................58
2.7 Microarrays...................................................................................................59
Figure 2[2]: Flow cbart indicating processing steps to microarrays......59
2.7.1 RNA extraction Qiagen method......................................................... 60
2.7.2 Reverse transcription & double-stranded cDNA synthesis............60
2.7.3 In vitro transcription of ds-cDNA, biotinylation & cRNA
fragmentation.......................................................................................................61
2.7.4 Quality control procedures and microarray hybridisation...........62
2.8 Proliferation and apoptosis......................................................................... 63
2.8.1 Cell viability as assessed by MTS......................................................63
2.8.2 Apoptosis by Annexin V, Propidium Iodide and FACS.................63
CHAPTER 3 -  RESULTS 1....................................................................................... 65
Defining a cohort o f  patients with true or apparent polycythaemia & characterising
normal and aberrant erythropoiesis in vitro ...............................................................65
3.1 Defining a cohort of patients with elevated haematocrit......................... 65
3.1.1 Clinical information and standard laboratory data....................... 65
Table 1[3]: Disease-specific drug therapy of the patient cohort................66
Table 2[3]: Other drug therapy of the patient cohort................................ 66
Table 3[3]: Routine laboratory investigations..............................................67
3.1.2 Erythropoietin independent colonies (EECs).................................. 68
Figure 1[3]: Erythroid colonies from a patient with PV in the presence
and absence of erythropoietin........................................................................ 68
Figure 2[3]: The mean number of erythroid and myeloid colonies & the 
erythroid : myeloid ratio from 80 assays (33 PV, 37 IE & 10 normals) 69
3.1.3 V617F JAK2 screening....................................................................... 70
Figure 3[3]: PCR products for wild type and V617F mutant Jak 2..........70
3.1.4 PRV 1 mRNA expression.................................................................... 71
Figure 4[3]: Semi-quantitative evaluation of PRVl mRNA upregulation71
3.1.5 Screening for Chuvash Polycythaemia.............................................72
Figure 5[3]: Mutational screening for Chuvash Polycythaemia................72
Figure 6[3]: Sequencing plot from a patient heterozygous for Chuvash 
Polycythaemia..................................................................................................73
3.2 Liquid culture of erythrohlasts...................................................................74
3.2.1 Optimisation of methodology.............................................................74
Figure 7 [3]: Cytospins of CD36 and CD71 selected mononuclear culture 
............................................................................................................................ 75
3.2.2 Erythroblast morphology................................................................... 77
Figure 8[3]: The morphological appearance of Day 9 erythrohlasts after 
cytospin and staining with MGG................................................................... 77
3.2.3 Erythroblast immunophenotype as assessed by flow cytometry ...78 
Figure 9[3]: Flow cytometric plots of Day 9 erythrohlasts from a patient 
with IE after incubation with a] CD36-FITC + Ig-PE, b] CD71-FITC +
CD117 PE, c] Ig-FITC + Glycophorin A-PE................................................79
Figure 10[3]: Flow cytometric findings from 43 separate patient-derived 
samples according to diagnosis...................................................................... 80
3.2.4 Erythroid colony-forming potential of basophilic erythrohlasts... 81 
Figure 11 [3]: The relationship between BFUe & CFUe according to the
number of days of liquid culture................................................................... 81
Figure 12[3]: Erythroid colonies from mononuclear cells in liquid culture 
 82
3.2.5 Proliferation profiles........................................................................... 83
Figure 13[3]: The number of mononuclear cells (xlO )^ per ml derived
from anticoagulated peripheral blood by JAK2 status.............................. 83
Figure 14[3]: Erythroblast yields from 81 venesection packs after 9 days
of in vitro culture according to JAK2 status................................................84
Figure 15 [3]: The proportion of mononuclear cells which went on to form 
erythrohlasts.....................................................................................................85
3.2.6 Resistance of PV erythrohlasts to erythropoietin deprivation 86
Figure 16[3]: Relative erythroblast viable cell number with erythropoietin 
deprivation as assessed by MTS assay in 24 separate experiments...........87
3.2.7 Apoptosis as assessed by Annexin V, Propidium Iodide & FACS 88 
Figure 17[3]: Mean values from 34 experiments evaluating apoptosis in 
erythrohlasts.....................................................................................................89
CHAPTER 4 -  RESULTS 2 ....................................................................................... 99
Signal transduction pathways in primary erythroid progenitors & haematopoietic
tumour cell lines............................................................................................................99
4.1 Signal transduction pathways activated by SCF and Epo differ between 
haematopoietic tumour cell lines & primary human erythroid progenitors 99 
Figure 1[4]: Simplified representation of the signalling pathways and 
small molecule inhibitors used in this chapter........................................... 100
Table 1[4]: Small molecule inhibitors of signalling pathways.................100
4.1.1 The kinetics of individual pathway stimulation & inhibition differ
101
Figure 2[4]: The early phase of GSK3 phosphorylation is dependent on 
both PI3K & MAPK pathways in haematopoietic cell lines whereas the
late phase is PI3K dependent only...............................................................102
Figure 3[4]: Phosphorylation of GSK3 is immediately PI3K dependent in 
erythroid progenitors....................................................................................103
4.1.2 Cytokine dose affects pathway activation in cell lines.................. 104
Figure 4[4]: Early GSK3 phosphorylation is PI3K dependent in 
haematopoietic cell lines when low doses of cytokine stimulation are used 
......................................................................................................................... 104
4.1.3 Cytokines may show overlapping pathway activation patterns in
erythroid progenitors....................................................................................... 105
Figure 5[4]: MAPK is phosphorylated by both Epo & SCF whilst STATS 
is independently phosphorylated by Epo but not SCF in erythroid
progenitors..................................................................................................... 105
Figure 6[4]: TPA can induce phosphorylation of GSK3 in primary 
erythrohlasts via the MAPK pathway........................................................ 106
4.1.4 There may be cross-talk between signalling pathways revealed by 
107
inhibitor studies.................................................................................................107
Figure 7 [4]: Phosphorylation of STATS can be PI3K dependent 107
4.2 Basal & stimulated primary erythroid progenitor signalling............. 108
4.2.1 Establishing a basis for investigating erythroblast signalling 109
Figure 8 [4]: Assessing activity of the PI3K, MAPK & ST AT pathways in
erythroid progenitors by day of in vitro culture.......................................109
Figure 9 [4]: Illustrative western blot results from erythrohlasts derived 
from a patient with Polycythaemia Vera starved and stimulated over a 
time course..................................................................................................... I l l
4.2.2 Protein phosphorylation patterns in erythrohlasts stimulated over
a short time course............................................................................................112
Figure 10[4]: Quantification of signal pathway activation in stimulated 
erythroid progenitors....................................................................................112
4.2.3 Protein phosphorylation patterns in erythrohlasts both starved 
and stimulated for a short time (<lhour) with erythropoietin and SCF.... 113
Figure 11 [4]: Comparing basal & stimulated pAKT, pERK & pGSK3
between PV & controls................................................................................ 113
Figure 12[4]: Comparing basal & stimulated pSTATS, pRSK and pp38 
MAPK between PV & controls................................................................... 114
4.2.4 Protein phosphorylation patterns in erythrohlasts both starved
and stimulated for a short time (<lhour) with erythropoietin alone.........115
Figure 13[4]: Relative phosphorylation in erythrohlasts starved or
stimulated with erythropoietin for <lhour................................................115
Figure 14[4]: Basal signalling of PV erythroid progenitors is increased in 
all pathways...................................................................................................117
4.2.5 Protein phosphorylation patterns in erythrohlasts both starved
and stimulated for longer periods (4 hrs, 8hrs & overnight) with 
erythropoietin and SCF................................................................................... 119
Figure 15[4]: Quantitative evaluation of the signalling activity of 
erythroid progenitors over a protracted time course.............................. 119
4.3 The effects of PI3K inhibition on aberrant signalling in PV 
erythrohlasts..........................................................................................................121
4.3.1 Assessing the effects of PI3K inhibition with LY294002 in PV ... 121 
Figure 16[4]: The effects of PI3K inhibition on aberrant PV signalling 121
4.3.2 The effects of novel PI3K inhibitors on signalling....................... 123
Figure 17[4]: Comparing the effects of LY294002 with the Class 1 PI3K
inhibitor, PI103 in tumour cells.................................................................. 123
Figure 18[4]: Comparing the effects of PI3K inhibitors in PV 
erythrohlasts..................................................................................................124
4.4 The effects of specific inhibitors of JAK2 on signalling...................... 125
4.4.1 JAK2 inhibitors & signalling in haematopoietic cell lines
expressing wild type & V617F JAK2............................................................. 125
Figure 19[4]: The effect of the JAK2 inhibitors Go6976 and Jak Inhibitor 
1 on signal transduction in haematopoietic cell lines............................... 126
4.4.2 The effects of specific inhibitors of JAK2 on erythroid signalling 
127
10
Figure 20[4]: The effects of JAK2 inhibition in PV & control erythroid
cells.................................................................................................................. 127
Figure 21 [4]: Basal and stimulated pSTATS are reduced with JAK2
inhibition 128
Figure 22[4]: JAK2 inhibition blocks Epo-induced Pim-1 expression in all 
erythroid progenitors and also basal upregulation in PV progenitors... 129
4.5 Discussion.................................................................................................... 130
CHAPTER 5 -  RESULTS 3 ......................................................................................136
The effects o f  small molecule inhibitors on erythropoiesis......................................136
5.1 The effects of JAK2 inhibition on erythroid colony formation & 
erythroblast viable cell number............................................................................136
5.1.1 The effects of JAK2 inhibition on standard colony assays........... 136
Figure 1[5]: JAK2 inhibition with Go6976 reduces erythroid &
myelomonocytic colony formation............................................................... 136
Figure 2[5]: Comparing the effects of Go6976 and Jak Inhibitor 1 on
erythroid colonies from 4 individuals......................................................... 137
Figure 3[5]: Results from 40 colony assays with added inhibitors of JAK2 
according to JAK2 status..............................................................................138
5.1.2 JAK2 inhibition of erythropoietin independent colonies............. 139
Figure 4[5]: EECs from 8 patients with PV in the absence or presence of 
Go6976 or Jak Inhibitor 1.............................................................................139
5.1.3 The effects of JAK2 inhibition on cell number in haematopoietic
cell lines and primary erythrohlasts................................................................ 140
Figure 5 [5]: Results from 8 experiments assessing the viable cell number 
of tumour cells expressing V617F or wild type JAK2 in the presence of
Go6976 or Jak Inhibitor 1.............................................................................140
Figure 6[5]: Results from 40 experiments assessing the viable cell number 
of primary erythroid cells expressing V617F or wild type JAK2 in the 
presence of Go6976 or Jak Inhibitor 1........................................................ 141
5.2 The effects of PI3 kinase pathway blockade on erythroid colony 142
formation & erythroblast viable cell number.................................................... 142
5.2.1 Comparing PI3K and JAK2 inhibition of erythrohlasts.............. 142
11
Figure 7[5]; Results from 6 experiments comparing the effects of PI3 
kinase & JAK2 inhibition on erythroblast viable cell number using MTS
assays............................................................................................................... 143
Figure 8[5]: Comparing the effects of PI3K inhibition with JAK2
inhibition on normal erythrohlasts in liquid culture.................................144
Figure 9[5]: MTS assay comparing PI3K and JAK2 inhibition in 
erythrohlasts................................................................................................... 145
5.2.2 The effects of PI3 kinase inhibitors on erythroblast cell number in 
liquid culture...................................................................................................... 146
Figure 10[5]: Results of 7 experiments exploring the effect of PI103 on the 
viable cell number of primary erythrohlasts.............................................. 146
5.2.3 The effects of PI103 & Rapamycin on standard colony assays and 
EECs 147
Figure 11 [5]: Comparing erythroid colonies between 4 patients with PV 
(& V617F JAK2) and 4 with IE (& wild type JAK2)................................147
5.2.4 Exploring the effects of inhibitors of PI3 kinase isoforms........... 148
Figure 12[5]: Expression of the alpha (a), beta (p), gamma (y) and delta (y)
isoforms in erythrohlasts...............................................................................148
Figure 13[5]: Pan-PI3K inhibitors reduce stimulated phosphorylation of 
AKT in erythrohlasts but specific inhibitors of individual PI3K isoforms
do not............................................................................................................... 149
Figure 14[5]: 4 experiments assessing the effect of specific PI3 kinase
inhibitors on erythroblast viable cell number............................................ 150
Figure 15[5]: The comparative effects of PI3K isoform inhibitors on 
erythrohlasts stimulated with erythropoietin (Epo) or stem cell factor 
(SCF)............................................................................................................... 150
5.3 Discussion.................................................................................................... 151
CHAPTER 6 -  RESULTS 4 ......................................................................................155
The molecular imprint o f Polycythaemia Vera....................................................... 155
6.1 Affymetrix GeneChip expression profiling of erythrohlasts................155
From patients with PV and control groups.........................................................155
6.1.1 Quality control...................................................................................155
12
Figure 1[6]: Boxplots showing consistent chip exposure in the 14 
microarrays.................................................................................................... 156
6.1.2 Statistical analysis of microarrays................................................... 156
6.1.3 Segregation of microarray signature by subject group................ 157
Figure 2[6]: Multidimensional scaling analysis of the microarray data
shows separation of the subject groups....................................................... 157
Table 1[6]: Genes with altered expression on U133a microarrays in PV
.......................................................................................................................... 159
Figure 3[6]: Heatmap showing 96 of the most discriminatory genes...... 160
6.1.4 Erythroid differentiation assessed by microarray analysis......... 161
Table 2[6]: Genes known to be associated with erythroid differentiation
 161
Figure 4[6]: Heatmap showing gene expression by erythroid 
differentiation marker in subject groups.................................................... 162
6.1.5 Janus-associated kinase (JAK2) gene expression...........................162
6.1.6 Candidate targets of Jak-STAT activation.....................................163
Table 3[6]: Published Jak-STAT targets.................................................... 163
Figure 5[6]: Heatmap showing gene expression of known Jak-STAT 
targets.............................................................................................................. 164
6.2 PCR validation of basal erythroblast gene expression..........................165
6.2.1 Quality control of real-time quantitative PCR (RQ-PCR) analysis 
165
Figure 6[6]: Standard curves for Taqman analysis...................................166
6.2.2 Pim-1 oncogene (PIM l).................................................................... 167
Figure 7[6]: PIMl expression by diagnostic group....................................167
6.2.3 Interferon-induced transmembrane protein 1 (IFITM l)............ 168
Figure 8[6]: IFITMl expression by diagnostic group...............................168
Figure 9[6]: Semi-quantitative analysis of IFITMl / GAPDH expression 
.......................................................................................................................... 169
6.2.4 Core binding factor, runt domain, a subunit 2, trans. to 3
(CBFA2T3)......................................................................................................... 170
Figure 10[6]: CBFA2T3 expression by diagnostic group..........................170
6.2.5 Leptin receptor (LEPR)................................................................... 171
13
Figure 11 [6]: LEPR expression by diagnostic group & V617F JAK2
status................................................................................................................ 171
6.3 PCR analysis of the modulatory effects on gene expression of 172
inhibitors of JAK2 in haematopoietic cell lines and primary...........................172
erythrohlasts........................................................................................................... 172
6.3.1 PIM l.....................................................................................................173
Figure 12[6]: The effect of JAK2 inhibitors on PIMl expression in HEL
cells.................................................................................................................. 173
Figure 13[6]: The effect of erythropoietin & JAK2 inhibition on PIMl
expression in TFl cells...................................................................................174
Figure 14[6]: The effect of erythropoietin & JAK2 inhibition on PIMl
expression in normal CD34+ derived erythrohlasts..................................175
Figure 15[6]: The effect of erythropoietin & JAK2 inhibition on PIMl 
expression in erythrohlasts derived from the peripheral blood of patients 
with Polycythaemia Vera..............................................................................176
6.3.2 IFITMl.................................................................................................177
Figure 16[6]: Semi-quantitative analysis of IFITMl with GAPDH using
RNA extracted from HEL cells exposed to JAK2 inhibitors.....................177
Figure 17[6]: The effect of JAK2 inhibitors on IFITMl expression in HEL
cells.................................................................................................................. 177
Figure 18[6]: The effect of erythropoietin & JAK2 inhibition on IFITMl
expression in TFl cells...................................................................................178
Figure 19[6]: The effect of erythropoietin & JAK2 inhibition on IFITMl
expression in normal CD34+ derived erythrohlasts..................................179
Figure 20[6]: The effect of erythropoietin & JAK2 inhibition on IFITMl 
expression in erythrohlasts derived from the peripheral blood of patients
with Polycythaemia Vera..............................................................................179
Figure 21 [6]: Induction of IFITMl by Interferon in a Jak dependent
manner............................................................................................................ 180
Figure 22[6]: The inhibitory effect of erythropoietin on IFITMl 
expression in CD34+ derived erythrohlasts................................................ 181
6.3.3 CBFA2T3............................................................................................182
14
Figure 23[6]: Results from 4 separate experiments using erythrohlasts 
from patients with PV exploring the effect of JAK2 inhibition on
CBFA2T3 expression.....................................................................................183
Figure 24[6]: Mean normalised CBFA2T3 expression in erythrohlasts 
with erythropoietin stimulation and JAK2 inhibition...............................183
6.3.4 LEPR...................................................................................................184
Figure 25[6]: Results from 4 separate experiments using erythrohlasts 
from patients with PV exploring the effect of JAK2 inhibition on LEPR
expression........................................................................................................ 185
Figure 26[6]: Mean normalised LEPR expression in erythrohlasts with 
erythropoietin stimulation and JAK2 inhibition.......................................185
6.4 Semi-quantitative analysis of gene expression using RNA................... 186
derived from neutrophils.......................................................................................186
6.4.1 Pim-1 oncogene (PIM l).................................................................... 186
6.4.2 Interferon induced transmemhrane protein 1 (IFITMl)............. 186
6.4.3 Nucleophosmin (N Pl)....................................................................... 186
6.4.4 Protein phosphatase 2 regulatory subunit alpha (PPP2R2A)...... 187
6.5 The contribution of Interferons & Leptin to erythroblast................... 188
proliferation & survival.........................................................................................188
6.5.1 Interferons..........................................................................................188
Figure 27[6]: Average results from 5 experiments assessing the effects of 
Interferon-G (IFN-G) on erythroblast viable cell number...................... 188
6.5.2 Leptin..................................................................................................189
Figure 28 [6]: Results from 5 experiments where Leptin was added to 
erythroid colonies with low level erythropoietin........................................189
6.6 Discussion....................................................................................................190
CHAPTER 7 -  CONCLUSIONS............................................................................. 197
FUTURE DIRECTIONS........................................... Error! Bookmark not defined.
REFERENCES...........................................................................................................200
PUBLICATIONS RESULTING FROM THIS WORK........................................224












SCF Stem cell factor
c-KIT Stem cell factor receptor
IGFl Insulin growth factor 1
IL3 Interleukin 3
EEC Erythropoietin independent erythroid colonies
BFUe Burst-forming unit, erythroid
CFUe Colony-forming unit, erythroid
JAK Janus-associated kinase
V617F Specific point mutation in JAK2 resulting in a valine-phenylalanine
substitution at position 617 of the JAK2 protein 
WT wild type form (usually referring to wild type JAK2)
HOM homozygous (mutant)
Het heterozygous (mutant)
CD344- haematopoietic progenitor cell expressing CD34 antigen
PI3K Phospho-inositide 3 kinase
MAPK Mitogen-associated protein kinase
ST AT Signal transducer & activator of transcription
PKC Protein kinase C
PIM l Pim-1 oncogene (& Pim-1 protein in relation to western blots)
BFTTM1 Interferon induced transmembrane protein 1
CBFA2T3 Core binding factor a  subunit 2 translocated to 3 
LEPR Leptin receptor
16
CHAPTER 1 -  INTRODUCTION
1.1 Normal Haematopoiesis
Haematopoiesis is the process by which multipotent stem cells proliferate and 
differentiate to produce mature blood cells. It is continually driven by highly co­
ordinated patterns of gene expression under the influence of growth factors and 
hormones. Haematopoietic stem cells are capable of self-renewal and of progression 
to committed progenitors which can differentiate down the erythroid, granulocytic, 
monocytic, megakaryocytic and lymphocytic lineages. Haematological diseases such 
as myeloproliferative disorders or leukaemias are the result of dysregulation at one or 
more stages of normal haematopoiesis (see Figure 1[1]).
After birth normal haematopoiesis is largely confined to the bone marrow although 
small numbers of haematopoietic stem cells [HSC] can be found in peripheral blood. 
The decision as to whether an HSC undergoes self renewal or lineage commitment is 
governed by the expression of a number of transcription factors and cytokines. Low 
levels of multiple cytokines maintain basal haematopoiesis with short lived 
amplifications of specific cytokines boosting production in response to 
haematopoietic stress. These responses are relevant to haematological disease states 
and can be exploited to produce committed progenitors in an in vitro setting.
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Figure 1[1J: Normal Haematopoiesis
(HSC can self renew and differentiate to common myeloid or lymphoid progenitors 
[CMP/CLPJ under the influence of stem cell factor [SCF], thrombopoietin [TPO] or 
interleukin-7 [IL-7]. Further differentiation from the CMPs produces myeloid 
erythroid progenitors [MEP] or granulocytic monocytic progenitors [GM] which 
further differentiate to progenitors which are megakaryocytic [MkP], erythroid [EP], 
monocytic [MP] or granulocytic [GP] and go on to produce their mature counterparts. 
Interleukins-3/5 [11-3/5], Granulocyte/monocyte colony stimulating factor [GM-CSF, 
G-CSF or M-CSF] and Erythropoietin [EPO] contribute to these pathways. Further 
differentiation from the CLPs is through T/Natural killer [TNK] or B cell [BCP] 




1.2 Background to polycythaemia
As mature red blood cells are the most numerous blood cells in peripheral blood they 
normally define the relative proportion of blood cells to plasma in terms of volume. 
This proportion is known as the haematocrit. The haematocrit may be high if the body 
red cell mass is increased (true polycythaemia) or if the plasma volume is decreased 
(apparent or spurious polycythaemia). True polycythaemia may occur as a primary 
abnormality or secondary to haematopoietic stress [SP] such as hypoxia resulting 
from chronic lung disease. A proportion of patients with true polycythaemia will have 
primary proliferative polycythaemia (commonly known as Polycythaemia Vera [PV]) 
due to an an acquired abnormality in haematopoietic stem cells. In many patients with 
true polycythaemia the cause is not clinically apparent and these patients are labelled 
as having Idiopathic Erythrocytosis (increased red cell mass of unknown cause, [IE]).
1.2.1 Polycythaemia Vera as a clinical syndrome within the group of 
myeloproliferative disorders
Polycythaemia Vera was defined by Vaquez in 1892 and identified as distinct from 
other causes of polycythaemia by Osier in 1903. In 1951 understanding was further 
transformed when Dameshek defined the ‘myeloproliferative disorders’. These 
disorders were subsequently subclassified into Polycythaemia (Rubra) Vera (PV), 
Essential Thrombocythaemia (ET), Idiopathic Myelofibrosis (IM) & Chronic Myeloid 
Leukaemia (CML). When the Philadelphia chromosome created by a translocation 
between chromosomes 9 and 22 resulting in a BCR-ABL fusion was described, CML 
moved into a class of its own. The remaining diseases are termed the ‘classical 
Philadelphia negative myeloproliferative disorders’ (MPDs) and include other, 
unusual conditions, such as systemic mastocytosis and hypereosinophilic syndrome.
Polycythaemia Vera develops with an incidence of 2.6 per 100,000 per year in the 
general population with typical age of onset in the 60-70 years group [Tefferi & 
Spivak, 2005]. The clinical syndrome is characterized by primary erythropoietin 
independent erythroid expansion. It has many features in common with the other 
MPDs including splenomegaly, hyperplasia of the bone marrow, elevation of the
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white cell and platelet counts and a predisposition to thrombosis or haemorrhage. PV, 
in common with ET can transform to IM with at a rate of around 0.3% per annum. 
Perhaps the most feared complication of all MPDs is the potential for leukaemic 
transformation. There is a 5 fold increase in the risk of leukaemia development for 
patients over the age of 70 years with MPDs. This risk is significantly higher for 
patients who have received alkylating agents or ionising radiation with ^^P and much 
lower for the under 50s. [Marchioli et al, 2005]
Whilst IM can readily be distinguished from PV and IE (idiopathic erythrocytosis) on 
a bone marrow biopsy, it can be difficult to clinically distinguish ET from PV without 
performing a red cell mass study. It has recently been recognized that a proportion of 
patients with ET may represent ‘red cell restricted’ PV [Campbell et al, 2005] and it 
now seems likely that PV and ET lie on a diagnostic continuum with co-operating 
genetic events such as aberrant expression or mutation of the thrombopoietin receptor, 
c-MPL, contributing to the development of ET [Moliterno et al, 2006; Pardanani et al, 
2006].
A major practical issue for haematologists is in differentiating Polycythaemia Vera 
from the other causes of an elevated haematocrit. In routine clinical practice the most 
likely cause for an elevated haematocrit is spurious polycythaemia due either to 
sampling errors or to reduced plasma volume (dehydration). Other patients will have 
true polycythaemia (but not PV) and are subcategorised into those with Idiopathic 
erythrocytosis (IE) and those with congenital or acquired secondary polycythaemia 
(SP). Making the distinction between PV & other conditions is vital because it will 
alter short, medium & long term clinical management. Key issues here are that the 
thrombosis incidence of 3.4% is almost certainly higher than that seen in IE or SP, 
[Pearson et al, 2000] and patients who do not have PV are not at risk of myelofibrotic 
or leukaemic transformation. From a scientific perspective, accurate diagnosis of PV 
facilitates understanding of disease pathogenesis, and opens up the potential for 
development of targetted therapy. As there is no single specific test that defines PV, 
the Polycythaemia Vera Study Group (PVSG) and World Health Organization (WHO) 
have defined diagnostic criteria for this disease. These criteria are subtly different and 
continue to evolve in response to new scientific knowledge. A simplified presentation 
of these criteria is shown in Figure 2[1].
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Figure 2[1]: Polycythaemia Vera Study Group [PVSG] and World Health 
Organization [WHO] diagnostic criteria for Polycythaemia Vera
FVSC Modified diagnostic criteria for polycythaemia vera [McMuUin et al, 2007]
JAlC7-pniitivR polyrythaRwiii vera
A1 High h aem a:ocn t (>D.52 in m en, ^0.48 m w om en) O R ra issd  red  cell m a;s (>25%  above predicted)^ 
A2 M utat.on in TAK2
Diagnosis requires both criteria :o be presen:
JAJK2 negative polycythaemia veri
A1 Raised rec  cell m ass (>25%  above predicted) OR haem atocrit >0.63 m men, >0.56 in  w om en 
A2 Absence o f  m utation in .A K 2  
A3 No caus; o f  secondary erythrocytosis 
A4 Palpable sobnom egaly
A5 P rese rre  o f  9n acquired  genetic ahnorm slity  (ev rliid  ng BCR-ART,) in the 'la en a to p o ie tir  ce ls 
B1 Thrcrr.bocytocic (p latele : coun: M 5 0  105/1)
B2 N cu jo p liil IcucccyLosis (ii:u liophil count > 1 0 *  109/1 in  noii-tinokc]s, >12.5 * 109/1 in tinokcis)
B3 Radiological evidence o f sp len om egaly
B4 Zr.dogenous erythroid colonies or low serum eryrhropoietin
D iagnosis requires a 1 +  A2 4 -A3 4- e i:her ano:h?r A  or tw o 3  criteria
*Dval p a th c lo g j (co-existent secondary  ery throcytosis or relative erythrocytosis) m ay rarely be present 
inpatients v/ith a JAK 2 -positive myeloproliferative disorder In this situation, it would be prudent to 
Reduce the haematocrit to the same target as tor polycythaem ia vera
HnviBBil W H O  c ritB ria  fu r  F o ly c y th a e n d a  V bt»  [Levine e t al, 2007]
M ^ a r  criteria
H aem oglob in  >18 5 g idl in men, 16.5 g/dl in  w om en, or other evidence o f  increased red cell volume 
Presence o fJA R 2  V 617F or orher functionally  sim ilar m uta tion  su :h  a; the JA K 2 exon 12 m utation 
M iliar criteria
"Rone m arrow  b iopsy  sh o w irg  hyperieH ularity  fo r age w ith t'ilin eag e  growth (panm yelosis) with 
prom inent erythroid. granulocytic , and m egalcaryorytic p rc livera tion
Serum  erythropoietin  level below  :he reference range for norm al
Endogenous ery thro id  co lony  form ation in  vitro
D iagnostic
R.eguire; the presence o f  b o th  m ajor c riteria  and one m inor criterion, or the presence o f  the first m ajor 
criterion together with tw o m inor criteria
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1.2.2 Polycythaemia Vera as a clonal stem cell disorder
In the 1970s it was recognized that PV results from clonal change in a multipotent 
haematopoietic progenitor [Adamson et al, 1976]. This clonal change has often been 
difficult to identify unlike that seen in the related disorder, CML: Standard 
cytogenetic abnormalities are detected in <20%  PV patients and X-linked clonality 
assays are most informative in younger female patients, who represent a minority of 
patients with the disease. A major breakthrough in understanding of the clonal nature 
of the disease came in 2005. Scientific research was published describing a specific 
G-T point mutation in the pseudo-kinase domain of the Janus-associated kinase 2 
(JAK2) gene. This mutation results in a V617F amino acid substitution in JAK2 
tyrosine kinase and was found to be highly associated with PV (65-97% cases). The 
mutation was also found in around half of ET & IM patients [James et al, 2005; 
Kralovics et al, 2005; Levine et al, 2005; Baxter et al, 2005; Zhao et al, 2005; Jones et 
al, 2005; Vainchenker et al, 2005].
It is not entirely clear why there is considerable variance (65-97%) in the detection of 
V617F JAK2 in PV in these studies. Some of the lower levels may be due to ‘false 
negatives’ explained by use of different diagnostic criteria for PV and low sensitivity 
of the mutant screening technique. Some patients with PV may be ‘true negatives’ 
with recognized alternative mutations in JAK2 such as those described in exon 12 
[Scott et al, 2007]. Others may potentially have mutations in different genes. Equally, 
there may be false positives within these studies. Whilst early work did not detect the 
V617F mutation in normal individuals or in patients with IE or SP, this mutation has 
subsequently been found in healthy individuals when a highly sensitive screening 
technique has been used: Sidon et al [2006] found the mutation in 5/52 individuals 
using a technique with sensitivity of 0.01%, Xu et al [2006] found the mutation in 
37/3935 normal donors using a technique with a sensitivity of 0.01%. Latterly 
Passamonti et al [2007] did not find the mutation in 75 outpatients using a technique 
with 1-2% sensitivity suggesting that this may be an appropriate cut-off level for 
testing.
V617F JAK2 is uncommon in haematological diseases outwith the MPD category but 
has been described in Myelodysplastic Syndrome, Leukaemias, Lymphomas &
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Myeloma [Steensma et al, 2005; Frohling et al, 2006; Fiorini et al, 2006; Melzner et 
al, 2006; Lee et al, 2006]. It is now known that the V617F mutation develops in a 
progenitor cell with lymphoid & myeloid potential but that it is present at low 
frequency in B & T-lymphocytes and Natural Killer cells [Delhommeau et al, 2007]. 
This may explain the predominant association of V617F JAK2 with 
myeloproliferative, rather than lymphoproliferative, disorders. It does not, of course, 
explain how a single mutation can give rise to 3 distinct conditions; PV, FT & IM, 
albeit with the highest prevalence in PV.
One explanation for the different MPD phenotypes associated with the V617F JAK2 
mutation may be an allele dose effect. Homozygous expression of V 6I7F found in 
association with the loss of heterozygosity of chromosome 9p is observed in 1/3 
patients with PV and is associated with higher haemoglobin [Kralovics et al, 2002]. 
Homozygosity for V617F JAK2 is, however, unusual in ET [Scott et al, 2006]. 
Although expression of V617F JAK2 has now been shown to be highly correlated 
with a diagnosis of PV, it is not yet clear whether or not this mutation may be a 
primary or secondary event in PV pathogenesis. Some insight into this may be gained 
by comparing PV patients homozygous & heterozygous for the mutation.
Homozygous expression of V617F JAK2 has been shown to be associated with 
increased duration of disease, [Levine et al, 2005] increased haemoglobin at diagnosis 
& increased progression to myelofibrosis [Tefferi et al, 2006]. It has not been found to 
be associated with either the thrombotic or haemorrhagic complications of PV or with 
the risk of leukaemic transformation [Theocharides et al, 2007]. Indeed there is some 
evidence to show that V617F JAK2 is not required for leukaemic transformation as 
wild type JAK2 has been detected in patients who developed acute leukaemia on a 
background of JAK2 mutant positive PV [Campbell et al, 2006].
If V617F JAK2 was the primary pathogenetic event in acquired PV, erythropoietin 
independent colonies (EECs) might be expected to be composed solely of JAK2 
mutant cells. However, recent data from a group working in the field of PV for many 
years has identifed wild type JAK2 in PV EECs [Nussenzveig et al, 2007]. If V617F 
JAK2 was the final pathogenetic event in MPD a clear clonal advantage to the mutant 
population might be expected but it has been shown in ET that low level clones can be 
stable at low level over many years [Gale et al, 2007]. It therefore seems likely that
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V617F JAK2 is only one of a number of ‘hits’ required for the full PV phenotype. 
Studies in familial polycythaemia have detected V617F JAK2 in these patients but 
found it to be a somatic (acquired) rather than a germline mutation implying that at 
least one other ‘hit’ is implicated in this disease also [Rumi et al, 2006].
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1.2.3 Polycythaemia Vera and erythropoietin independence
The gold standard test for PV has been the potential for circulating haematopoietic 
progenitors to develop erythroid colonies in the absence of added erythropoietin 
(EECs). EECs are not produced from normal individuals, nor from patients with 
secondary polycythaemia but are found in the majority of patients with PV [Zanjani et 
al, 1977; Lemoine et al, 1986]. EECs are a highly sensitive diagnostic tool having 
been detected in patients who had not previously been identified as having PV, but 
who go on to have an atypical thrombosis which reveals an underlying 
myeloproliferative disorder [De Stefano et al, 1997; Chait et al, 2005]. EECs were 
therefore incorporated into both the Polycythaemia Vera Study Group (PVSG) and 
World Health Organization (WHO) diagnostic criteria for PV (see Figure 1 [2]).
The mechanism of EEC formation is not fully understood but it is believed that EECs 
result from an intrinsic abnormality in progenitor cells as they cannot be abolished by 
anti-erythropoietin or anti-erythropoietin receptor antibodies [Fisher et al, 1994].
EECs are normally cultured directly from mononuclear cells derived from PV blood 
or bone marrow but have also been cultured from PV erythroblasts which had 
previously been differentiated in liquid culture conditions [Silva et al, 1998, Ugo et al, 
2004]. Erythropoietin independence is therefore a characteristic feature of PV which 
is of diagnostic significance and may have functional relevance for maturing erythroid 
progenitors.
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1.3 Signal Transduction in tumour cells & erythroid progenitors
1.3.1 Basic haematopoietic signalling
Intracellular signal transduction is initiated by binding of a ligand to its cognate 
receptor. This binding triggers recruitment and activation of intracellular molecules 
which in turn activates downstream targets ultimately resulting in activation of target 
genes in the cell nucleus. Each signalling pathway can be activated by a spectrum of 
ligand / receptor associations but this may vary according to the type / dose of ligand. 
There is overlap and ‘crosstalk’ between different pathways. Inhibitors may have 
predominant effects on one pathway but may crossreact with others by either inducing 
or suppressing activation. The contribution of each pathway to cellular activation 
varies with cell type. Artificial in vitro systems may not reflect the multiple factors 
participating in vivo. All of these factors must be taken into consideration when 
developing new understanding of intracellular signalling mechanisms.
Tyrosine kinase activation is critical to intracellular signalling. Members of the 
cytokine receptor superfamily such as the Erythropoietin Receptor (EpoR) & the 
Thrombopoietin Receptor (c-MPL) lack intrinsic tyrosine kinase activity. They 
activate intracellular signalling by associating with Janus-associated kinases (JAKs) 
which act as cytosolic tyrosine kinases. Other receptors involved in haematopoiesis 
which are not part of the cytokine receptor superfamily including the Stem Cell Factor 
receptor (c-KIT) and the FMS-like Tyrosine Kinase 3 receptor (FLT3) possess a 
tyrosine kinase domain in their intracellular portion and are therefore theoretically 
JAK independent.
There are 4 known members of the JAK family, JA K l, JAK2, JAK3 & Tyk2. JAK3 
expression is predominantly found in haematological cells but JAKs 1 & 2 and Tyk2 
are ubiquitously expressed. JAKs have a unique domain structure amongst tyrosine 
kinases. There is a C-terminal kinase domain (JAK homology 1 [JHI]) adjacent to a 
catalytically inactive ‘pseudokinase’ domain (JH2). The N-terminal region (JH3-4) 
resembles a Src homology 2 (SH2) domain but its function is not clearly understood 
& the domain structure is completed by an amino-terminal FERM (band 4.1, ezrin.
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radixin, moiesin) domain, JH5-7, which mediates JAK binding to cytokine receptors. 
[Khwaja A, 2006] JAK2 is known to be critical to erythrogenesis as knockdown of 
JAK2 resulted in early embryonic lethality in mice due to failed erythropoiesis 
[O’Shea ct al, 2002]. The V617F JAK2 mutation found in PV lies in the JH2 domain 
within what is believed to be a ‘hinge’ region of the protein, (see Figure 1[3])
Figure 3[1]: Schematic representation of the JAK2 gene showing the position of 
the V617F mutation
(diagram illustrates the four functional domains of JAK2 including the FERM domain 
[receptor association], the SH2 domain [phosphotyrosine binding], the JH2 domain 
[negative regulation of kinase or pseudokinase activity] and the JFIl domain [tyrosine 
kinase]. The V617F JAK2 mutation lies in the JH2 domain as indicated)
FERM Pseudo TK
V617F
There are several downstream targets of JAKs including the signal transducers and 
activators of transcription (STATs), the phosphoinositide-3-kinases (PI3K) and the 
mitogen associated protein kinases (MAPK) [Rane & Reddy, 2002]. This is 
represented in Figure 1[4]. The JAK / STAT pathway is important for many 
biological responses including differentiation, proliferation & oncogenesis. STATs 
are however, not only induced by JAKs, but can also be activated by serine 
phosphorylation via pathways including MAPK, and by tyrosine phosphorylation 
independent of JAK [Khwaja, 2006].
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Figure 4[1J: Schematic representation of signal transduction via JAK2
(cytokine binds to receptor resulting in association & phosphorylation of JAK2. This 
then results in recruitment of signal transducer and activator of transcription [STAT] 
signalling proteins and phosphorylation & activation of downstream signalling 
pathways including Stat transcription factors, mitogen activated protein kinase 
[MAPK] signalling proteins and the phospholtidylinositol 3-kinase [PI3K] -  AKT 
pathway)
Cytokine ligand binds to receptor
CELL MEMBRANE
JAK2 JAK 2phosphcryiation
Activation o f downstream  
sionalling pathways
NUCLEUS
Activation o f target genes
PI3K are ubiquitously expressed enzymes which are central to cell survival & 
proliferation and can be divided into 3 classes. Class la PI3K consist of a 110 kDa 
catalytic unit (pi 10a, p i 10(3 or p i 106), and a regulatory 85kDa unit (p85). Class Ib 
PI3K includes pi lOy. These pi 10 variants are referred to as PI3K isoforms. 
Expression of PI3K isoforms varies with cell type and there is emerging evidence to 
suggest that differential inhibition may offer a therapeutic opportunity [Anderson & 
Jackson, 2004; Billotet et al, 2006]. AKT, a serine / threonine kinase is a key mediator 
of PI3K signalling and is responsible for phosphorylation of a number of downstream 
targets including glycogen synthase kinase 3 (GSK3), mammalian target of rapamycin 
(mTOR) & p70S6K. There is now overwhelming evidence to show that PI3K, AKT
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and downstream targets contribute to the pathophysiology of human tumours 
[Vivanco & Sawyers, 2002].
MAPK are widely expressed serine / threonine kinases which lie downstream from 
RAS and have important roles in cell survival & proliferation. RAS mutations 
resulting in hyperactivation of RAS and its downstream targets have been described in 
myelodysplastic / myeloproliferative disorders [Side et al, 1998]. MAPK can be 
divided into 3 different groups; the extracellular signal regulated kinase (ERK) family, 
the pSSMAPK family & the JNK family. Simultaneous activation of several 
signalling pathways including ERK has been shown to be associated with poor 
prognosis in haematological malignancy [Kornblau et al, 2006].
Following the discovery of V617F JAK2 in association with PV, several groups have 
focussed on the effects of cellular transfection with V617F JAK2 using this as a 
model for PV. When co-expressed with the erythropoietin receptor (EpoR) in BAF3 
cells, V617F JAK2 induced erythropoietin (Epo) - independent growth and Epo 
hypersensitivity as is seen in PV. [Levine et al, 2005] When coexpressed with c-MPL 
or the G-CSF receptor (GCSFR), V617F JAK2 induced factor independence and 
constitutive phosphorylation of STAT5 [Lu et al, 2005]. Using a similar approach 
James et al [2005] noted constitutive activation of PI3K, MAPK & ERK in V617F 
JAK2 transfected cell lines.
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1.3.2 Erythropoietin, stem cell factor & erythroid signalling pathways
Erythropoiesis is regulated by a number of growth factors with Erythropoietin (Epo) 
and Stem cell factor (SCF) playing central roles. Committed erythroid progenitors 
with Burst Forming Units -  Erythroid (BFUe) & Colony Forming Units -  Erythroid 
(CFUe) potential are initially produced without Epo but definitive erythropoeisis 
(proliferation, survival & differentiation) cannot normally take place in the absence of 
Epo or EpoR [Wu et al, 1995; Lin et al, 1996]. SCF has also been shown to be critical 
to erythropoiesis as deletion of c-KIT leads to anaemia in mice resulting in embryonic 
lethality [Munugalavadla V & Kapur R, 2005].
When SCF binds to c-KIT the receptor dimerises & autophosphorylates. This creates 
binding sites for a variety of SH2 domain-containing enzymes and adaptor proteins 
such as the p85 component of PI3K, Ras GTPase activating protein & Src kinases. 
When Epo binds to EpoR, the associated JAK2 tyrosine phosphorylates the receptor 
[Munugalavadla V & Kapur R, 2005]. Receptor activation creates binding sites for 
SH2 domain-containing proteins including STAT5 and the p85 component of PI3K 
[Munugalavadla V & Kapur R, 2005]. It can therefore be seen that SCF & Epo signal 
via different mechanisms but show overlapping downstream effects.
The precise physiological role of each signalling pathway in erythropoeisis is not fully 
elucidated. The PI3K pathway via phosphorylation of AKT and its downstream target 
GSK3 has been shown to be critical to erythroid proliferation, differentiation & 
survival. [Haseyama et al, 1999; Somervaille et al, 2001] The MAPK & STAT 
pathways have individually and collaboratively been shown to support erythropoiesis 
& erythroid expansion [Sui et al, 1998; Sasaki et al, 2000].
It is difficult to separate out the contributions of Epo & SCF to individual signal 
pathway component in erythroid cells. Taken simplistically, Epo (but not SCF) 
directly induces phosphorylation of STAT5 via JAK2 in erythroid progenitors. Epo 
also transiently induces phosphorylation of ERK in normal erythroid cells. SCF acts 
as the major contributor to phosphorylation of AKT in early erythroid progenitors 
(although Epo has some independent effect), but also sustains phosphorylation of 
ERK in these cells [Arcasoy & Jiang, 2005].
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1.3.3 Effect of inhibition of signalling pathway components on erythropoiesis
Blockade of each of the PI3K, MAPK & STAT5 pathways has been shown to affect 
erythroid signalling. LY294002 is a small molecule PI3K inhibitor which has been 
shown to reduce phosphorylation of AKT and to reduce the Epo & SCF supported 
proliferation and maturation of erythroblasts [Myklebust et al, 2002].UO126 is a small 
molecule MAPKK inhibitor which has been shown by some [Mori et al, 2003] though 
not by others [Somervaille et al, 2001] to affect erythroid survival. Absence of 
STAT5 in mice has been shown to reduce erythroblast survival & differentiation. 
[Sokolovsky et al, 2001].
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1.4 Erythroblast proliferation & survival
1.4.1 Aberrant proliferation in Polycythaemia Vera
Erythropoietin independent colonies are highly associated with a diagnosis of PV but 
Epo-independence is not due to mutations in either Epo or EpoR. [Hess et al, 1994] 
Epo levels are lower in untreated PV than in control subjects but there is evidence to 
suggest that treatment of PV with phlebotomy or hydroxyurea is associated with 
relatively higher levels of Epo, with hydroxyurea having the greater effect [Shih et al, 
1998; Andreasson et al, 2000; Johansson et al, 2006]. This suggests that the low levels 
of Epo observed in PV occur as a result of physiological feedback.
The haematopoietic expansion observed in PV in vivo occurs despite reduced levels 
of Epo. One explanation for excessive proliferation in PV could be hypersensitivity to 
Epo and indeed this has been described [Montagna et al, 1994]. However, 
hypersensitivity to Interleukin-3 [Dai et al, 1991], Granulocyte/Monocyte-Colony 
Stimulating Factor [Dai et al, 1992], Stem Cell Factor [Dai et al, 1994] & Insulin 
Growth Factor-1 [Correa et al, 1994] has also been reported. Therefore increased 
proliferation in PV is neither cytokine specific nor restricted to those cytokines known 
to activate signal transduction predominantly via JAK2.
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1.4.2 The effects of JAK2 inhibition on erythropoiesis
Small molecule inhibitors of JAK2 include the tyrphostins (AG490), the 
indolocarbazoles (Staurosporine, Go6976) and a pyridine containing tetracycle called 
Compound 6 (also known as Jak Inhibitor 1). None of these groups of inhibitors are 
absolutely specific for JAK2. Tyrphostins are protein tyrosine kinase inhibitors that 
were initially explored as inhibitors of epidermal growth factor expression. [Margolis 
et al, 1989] They were subsequently found to also inhibit cyclin dependent kinases 
[Kleinberger-Doron et al, 1998] Indolocarbazoles were described as inducers of DNA 
topoisomerase I [Yamashita et al, 1992] before their inhibitory effects on Protein 
Kinase C (PKC) [Martiny-Baron, 1993] and later, JAK2 & FLT3, [Grandage et al,
2006] became apparent. Jak Inhibitor 1 was more recently described as a Jak inhibitor 
with predominant effects on JAK2 & Tyk2 but some effect on JAK l & JAK3. 
[Thompson et al, 2002]
Inhibitors of JAK2 have been tested in tumour cell lines and have generally been 
shown to reduce viable cell number and cell growth. Thompson et al [2002] found 
that Jak Inhibitor 1 reduced proliferation in a murine T-cell lymphoma cell line, 
Spiekermann et al [2001] detected growth arrest with AG490 in AML cell lines and 
lankov et al [2002] found that Go6976 blocked proliferation in a plasmacytoma cell 
line. Work in primary cells has also consistently shown that JAK2 inhibition reduces 
cell growth. Me y dan et al [1996] found that AG490 reduced the proliferation of 
primary acute lymphoblastic leukaemia cells in vivo and in vitro. Grandage et al 
[2006] described reduced proliferation of primary acute myeloid leukaemia cells by 
Go6976 in a PKC independent fashion. Ugo et al [2004] found that AG490 reduced 
erythroblast survival and differentiation.
Transplantation studies in murine models have shown that bone marrow progenitors 
transfected with V617F JAK2 induce erythroid expansion [James et al, 2005] and that 
this expansion can be reduced by inhibitors of JAK2 [Zaleskas et al, 2006]. Some 
groups have looked at whether JAK2 inhibitors might have differential effects on 
V617F JAK2 mutant compared to wild type JAK2 expressing tumour cells. Walz et al 
[2006] compared effects of Jak Inhibitor 1 on HEL cells (V617F JAK2) and K562 
cells expressing transformed BCR-ABL (but wild type JAK2). They found reduced
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cell growth in the HEL cells but not in the K562 cells. Interestingly apoptosis as 
assessed by Annexin V staining was only minimally increased in the Jak Inhibitor 1 
exposed HEL cells with no effect seen on the control K562 cells. Walters et al [2006] 
similarly found a greater reduction of cell growth in V617F JAK2 expressing cell 
lines (HEL, SET-2, UKE-1) than in wild type JAK2 controls (K562, SKM). These 
findings suggested that mutant JAK2 may be more sensitive to inhibition than wild 
type JAK2.
Kawada et al [1997] recognized that Staurosporine could reduce erythroid colony 
formation from peripheral blood and bone marrow. These authors found that the 50% 
inhibitory concentrations (IC50) for Staurosporine were higher in PV than in normal 
controls. If we assume that the PV cells used in these experiments were V617F JAK2 
mutant cells, this would imply reduced sensitivity of primary mutant cells to 
inhibition. Jamieson et al [2006] investigated the effects of AG490 on erythroid 
colony formation in PV & normal controls and found that erythroid colonies were 
reduced by JAK2 inhibition. However, this inhibition preferentially affected normal 
colonies as V617F mutant colonies were not reduced in 3/4 PV patients. This 
evidence in primary cells suggests that the V617F JAK2 mutation may confer relative 
resistance to JAK2 inhibition.
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1.4.3 The effects of PI3K inhibition on erythropoiesis
The PI3K system is highly complex. LY294002 is a potent small molecule pan-PI3K 
inhibitor with an IC50 of 1.4uM and its effects have been widely studied [Vlahos et al, 
1994]. LY294002 has been shown to reduce the Epo & SCF supported survival of 
normal erythroblasts [Somervaille et al, 2001; Myklebust et al, 2002]. Latterly it has 
become clear that LY294002 also inhibits Pim-1 (a downstream target of JAK/STAT) 
and Casein Kinase 2 (CK2) [Jacobs et al, 2005] and so alternative and more specific 
inhibitors of PI3K and downstream targets are being developed.
As yet there is little published data on the effects of PI3K inhibitors on survival in PV 
erythroid progenitors: Ugo et al [2004] observed similar effects of PI3K inhibition on 
erythropoietin dependent and independent erythroblast differentiation in PV but found 
little impact on erythroid progenitor survival.
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1.5 Gene expression in erythroid progenitors
1.5.1 Gene expression studies in Polycythaemia Vera
Gene expression profiling could theoretically contribute to the understanding of 
disease by offering a diagnostic tool, in the sub-classification of disease entities with 
potential for prognostic impact and in identification of genes which may be involved 
in the molecular pathophysiology of disease. Gene profiling of progenitor cells has 
been extensively explored in haematological malignancy and is well described as a 
classification tool in Idiopathic Myelofibrosis [Jones et al, 2005; Guglielmelli et al
2007]. To date there is little published data on expression profiles in Polycythaemia 
Vera progenitors.
Three separate groups have published data on the gene expression profile of 
neutrophils in PV [Pellagatti et al, 2003; Goerttler et al, 2005; Kralovics et al, 2005]. 
Pellagatti et al compared profiles between 11 PV & normal controls and found 147 
genes with >2.5x upregulation in PV of which 11 were upregulated in all 11 PV 
patients representing a possible gene signature. These upregulated genes included 
protease inhibitors known to inhibit neutrophil apoptosis, and other antiapoptotic and 
survival factors. Goerttler et al compared profiles between 40 PV and 12 SP and 
found that 64 genes effectively differentiated the signatures. They noted that 253 
genes were >1.5x upregulated & 391 downregulated in PV and went on to focus on 
the upregulation of transcription factors including NF-E2. Kralovics et al examined 
profiles in 98 patients with PV (54 PV, 33 ET, 11 MF), 4 with SP, 4 with reactive 
neutrophilia, 3 G-CSF mobilised normal subjects and 28 normal controls. They found 
280 genes to be significantly dysregulated in MPD; however the 13 most predictive 
genes and 3 others shown to be affected were also G-CSF inducible in subjects with 
wild type JAK2 limiting the pathophysiological interpretation of this data. 
Significantly, looking at the data presented, there was no commonality in altered gene 
expression profiles between the studies.
One group has compared the expression profiles of PV CD344- progenitor cells 
derived from bone marrow with CD344- bone marrow cells from normal volunteers
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[Steidl et al, 2005]. They found differential expression of 107 genes describing 
downregulation of pro-apoptotic genes and upregulation of fibrosis stimulating 
growth factors in PV. They also identified upregulation of a number of receptors, 
protein kinases & proteasome components which, they observed, might represent 
therapeutic targets in PV and went on to focus on the retinoic acid receptor 
components and the potential treatment role of all-trans retinoic acid (ATRA).
Polycythaemia Vera is a clonal myeloid disorder and, in the case of the V617F JAK2, 
it has been shown that this mutation can be detected from lymphomyeloid progenitors 
to each of their mature progeny. [Delhommeau et al, 2007] This finding supports the 
diagnostic relevance in PV of screening gene expression in myeloid cells, whether 
these are neutrophils or progenitor cells. Polycythaemia Vera is however, by 
definition, a disorder with predominant effects on the erythroid lineage and it is this 
feature which discriminates PV from other myeloproliferative disorders. Committed 
erythroid progenitors have distinct expression profiles and, as might be predicted, the 
gene expression of committed erythroid progenitors differs from that of other lineage- 
specific progeny from common CD34-I- stem cells [Gubin et al, 1999; Komor et al, 
2005]. It has been suggested that the erythroid expansion which predominates in PV 
might be due to co-operating genetic events not related to the V617F kinase activity 
[Vainchenker et al, 2005]. As yet there is no published information on the gene 
expression profiles of committed erythroid progenitors in PV which might indicate 
such co-operating genetic events in these cells.
The aim of this thesis was to explore the functional and molecular changes apparent in 
erythroid progenitors from a well characterised cohort of patients with Polycythaemia 
Vera. Comparison was to be made with erythroid progenitors derived from patients 
with Idiopathic Erythrocytosis, Secondary Polycythaemia and normal controls. 
Functional assessments were to include analysis of growth and survival, exploring the 
signalling platforms underlying these processes. Molecular assessments were to 
establish a ‘snapshot’ of erythroid progenitor gene expression using a broad 
expression profiling tool and selected single gene analysis. The therapeutic potential 
of small molecule inhibitors was to be tested by introduction into each of these 
systems.
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CHAPTER 2 -  METHODS
2.1 The Polycythaemia Clinic
The Polycythaemia Clinic at University College Hospital, London accepts referrals of 
patients with elevated haematocrit from general practitioners and other hospitals in 
the North Thames region. All patients were clinically assessed, investigated, 
diagnosed and managed according to standard protocols by myself [McMullin et al, 
2005]. Informed consent was obtained for processing and storage of patient samples. 
Research results were discussed with patients.
2.1.1 Clinical profiling
A standard clinical history and examination was performed on all patients which 
included specific questions about symptoms or signs which might be associated with 
PV and those which might suggest an alternative cause for an elevated haematocrit.
2.1.2 Routine laboratory profiling
Full blood count with differential was performed on at least 3 occasions and a blood 
film reviewed. Routine biochemistry was performed to check renal and liver function 
searching for secondary causes of an elevated haematocrit and as a clinical baseline 
against further therapy. ESR, urate and serum vitamin B12 were checked as low ESR, 
high urate and high vitamin B 12 are often observed in PV. Serum erythropoietin was 
measured by ELISA as low levels are highly associated with a diagnosis of PV and 
high levels are suggestive of a secondary cause for polycythaemia.
Patients with a sustained increase in haematocrit (but <0.58 for females and <0.6 for 
males) underwent radio-isotopic investigation for assessment of red cell mass and 
plasma volume if there was no clinical imperative for early treatment. True 
polycythaemia was defined where red cell mass was >25% above the mean of the 
normal predicted value for weight. Borderline cases were noted and the diagnosis kept 
under regular review. One borderline patient went on to develop PV.
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Pseudopolycythaemia was diagnosed where plasma volume was low or normal and 
red cell mass normal and these patients were not investigated further: consideration 
was given to the body mass index in individual patients as obesity can give spuriously 
low prediction of red cell mass as assessed by weight in these circumstances.
Capillary oxygen saturation at rest and on exercise was performed to assess 
respiratory function. Younger patients or patients in whom the clinical diagnosis was 
unclear were encouraged to have bone marrow assessment by aspirate with 
cytogenetic analysis and trephine with histopathological review. Chest X-ray and 
abdominal ultrasound scanning was performed as a search for a secondary cause for 
polycythaemia and to look for the presence of splenomegaly. Further investigations 
were performed as necessary in individual patients to explore causes for secondary or 
constitutive polycythaemia.
A diagnosis of Polycythaemia Vera was made at the time of this study according to 
the Polycythaemia Vera Study Group (PVSG) criteria [Pearson & Messinezy, 1996]. 
These criteria have subsequently been updated and are shown in Figure 1[2]. The 
change in criteria did not alter the diagnosis of any individual assessed in this study. 
The remaining patients with true polycythaemia were classified as having secondary 
polycythaemia or idiopathic erythrocytosis according to individual clinical and 
laboratory parameters.
2.1.3 Venesection procedure
Therapeutic venesection was performed with a clean technique by specialist 
haematology nurses on the haematology day care unit. As per guidelines patients were 
venesected if their haematocrit exceeded threshold (0.45 for PV, 0.5 for lE/SP & 
Pseudopolycythaemia). Approximately 450ml venous peripheral blood was taken into 
“wet packs” (CPDA-1 single blood collection system, R8104 containing 63ml CPDA- 
1 anticoagulant solution, Baxter).
39
2.2 Processing and liquid culture of primary haematopoietic cells
Figure 1[2]: Flow chart for initial processing of primary cells
(this chart outlines the first steps of cell separation from the day of sampling with the 
methodological detail defined in the subsequent text)
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2.2.1 Sources and initial storage of primary haematopoietic cells
Venesection packs from patients attending the Polycythaemia Clinic were the 
principal source of primary cells. Packs were taken from patients with PV, IE and 
Pseudopolycythaemia. The majority of venesection samples were held at room 
temperature before processing the same day. A few samples received late in the day 
were stored at 4^C overnight and allowed to warm to room temperature prior to 
processing the next day.
Normal peripheral blood was donated by volunteers within the Department of 
Haematology at UCL. Some normal cells were obtained as ‘Buffy Coat Residues’ 
supplied by the National Blood Service (In order to produce platelets the NBS pools 4
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normal donor buffy coats. Platelets were removed from these buffy coats by slow 
centrifugation leaving a highly cellular buffy coat residue rich in white cells.) These 
Buffy Coat Residues were delivered on the same day as sampling. Normal cells were 
stored and processed in the same way as patient samples.
A third source of ‘normal’ control cells for experiments was CD34+ rich cell 
collections available as surplus to clinical requirements from the haematology day 
care unit at UCH. These cells had been collected from normal volunteer donors either 
by bone marrow harvest or by G-CSF mobilization. Others were obtained by G-CSF 
4- chemotherapy mobilization from patients in remission from haematological disease. 
The protocol for use of CD34-I- cells for research purposes was approved by the local 
Ethics Committee. These cells were either processed fresh within 24 hours of 
sampling or recovered from stocks frozen in liquid nitrogen.
For freezing, cells were suspended in RPMI (Gibco RPMI 1640 with Glutamine, 
21875-034, Invitrogen Life Technologies) with 50% added fetal calf serum (Gibco, 
heat inactivated at 56°C for 30 mins) & 10% dimethyl sulfoxide (DMSO). Cells were 
initially frozen at -SO^C and subsequently transferred to liquid nitrogen at -ISO^C. 
Frozen aliquots of cells were thawed as needed by rapid transfer to a 37°C water bath 
followed by dilution with RIO, (RPMI + 10% added fetal calf serum) & 
centrifugation at 350g. A single wash in phosphate buffered saline (Gibco D-PBS -  
CaCl] -MgCE, 14190-094, Invitrogen Life Technologies) was performed prior to 
resuspension in the appropriate culture medium.
2.2.2 Manual separation of cells from peripheral blood
All processing was performed in a laminar air flow cabinet with sterile instruments 
and reagents. Anticoagulated blood was decanted into 50ml containers using sterile 
transfer units (Plasma transfer set with coupler and Luer adaptor, VMC2240, Baxter). 
Samples from patients with markedly elevated haematocrit were diluted 1:1 with 
sterile PBS. Buffy coat residues were diluted 1:5 as the haematocrit of these packs 
was very high. Samples were centrifuged at 800 rpm/150g for 20 minutes following 
which the overlying platelet rich plasma was aspirated and discarded.
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Red cell depletion was then performed by dextran precipitation. Five millilitres of an 
isotonic 10% dextran solution (25g Dextran, 17-0320-02, Amersham Biosciences 
with 2.25g NaCl in 250ml deionised distilled water [DDW], autoclaved) was added to 
45ml of cells. Mixing was performed by gentle inversion and uncapped samples were 
left to stand for 20 minutes following which the red cell depleted supernatant was 
harvested. This supernatant was then carefully layered in 25ml aliquots onto 20ml 
Ficoll-Paque TM Plus (17-1440-03, Amersham Biosciences) in 50ml containers.
These samples were then centrifuged at 1800 rpm/SOOg for 20 minutes.
Following centrifugation approximately 20ml supernatant was aspirated and discarded. 
The mononuclear cell layer was carefully aspirated into a fresh container. The 
remaining Ficoll was aspirated and discarded and the red cell + granulocyte pellet was 
suspended in 2.5ml PBS before further processing.
The mononuclear cell layer was centrifuged at 1 SOOrpm/SOOg for 6 minutes to remove 
residual Ficoll. The residual pellet was then resuspended in 5ml Ficoll and made up to 
50ml with CliniMACS Buffer (700-25, Miltenyi Biotec). Samples were centrifuged at 
800rpm/150g for 20 minutes and the supernatant containing residual platelets was 
aspirated and discarded. Mononuclear cells were suspended in 50ml PBS and 
centrifuged at 1300rpm/350g for 5 minutes to remove residual Ficoll then 
resuspended in RIO. The number of residual viable cells was counted by addition of 
0.4% Trypan blue solution (T8154, Sigma) followed by enumeration with the aid of a 
haemocytometer.
2.2.3 Purification & storage of neutrophils from peripheral blood
The red cell 4- granulocyte suspension derived in 2.2.2 was subject to controlled cold 
hypotonic lysis to destroy residual red cells: 8ml of deionised distilled water (DDW) 
at 4^C was added to the suspension, inverted to mix and allowed to stand for 1 minute. 
Residual cells were rescued by addition of 4ml of 3.5% NaCl chilled to 4°C. The 
sample was centrifuged at 2000rpm/850g for 5 minutes. Lysed red cells were rinsed 
off with PBS and the residual pellet was suspended in 10ml PBS. A cell differential 
was performed with an automated cell counting system (Sysmex) to document that the 
cellular population was >95% neutrophils.
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Neutrophils for future RNA extraction were suspended at a concentration of 10 
million / ml in Trizol Reagent (15596-026, Invitrogen) then stored at -20°C. 
Neutrophils for subsequent DNA extraction were suspended in 2.5ml PBS, made up 
to 7ml with 7.5M DTAB solution (DTAB, D-8638, Sigma 20g + NaCl 22g + IM Tris 
solution, pH 8.6, 25ml + 0.5M EOT A solution 25ml + up to 250ml with D D W ), 
mixed, incubated at 68^C for 5 minutes in a waterbath and then stored at -20°C.
2.2.4 Liquid culture of mononuclear cells promoting erythroid expansion & 
differentiation
Mononuclear cells derived in 2.2.2 were suspended at a density of 2.5-5 xlO^/ml in a 
medium which differentially promoted erythroid differentiation and amplification 
over other myeloid lineages. (Gibco IMDM, 21980-032, Invitrogen Life Technologies 
40ml + fetal calf serum 10ml + human SCF, 300-07, Peprotech Inc at lOug/ml + 
human IGF-1, 100-11, Peprotech Inc at 40ng/ml 4- recombinant human erythropoietin, 
Eprex, Janssen-Cilag Inc at liu/ml + recombinant human Interleukin 3 , 14144, Sigma 
at 0.5ng/ml + Beta Estradiol E2257, Sigma at 0.15uM + Dexamethasone at luM). 
Samples were incubated in tissue culture flasks at 37°C 5% CO2 for 6 days.
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2.2.5 Negative selection of mononuclear cells & subsequent culture
Day 6 cells (2.2.4) were carefully aspirated to avoid dislodgement of adherent 
macrophages. Aspirated cells were counted and centrifuged at ISOOrpm for 5 minutes. 
Cells were suspended in CliniMACS buffer (see 2.2.2) which had been stored at 4^C 
and then incubated for 15 minutes at room temperature with microbeads conjugated to 
antibodies to CD2, CD 14 & CD 19 at 20ul per 10  ^cells (human CD2 MicroBeads 
130-091-114, human CD 14 MicroBeads 130-050-201, human CD 19 MicroBeads 
130-050-301, Miltenyi Biotec).
Following incubation, cells were washed to remove unbound antibody and 
resuspended in fresh CliniMACS buffer. Samples with cell number >5x10^ then 
underwent selection with the VarioMACS system (LS Separation Column, 130-042- 
401 4- Pre-separation filter, 130-041-407, Miltenyi Biotec). Samples with cell number 
<5x10^ then underwent selection with the MiniMACS system (MS Separation 
Column, 130-042-201 & Filter, Miltenyi Biotec). The unbound fraction was collected 
and passed down a second column. The final unbound fraction was collected, 
centrifuged at 1300rpm/350g for 5 minutes and suspended at a density of 0.2- 
IxlO^/ml in the erythroid differentiating medium described in 2.2.4 but without added 
Estradiol or Dexamethasone.
The negatively selected population was then cultured at 37°C 5% CO2 for 3 days in 
tissue culture flasks. If the cells contained residual non-erythroid precursor cells by 
visual inspection, they were reselected or adhesion-depleted in the case of 
macrophage contamination. If there was excessive debris or red cell contamination the 
samples were flcolled to remove these unwanted components. Unless specifically 
stated otherwise cells were used for experiments on Day 9 of culture as this was found 
to be optimal in terms of cell number and homogeneity of the cellular population.
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2.2.6 Erythroid differentiation of CD34+ rich samples
Progenitor rich samples derived as per 2.2.1 were positively selected up front to 
obtain a pure population of CD34+ cells. Cells were suspended in CliniMacs Buffer 
and incubated for 15 minutes with human CD34+ microbeads (130-046-702, 
Miltenyi-Biotec) according to the manufacturer’s instructions. A washing step was 
performed and cells were passaged down a magnetic column with filter using the 
VarioMacs sytem. The CD34+ fraction was then collected according to 
manufacturer’s instructions and cells were incubated for 6-11 days in erythroid 
medium as per 2.2.4. Derived cells were 80-90% erythroblasts at this stage with 10- 
20% non-erythroid myelomonocytic precursors as assessed by May-Grunwald- 
Giemsa staining of cytospins.
2.2.7 Evaluation of samples by morphological analysis
A standard cytospin using 5x10"  ^cells in 75ul medium was performed. Dried samples 
were fixed, stained & counterstained using methanol and the May-Grumwald-Giemsa 
system and then microscopically evaluated. Day 9 cells were deemed suitable for 
microarray analysis if they were >95% pure erythroblasts or suitable for other work if 
they were >90% pure erythroblasts. CD34-k samples were used if the population was 
>80% erythroblasts.
2.2.8 Evaluation of samples by immunophenotyping
Immunophenotyping was performed on the derived cells by flow cytometric counting 
(Epics Elite, Beckman Coulter, High Wycombe, UK) following labelling with 
Phycoerythrin or FITC-conjugated antibodies to Glycophorin A, CD36, GDI 17,
CD71 and IgG (PE anti-human Glycophorin A, 555570, PharMingen & FITC anti­
human CD36, 555454, PharMingen & anti-human CD71/FITC, F0829, 
DakoCytomation & Human GDI 17, GDI 1704-4, Galtag Laboratories & mouse anti 
IgG-FITG 345815, Becton Dickinson & normal mouse IgGl PE, sc-2866, Santa Gruz 
Biotechnology). Samples were deemed suitable for further experiments if (in addition 
to morphological analysis) they showed intermediate positivity for Glycophorin A, 
strong positivity for GD36 & GD71 and weak expression of GDI 17.
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2.3 Colony assays
Colony assays were performed in triplicate with IxlO'Vml mononuclear cells in semi­
solid culture medium aliquoted into 24-well tissue culture plates. Erythroid (both 
BFUe and CFUe) and granulocyte-macrophage colonies were enumerated 
microscopically after 13-14 days of culture in a humidified atmosphere at 37°C, 5% 
CO]. Equivocal samples were reviewed by an independent assessor.
2.3.1 Standard colony system
Standard colony assays were performed as above using aliquots from a 100ml stock 
made up of 80ml Methocult (H4230, Stem Cell Technologies) 4- 20ml IMDM 
+30ng/ml human IL3 4- liu/ml Erythropoietin 4- lOng/ml SCF (see 2.2.4) 4- 25ng/ml 
G-CSF (Filgrastim-Neupogen, Amgen) and 25ng/ml GM-CSF (gift from Hoechst, 
UK).
2.3.2 Erythropoietin independent colonies (EECs)
Erythropoietin independent colony assays were performed as above using Methocult 
without added erythropoietin (H4531, Stem Cell Technologies). Erythropoietin was 
added to this medium at concentrations of 2, 1, 0.5, 0.25, 0.12, 0.06, 0.03 and 0 iu/ml.
2.3.3 Colonies with added inhibitors & cytokines
The effect of small molecule inhibitors on colony assays was assessed by addition of 
specified concentrations of inhibitor or cytokine to colony assay media (either 
standard or EECs) prior to plating.
The following cytokines were used:
Interferon alpha (Roferon, Roche Pharmaceuticals)
Interferon gamma (13265, Sigma)
Recombinant Human Leptin (300-27, PeproTech EC)
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The following inhibitors were used:
PI3 kinase inhibitor: PI 103 (528100, Calbiochem)
Jak 2 inhibitors: Go6976 (365250, Calbiochem), Jak Inhibitor 1 (420097, Calbiochem)
PKC inhibitor: Go6983 (365251, Calbiochem)
mTOR inhibitor: Rapamycin (R5000-5M, LC Laboratories)
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2.4 DNA & RNA extraction & processing
Samples suitable for DNA or RNA extraction were stored at -20^C prior to processing.
2.4.1 DNA extraction chloroform technique
Samples from 2.2.3 were thawed at room temperature prior to addition of an equal 
volume of Chloroform (100776B, AnalaR). Vigorous mixing was performed prior to 
centrifugation at BOOOrpm for 20 minutes at 4^C. The upper layer was then carefully 
removed to a clean tube, an equal volume of 100% Ethanol (10107, AnalaR) was 
added and the sample was gently mixed. Precipitated DNA was transferred to a 1.5ml 
centrifugation tube and washed with 0.5ml 70% Ethanol, then centrifuged at BOOOrpm 
for 5 minutes. Residual ethanol was removed and the DNA pellet was suspended in 
DDW. To ensure solubilization, samples were left on a rotating shaker at 4°C 
overnight prior to storage at 4°C.
2.4.2 RNA extraction chloroform technique
Trizol samples (0.5ml) from 2.2.B were thawed at room temperature prior to addition 
of 200ul Chloroform. Vigorous mixing was performed prior to centrifugation at 
lB,000rpm for 15 minutes at 4°C. The upper layer from this spin was then carefully 
aspirated and transferred to a fresh container. Five hundred microlitres of Propan-2-ol 
(102246L, AnalaR) was added and the samples incubated for 10 minutes at room 
temperature prior to centrifugation at lB,000rpm for 10 minutes at 4°C. The 
supernatant was aspirated and discarded and the RNA pellet washed with 1ml 70% 
Ethanol prior to centrifugation for 5 minutes at 4^C. Residual ethanol was removed 
and the RNA pellet was suspended in DDW. To ensure solubilization, samples were 
left on a rotating shaker at 4^C overnight prior to storage at -20^C.
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2.4.3 Reverse transcriptase polymerase chain reaction (RT-PCR)
Oligo dTs were diluted in sterile water to a final volume of 8 .8 ul and 2ul of the RNA 
extracted as per 2.4.2 was added to this. Dénaturation was performed at 65°C for 5 
mins followed by cooling to room temperature. Reverse transcription was then 
performed by addition of 9.2ul of a mixture consisting of 2ul 10 x NH4 Reaction 
Buffer (Bioline) + 4.2ul 25mM MgCl] (Bioline) + 2ul lOmM dNTPs (Bioline) + 0.5ul 
RNAse Inhibitor (N2611, Promega) + 0.5ul AMV Reverse Transcriptase (M5108, 
Promega). Mixed samples were incubated at 42°C for 1 hour for reverse transcription 
to occur followed by incubation at 95°C for 5 minutes to terminate the reaction. 
cDNA was stored at 4^C pending subsequent use or used immediately for PCR 
reactions.
2.4.4 Semi-quantitative analysis of transcripts of PRVI and other genes
A multiplex PCR reaction for PRY 1 with GAPDH as a housekeeping gene was 
performed within the same tube to allow semi-quantitative analysis of products. An 
18ul mix consisting of 1.8ul 10 x NH4 Reaction Buffer (see 2.4.3) 4- 0.2ul lOmM 
dNTPs 4- 0.4ul 25mM MgClz (see previous) 4- 12.6ul sterile water 4- lul Biotaq DNA 
Polymerase (BIO-21040, Bioline) 4- 0.5ul each of forward and reverse primers for 
PRVI (forward 5’-ATTGAGAGCGGACCCCAAGTGA-3’, reverse 5 ’- 
CTTGGTATTCGATGTGGTCCA-3') & GAPDH (forward 5’- 
GCCGAGCCACATCGCTCAGA-3’, reverse 5 ' -GAGGCATTGCTGATGATCTTG- 
3’) was added to 2ul sample cDNA (from 2.4.3). PCR was performed as follows;
95°C for 5 minutes, then 30 cycles of 95°C for 30 seconds 4- 64°C for 30 seconds 4- 
72°C for 30 seconds followed by completion with 1 cycle of 72°C for 10 minutes. 
PCR products were mixed with 3ul 6x Loading Dye (R0611, Fermentas) and run on a 
1.5% agarose gel with added Ethidium Bromide to allow separation and visualisation 
of products. Bands were referenced to those for 2 control samples in which PRV 1 
expression had previously been ascertained; one with overexpression and one with 
low expression of PRV 1. In comparison with an adequate GAPDH band, PRV 1 
expression was said to be absent if no band of the correct size was seen, low level if a 
faint band was seen and high level if a strong band was seen.
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Semi-quantitative analysis was performed in a similar manner with the following 
genes and primers:
IFITM l, amplification at 62 °C.
Forward 5 ’ - AG ATGC AC A AGG AGG A AC ATG AG-3 ’
Reverse 5 ’ - ACTGTC AC AG AGCCG A AT ACC A-3 ’
PIM l, amplification at 62 °C.
Forward 5 ’ -C A AGG ACG A A A AC ATCCTT ATCG A-3 ’
Reverse 5 ’ -ATCTTGCATCCATGGATGGTTC-3 ’
2.4.5 Screening for Chuvash polycythaemia
The most common mutation described in Chuvash polycythaemia is caused by a point 
mutation in exon 3 of the Von Hippel Lindau (VHL) resulting in the Arg200Trp 
substitution in the VHL protein. Screening for this mutation was performed using a 
direct restriction digest technique. A 19ul mix was made up consisting of: 2ul 10 x 
Bioline Reaction Buffer 4- 0.4ul lOmM dNTPs 4- O.Sul 25mM MgCL 4- 12.1ul sterile 
water 4- 1 ul each of forward and reverse primers (forward: 5’- 
CCTTGTACTGAGACCCTAGTC-3', reverse: 5’-
AGG AAGG A ACC AGTCCTGT ATC-3 ' ) 4- 2ul Betaine + OAu\ Biotaq DNA 
polymerase. Sample DNA was diluted 1:10 and lul added to the reaction mix. PCR 
was performed with 35 cycles of 95^C for 30 seconds 4- 62°C for 30 seconds 4- 72^C 
for 30 seconds followed by termination at 72^C for 5 minutes. Digestion was 
performed in a waterbath at 37°C for 4-16 hours with 5ul PCR product added to 0.5ul 
BsrBl 4- 2ul lOxNEBuffer 2 (R0102S, New England Biolabs) 4- 3.5ul sterile water. 
Products were resolved on 1.5% agarose gel with added Ethidium Bromide and 
assessed as per figure a. Samples showing undigested bands were sequenced to 
confirm presence of the mutant.
2.4.6 Screening for V617F Jak 2 mutation
Screening was performed by PCR with a mismatched primer designed to introduce a 
restriction digest site for the Afl III enzyme into wild type Jak 2 products: An 18.5ul 
mix was made up consisting of 2ul 10 x Bioline Reaction Buffer 4- 0.4ul lOmM 
dNTPs 4- O.Sul 25mM MgCL 4- 13.3ul sterile water 4- 0.5 ul each of forward and
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reverse primers (forward = 5’CAAGCATTTGGTTTTAAATTATGGAGTACGT-3’, 
reverse = 5’ TAAATTATAGTTTACACTGACACCTAG-3’). 18.5ul per sample was 
aliquoted out and a drop of mineral oil was overlaid. Sample DNA solution 0.5ul was 
added through oil and the samples were incubated at 95°C for 5 mins then held at 
85°C for addition of lul Biotaq DNA Polymerase diluted 1:10 with sterile water. PCR 
was performed with 33 cycles of 95°C for 30 seconds + 60^C for 30 seconds + 72^C 
for 30 seconds followed by extension at 72°C for 10 minutes.
Overlying oil was removed and PCR products were then underwent digested: 8ul PCR 
product was added to 2ul sterile water + O.Sul Afl III (R0541L, New England 
BioLabs) + lul lOx NEBuffer 3 + O.Sul BSA (both New England Biolabs). Samples 
were incubated for 3-16 hours at 37°C together with undigested controls. Products 
were then mixed with 3ul 6x Loading Dye (see 2.2.4) and loaded onto a 4% agarose 
gel with added Ethidium Bromide and concomitant known mutant and wild type 
controls.
2.4.7 Quantitative RQ-PCR by the SYBR Green technique
Reverse transcription was performed as per 2.4.3. Standard curves were created for all 
primers using the SYBR Green technique and compiled as described in 6.2.1.
Reactions were performed in duplicate or triplicate with negative controls. cDNA (Sul)
was added to a 20ul mixture of 6.Sul sterile water, O.Sul each forward & reverse
primers (IFITMl forward S’-CGACCATGTCGTCTGGTCCCTG-3’, IFITM l reverse
S’-CAGATGTTCAGGCACTTGGCGGTG-3’, Pim l forward S’-
CGAGCATGACGAAGAGATCAT-3’, Pim l reverse S’-
TCGAAGGTTGGCCTATCTGA-3', ABE forward S’-
TGG AG AT A AC ACTCT AAGC AT AACT AAAGGT-3 ', ABE reverse S’-
GATGTAGTTGCTTGGGACCCA-3’, Beta 2 microglobulin forward S’-
TCCTGAAGCTGACAGCATTCG-3', Beta 2 microglobulin reverse S’-
TCCATTCTCTGCTGGATGACG-3') & 12.Sul SYBR Green PCR Master Mix
(4309ISS, Applied Biosystems). Reactions were performed using default settings on
an ABI Prism 7700 and analysed using Sequence Detector v l.7  software (Applied
SI
Biosystems). Average threshold cycle (Ct) was calculated and results plotted using the 
formula 2 ' “ “  c, gene of in.erest) ^ ^ standard histograms.
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2.5 Tumour cell lines
Tumour cell lines were recovered from in house samples stored in liquid nitrogen as 
per 2.2.1. They were routinely cultured at 37^C 5% CO2 in RPMI or IMDM with 10% 
added fetal calf serum and appropriate added cytokines [RIO, 110].
2.5.1 Cytokine dependent cell lines
The following cytokine dependent cell lines were used:
TFl human erythroleukaemia
BAF3 murine pro-B lymphoid line
Mo7e human acute megakaryoblastic leukaemia
3 2D murine myeloid line
Human cells were cultured in RIO + 20ng/ml GM-CSF. Murine lines were cultured in 
RIO + lOng/ml mIL3 (Peprotech EC Ltd).
2.5.2 Cytokine independent cell lines
The following cytokine independent cell lines were used from culture in RIO:
HEL human erythroleukaemia
K-562 human chronic myeloid leukaemia in blast crisis
FDCPl* murine bone marrow * stably expressing BCR-ABL (gift from
R.Chopra, Paterson Institute of Cancer Research)
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2.6 Western blotting
2.6.1 Starvation, Pre-inhibition & stimulation of cells
All cells were selected to give 10  ^cells per experimental point. Cytokine dependent 
cell lines were washed 3 times in 50ml PBS and resuspended at a density of 10^/ml in 
fresh RIO overnight without added cytokines at 37°C 5% CO2. Primary cells were 
selected and washed in the same way but resuspended in IMDM with 5% BIT (serum- 
free medium, BIT 9500, Stem Cell Technologies containing bovine serum albumin, 
human recombinant insulin and human transferrin in IMDM) for 2-3 hours. Inhibitors 
were added at the desired concentration and samples were further incubated for 30-60 
mins at 37°C (+5%  CO2 if experimental period >2 hours) Stimulation was performed 
with the appropriate cytokine added for incubation periods of 10 mins to overnight.
The following inhibitors were used:
PI3 kinase inhibitors:
LY294002 (L-7962, LC Labs), PI 103 (528100, Calbiochem), PI387 (Piramed 
Pharma, Slough UK), TGX-221 (10007349, Cayman Chemical Company), 
D030 (kind gift of Prof B. Vanhaesebroeck, Ludwig Institute for Cancer 
Research, London)
Jak 2 inhibitors:




U0126 (U-6770, LC Labs & V I 121, Promega) 
mTOR inhibitor:




Imatinib (Gleevec, Novartis Pharmaceuticals)
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The following cytokines and stimulatory agents were used:
Erythropoietin, GM-CSF, Interferon alpha, rhIL3, IGF, mIL3, SCF (see 2.2.4, 2.3.3) 
Thrombopoietin (gift from Amgen Inc, Seattle, USA)
TPA tetradecanoyl phorbol-myristate acetate (Calbiochem)
2.6.2 Protein lysates
At the designated time point cells were recovered, centrifuged at 2000 rpm/400g for 3 
mins, washed in 1ml PBS then centrifuged at 2000 rpm for 3 mins again. The liquid 
phase was removed and the cell pellet suspended in 40ul ice cold lysis buffer and 
incubated on ice for 10-60 mins (Lysis buffer: Tris pH 7.5 50mM, NaCl lOOmM, 
Triton X-100 1% [X-IOO-RS], DDW & serine protease cocktail 1:100 [P8340, Sigma- 
Aldrich]). Samples were then centrifuged at 14,000 rpm for 10 mins at 4°C. The 
liquid phase was aspirated to a fresh tube and lOul 5 x sample buffer added (5 x 
Sample buffer: 0.5M Sucrose, 15% Sodium dodecyl sulphate, 312.5mM Tris pH 6.9, 
lOmM FDTA, 0.05% Beta-mercaptoethanol & 0.0025% Bromophenol blue [Sigma- 
Aldrich]). Samples were boiled for 5 mins then stored at -20°C pending 
electrophoresis.
2.6.3 Sodium dodecyl sulphate -  polyacrylamide gel electrophoresis (SDS- 
PAGE) & nitrocellulose transfer
Gels were prepared at 10%, 7.5% or 12.5% polyacrylamide concentration using the 
following components (DDW, IM Tris pH 8.8 (pH 6.8 for stacking gel), ProtoGel 
(A2-0072, Geneflow Ltd), Sodium Dodecyl Sulfate (L4509, Sigma-Aldrich), 
Ammonium Persulfate (A3678, Sigma-Aldrich), TFMFD (T9281, Sigma-Aldrich). 
The separating gel was prepared and poured into a Mighty-Small Hoefer gel caster 
(Hoefer scientific instruments). Isobutanol was layered on top and the gel was 
allowed to polymerise at room temperature. The isobutanol layer was then removed 
and rinsed off with DDW. A stacking gel was prepared, layered on top and a 10 or 20 
well comb inserted. Once set the comb was removed and the wells rinsed to remove
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unpolymerised acrylamide with 1 x Running buffer (10 x Running buffer: Tris 30.3g, 
Glycine 144.2g, SDS lOg & DDW 1 litre). The gels were then transferred to the 
running apparatus.
One sample well was loaded with pre-stained molecular size marker (S6-0028 
ProtoMarkers, Geneflow Ltd) with equal volumes of sample lysate in each subsequent 
well (approximately 0.3 x 10  ^lysed cells per point). Gels were electrophoresed 
through Ix Running buffer using Hoefer gel apparatus at 150V until adequate 
separation had occurred. Gels were transferred using a semi-dry blotter (TE77 PWR, 
Amersham Biosciences) over 1 hour at a constant current of 0.8 amps with Ix 
Transfer buffer (10 x Transfer buffer: Tris 30.3g, Glycine 144.2g, Methanol 100ml & 
DDW 1 litre) onto Hybond-C Extra nitrocellulose membranes (RPN82E, GE 
Healthcare Life Sciences). Following transfer, membranes were blocked using 5% 
dried non-fat milk (Marvel) in PBST (PBS 4-0.1% Tween-20 [P5927, Sigma-Aldrich]) 
for 1 hour then washed 3 times in PBST prior to incubation with primary antibodies.
2.6.4 Primary antibodies & incubation
Primary antibodies were made up according to manufacturers’ instructions in PBST 
with 5% Bovine serum albumin (Sigma-Aldrich). Where phospho-specific antibodies 
were used membranes were incubated overnight at 4^C. For other antibodies 
incubation was for 1-4 hours at room temperature.
The following Phospho-specific antibodies were used:
Phospho-Akt (Ser 473) 
Phospho-Akt (Thr 308) 
Phospho-Akt (Ser473)
Phospho GSK3 a/b (Ser 21/9) 
Phospho p44/42 (Thr202/Tyr204) 
Phospho Stat 5 (Y694)
Phospho Jak 2 (Y1007/1008) 
Phospho Stat 3 (Tyr 705)
Phospho Stat 1 (Tyr 701)
9271, Cell Signalling Technology
9275S, New England Biolabs
44-62IG, Biosource
933IS, Cell Signalling Technology
9211, Cell Signalling Technology
9351, Cell Signalling Technology
44-426G, Biosource
9131, Cell Signalling Technology
9171, Cell Signalling Technology
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Phospho P70S6 kinase (Thr389) 9205, Cell Signalling Technology
Phospho 8 6  ribosomal protein (Ser 235/236)221 IS, Cell signalling Technology 
Phospho RSKl (Thr359/Ser363) 04-419, Upstate Biotechnology Inc







S6  ribosomal protein
sc-13513, Santa Cruz Biotechnology Inc 
T-3526, Sigma
C-17, Santa Cruz Biotechnology Inc 
9272, Cell Signalling Technology 
C-14, sc-154, Santa Cruz Biotechnology Inc 
610154, BD Transduction Laboratories 
54D2, 2317, Cell Signalling Technology
PI 1 0  alpha 
PI 10 beta 
PI 10 gamma 
PI 10 delta
4254, Cell Signalling Technology
SC-603, Santa Cruz Biotechnology Inc
4252, Cell Signalling Technology
gift of Prof B. Vanhaesebroeck, Ludwig Institute
for Cancer Research, London
2.6.5 Secondary antibodies & chemiluminescent analysis
After incubation with primary antibody, membranes were washed 3 times in PBST, 
and incubated for 1 hour in 1 : 1 0 , 0 0 0  horseradish peroxidase conjugated anti-mouse or 
anti-rabbit immunoglobulin (NXA931, NA934V Amersham Biosciences UK Ltd) 
made up in PBST with 2% Marvel. After incubation with this secondary antibody, 
membranes were washed 3 times and protein bands detected by enhanced 
chemiluminescence (ECL Plus, RPN2132, GE Healthcare Life Sciences or EZ-ECL, 
20-500-120 Geneflow Ltd) as per manufacturers instructions. The nitrocellulose 




Exposed autoradiography films were scanned using an Epson Stylus Photo RX620 
scanner and densitometry performed with ImageJ software for PCs downloaded from 
the NIH website (rsb.info.nih.gov/ij/download.html)
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2.7 Microarravs
Gene expression profiling of erythroblasts was performed using Affymetrix U133a 
GeneChips according to the Affymetrix standard protocols represented in Figure 2[2] 
and detailed in the following sections. Fourteen GeneChips were performed in total. 
Of these 14, 6  were from patients with PV (2 homozygous, 4 heterozygous for V617F 
JAK2), 4 were from patients with IE and high / normal serum erythropoietin & 4 were 
from normal volunteers.
Figure 2[2]: Flow chart indicating processing steps to microarrays
(steps according to standard Affymetrix protocols for U133a GeneChips)
RNA extraction from >95% pure erythroid 
prngenitnrF^ usin] thft OiAQen Mni Kit
R everse  transcription & sy n th es is  of double-stranded  
DKA using S  jperscript Choir A Cystmm
i
DNA clean up using P h a s e  Lock C els
In vitro transrnption ü biotirylatinn using tho 
B icArray High Yield RNA Transcript Labe ing K it
i
Quality control usi ng the Agilent B ioanalyser
i
hybridization tc Human Genome U133a GeneChip Arrays using 
the Affym etrix Hybridization control Kit
i
Staining I W ashing f Scanning / Data analysis
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2.7.1 RNA extraction Qiagen method
RNA was extracted from Day 9 erythroid precursors where >1 x 10  ^cells of >95% 
purity as assessed by morphology and immunophenotyping had been produced. RNA 
was extracted using the RNeasy Mini Kit (74104, Qiagen) using sterile equipment and 
according to the manufacturers’ instructions. Samples were centrifuged at 1300 rpm 
for 5 mins and washed with 1.5ml PBS. Cells were vigorously lysed in 350ul RLT 
buffer with added beta-mercaptoethanol and 70% ethanol was added for RNA 
precipitation. This solution was passed down an RNeasy mini column by brief 
centrifugation at 13,000 rpm and the column was washed with R W 1 and RPE buffers. 
RNA was recovered into 30ul DDW in a clean tube. Quantity and quality were 
assessed by spectrophotometry using the Gene Quant pro (Amersham-Pharmacia) and 
suitable samples (A260/A280 = 1.9-2.1) were stored at -lOPc pending further 
processing.
2.7.2 Reverse transcription & double-stranded cDNA synthesis
Double stranded DNA was produced from RNA using the Superscript Choice System 
(18090-019, Invitrogen) using sterile equipment & according to the manufacturer’s 
instructions as outlined here: Five micrograms of RNA was added to luL  Affymetrix 
generic primer in DDW to achieve a final volume of 20ul and this sample was 
incubated for 5 minutes at 70°C. Cooled samples were mixed with 4ul 5 x first strand 
cDNA buffer 4- 2ul O.IM DTT 4- lul lOmM dNTP and heated to 42^C for 2 mins. 
Superscript II reverse transcriptase lul was then added and reverse transcription was 
allowed to proceed at 42^C for 1 hour. The single stranded cDNA was then cooled 
prior to further processing.
Double stranded cDNA was then synthesised as follows: The single stranded cDNA 
product was mixed with 9 lul water 4- 30ul 5 x second strand reaction buffer 4- 3ul 
lOmM dNTP mix 4- lul E. coli DNA ligase (lOU/ul) 4- 4ul E. coli DNA Polymerase I 
(lOu/ul) 4- lul E. coli Rnase H (2u/ul) and placed in a 16°C cooling incubator for 2 
hours. T4 DNA Polymerase 2ul was added and samples were incubated at 16°C for a 
further 5 mins. EDTA 0.5M lOul was then added to block enzyme activity and 
samples were stored at -20^C prior to clean-up.
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Double-Stranded cDNA was cleaned with use of Phase Lock Gels (Eppendorf): 
Double stranded cDNA was mixed with 162ul of 25:24:1 Phenol : Chloroform: Isoamyl 
alcohol (saturated with lOmM Tris-Hcl ph 8.0, ImM EDTA). Mixed samples wre 
loaded onto Phase Lock Gels which had been pelleted at 12,000 rpm for 30 secs and 
subsequently centrifuged at 12,000 rpm for 2 mins. The residual aqueous upper phase 
was then transferred to a clean tube.
Ethanol precipitation of cDNA was performed by mixing in 0.5 volumes 7.5M 
NH4OAC and 2.5 volumes absolute ethanol (stored at -20^C) with 0.5ul Glycogen (for 
visualization of the pellet) and centrifugation at 12,000 rpm for 20 mins. The cDNA 
pellet was carefully washed twice with 80% ethanol (stored at -20°C) with 
centrifugation at 12,000 rpm for 5 mins in between each wash. The air dried pellet of 
ds-cDNA was then suspended in 12ul RNase-free water and stored at -20°C.
2.7.3 In vitro transcription of ds-cDNA, biotinylation & cRNA fragmentation
In vitro transcription (IVT) to produce biotinylated cRNA was performed using the 
BioArray High Yield RNA Transcript Labeling Kit (42655, Enzo) as per 
manufacturer’s instructions. Five microlitres of ds-cDNA in solution was added to 4ul 
each of Tubes 1-4 4- 2ul Tube 5 & 18ul DDW. Samples were mixed & incubated at 
37^C for 5 hours.
Half of the biotinylated IVT product was then purified using the Qiagen RNeasy Mini 
Kit: Twenty microlitres of biotinylated cRNA was mixed with 80ul sterile water and 
350ul RLT buffer (containing lOul fresh beta-mercaptoethanol / ml buffer) and 250ul 
100% ethanol. The mixture was loaded onto a mini column and briefly centrifuged at 
12,000 rpm. The column was washed twice with RPE buffer and the cRNA then 
eluted into 25ul DDW by centrifugation at 12,000 rpm for 1 minute. The quantity and 
quality of the product was checked by spectrophotometry as previously and quantity 
was adjusted for RNA input using the formula:
Adjusted cRNA = RNA post IVT -  (RNA starting dose) x 5/24
61
Twenty micrograms of the biotinylated cRNA in solution was mixed with 2ul of 5 x 
fragmentation buffer for each 8 ul of cRNA and made up to 40ul with sterile water. 
The mixture was incubated at 94°C for 35 mins then stored at -20°C after adequate 
fragmentation had been verified by running a small quantity of the product on an 
agarose gel.
2.7.4 Quality control procedures and microarray hybridisation
Once all 14 samples of fragmented biotinylated cRNA had been derived for the study, 
( 6  patients with PV, 4 patients with IE and 4 normal control subjects), fragmented 
cRNA samples were sent to the MRC Gene Service for quality control (QC) checks 
and hybridisation. QC procedures were carried out using the Agilent bioanalyser. 
Three samples were subsequently prepared for hybridization using the Affymetrix 
hybridization control kit and hybridized to Test3 GeneChip arrays for 16 hours. 
Following hybridization the GeneChip arrays were stained and washed on the fluidics 
station and then scanned. At a later date all samples were prepared for hybridization 
using the Affymetrix hybridization control kit and hybridized to Human Genome 
U133a GeneChip arrays for 16 hours. Following hybridization the GeneChip arrays 
were stained and washed on the fluidics station and finally scanned.
U133a GeneChips were produced by Affymetrix following publication of the draft 
Human Genome data. With over 500,000 distinct oligonucleotide features and 
>2 2 , 0 0 0  probe sets a single array can be used to comprehensively assess gene 
expression including that of 14,500 well characterised human genes. The accurate 
statistical assessment of output data is complex given the large number of variables. 
Data from the 14 arrays studied in this project was supplied by the MRC Gene 
Service via web-based access directly to a University College London specialized 
biostatistician (Stephen Henderson) for analysis.
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2.8 Proliferation and apoptosis
2.8.1 Cell viability as assessed by MTS
The MTS assay (CellTiter 96 Aqueous one Solution Cell Proliferation Assay, G3580, 
Promega) indirectly measures total viable cell number by evaluating dehydrogenase 
enzyme activity found in metabolically active cells. This assay was used to compare 
viable cell numbers between aliquots of identical cells (Day 9 erythroid precursors or 
specified cell lines) incubated under variable conditions to give a quantitative measure 
of relative cell survival.
The selected cells were washed 3 times in sterile PBS and resuspended in IMDM +
5% BIT or RIO at a density of 1-2 x lOVml. Two hundred microlitre aliquots were 
added to a flat-bottomed 96 well tissue culture plate with one well containing medium 
only as a colorimetric baseline. Viable cell number under differing circumstances was 
evaluated by adding different concentrations of cytokines and / or inhibitors to each 
well with duplicates or triplicates of each experimental point. Plates were incubated at 
37^C, 5% CO2 overnight or for longer where specified. MTS reagent (20ul) was then 
added to each well and colorimetry evaluated at 1-8 hours using Anthos 2001 (Anthos 
Labtec Instruments) with STINGRAY software. Derived data was exported into Excel. 
The mean of replicates was calculated after adjustment for background exposure 
(medium, no cells) and appropriate curves were constructed.
2.8.2 Apoptosis by Annexin V, Propidium Iodide and FACS
Cells were selected to allow 5 x 10"^  / experimental point. Cells were washed 3 times 
in sterile PBS and resuspended in 0.5ml IMDM -1- 5% BIT or RIO with or without 
added cytokines or inhibitors at 37^C, 5% CO2 for 6  hours to overnight.
When incubation was complete, a mixture of 200ul Annexin V buffer (lOmM HEPES 
pH 7.4, 140mM NaCH, 5mM CaCH 4- DDW) + 15ul Annexin V Fluos (1828681, 
Roche) -I- 15ul Propidium Iodide solution (P4864, Sigma-Aldrich) was made up and 
lOul of this was added to each test sample. These samples were then incubated on ice
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for 10 mins-1 hour. Flow cytometry was performed (Epics Elite, Beckman Coulter, 
High Wycombe, UK) to assess for the percentage of viable cells, early apoptotic cells 
(Annexin V positive only) and dead cells (Annexin V & PI positive).
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CHAPTER 3 -  RESULTS 1
Defining a cohort o f patients with true or apparent 
polycythaemia & characterising normal and aberrant
erythropoiesis in vitro
3.1 Defining a cohort of patients with elevated haematocrit
During the 3 years of the study several hundred new patients with an elevated 
haematocrit were referred to the the Polycythaemia Clinic at UCLH. I saw all new 
patients and continued the care of the patients already in the clinic. The information 
presented in this chapter is derived from these patients. All patients with a suspected 
diagnosis of Polycythaemia Vera (PV) underwent research analysis during the study 
period. Material from other patients and normal controls was collected for 
comparative purposes. Research findings were discussed with patients and entered 
into their clinical notes.
3.1.1 Clinical information and standard laboratory data
Full clinical data was available on 62 patients with true polycythaemia, 4 patients with 
pseudopolycythaemia (Ps) and compared with 10 normal individuals. Of the 62 
patients with true polycythaemia, 27 met the Polycythaemia Vera Study Group 
(PVSG) diagnostic criteria for PV. [Pearson et al, 1996] Of the 35 remaining patients 
11 were classified as having Secondary Polycythaemia (SP) with a recognized 
primary medical cause for a polycythaemic state. The 24 remaining patients were 
classified as having Idiopathic Erythrocytosis (IE). Some of the individuals with SP 
and IE appeared to spontaneously remit during the study period in that they became 
independent of venesection for haematocrit control. In the PV group 1 heavy smoker 
died of pneumonia aged 85 and 1 patient went on to develop Acute Myeloid 
Leukaemia.
Disease-specific drug therapy for all patients was based on clinical guidelines 
[McMullin et al, 2005] but adapted to individual circumstances and preferences.
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Actual treatment is shown in Table 1[3]. Other diagnoses including hypertension (HT), 
elevated lipids (lipids), diabetes mellitus (DM) and gout are shown in Table 2[3].
Table 1[3]: Disease-specific drug therapy of the patient cohort
(numbers of patients shown, +HC = also on Hydroxycarbamide, in the Aspirin group*
1 patient ceased aspirin due to complications, ** 1 patient changed to clopidogrel due 
to complications with aspirin)
Aspirin Warfarin
Total alone +HC alone +HC
Polycythaemia Vera 27 8 5* 1 2
Idiopathic erythrocytosis & 
Secondary polycythaemia
35 11** 7 0 0
Pseudopolycythaemia 4 2 0 0 0
Table 2[3]: Other drug therapy of the patient cohort
(numbers of patients shown receiving drugs to treat the indicated conditions, HT 
hypertension. Lipids = elevated lipids, DM = Diabetes Mellitus)
Total HT Lipids DM Gout
Polycythaemia Vera 27 8 3 2 3
Idiopathic erythrocytosis & 
Secondary polcycythaemia
35 4 3 2 3
Pseudopolycythaemia 4 4 2 0 0
Of the 27 patients with PV, 3 had had an arterial vascular event and 4 a venous 
thrombosis. Of the 35 patients with lE/SP, 6  had had an arterial and 5 a venous event. 
Two of the pseudopolycythaemics had had an arterial event, none had had a venous 
event. Two in each of the PV and lE/SP groups had an unconjugated 
hyperbilirubinaemia. Three patients in the PV group and 1 in the lE/SP group had a
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family history of polycythaemia or thrombocythaemia. One patient in each of these 
groups had a family history of venous thromboembolism.
Of the 27 patients with PV, 13 had splenomegaly, either diagnosed on abdominal 
ultrasound scan, or mildly-moderately clinically palpable. In the lE/SP group 1 patient 
had mild splenomegaly and 1 had had a splenectomy for massive splenomegaly 
following a portal vein thrombosis in pregnancy (this patient was subsequently shown 
to be a compound heterozygote for the G20210A Prothrombin gene mutation & for 
Protein S deficiency).
Routine laboratory investigations are shown in Table 3 [3]: Only high white cell count 
(WCC) and platelet count (Pit) were predictive of PV in this cohort. Serum 
Erythropoietin was only available for 9 patients with PV & was subnormal in 4 and 
low normal in 5. One patient who had borderline polycythaemia (red cell mass 
elevated but not at threshold) subsequently developed PV and went from a normal to a 
subnormal serum erythropoietin. In the lE/SP group 23 had normal, 4 had high and 
none had subnormal serum Erythropoietin.
Table 3[3]: Routine laboratory investigations
(numbers of patients shown. High B12 = serum B12 above the upper end of the 
normal range. Urate = serum urate, WCC = white cell count. Pit = platelet count)
Total High B12 High Urate High WCC High Pit
Polycythaemia
Vera





35 5 4 2 0
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3.1.2 Erythropoietin independent colonies (EECs)
Erythroid colonies grown in the presence of erythropoietin are easily identifiable by 
light microscopy. The erythropoietin-independent colonies which are characteristic of 
PV are much harder to identify as shown in Figure 1 f3] as they are considerably less 
numerous, smaller and less well haemoglobinized than their erythropoietin-replete 
counterparts. Where there was any doubt as to the presence or absence of EECs, 
culture plates were reviewed by an independent assessor and/or repeated on 
subsequent peripheral blood samples if possible.
Of the 27 patients with PV 25/27 (93%) had positive erythropoietin independent 
colonies (1 equivocal, 1 not done). Of the 35 patients with IE or SP none had positive 
EECs. Fourteen control subjects including 10 normal individuals had negative EECs. 
In 27 experiments where EECs were positive, the mean total numbers of erythroid 
colonies formed were 10 (no Epo) and 54 (Epo 2iu/ml). Thus EECs represented 19% 
of erythroid colonies in subjects with PV.
Figure 1[3]: Erythroid colonies from a patient with PV in the presence and 
absence of erythropoietin
(tissue culture plates showing both erythroid & non-erythroid colonies. Erythropoietin 
independent colonies are small and less well haemoglobinized as indicated within the 
red circles in b)
a] added erythropoietin b] no erythropoietin (EECs)
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In order to confirm that the presence of EECs in PV was not just due to an increased 
relative proportion of committed erythroid progenitors in mononuclear cell input, data 
from 80 EEC assays (including 33 PV, 37 IE & 10 normals) looking at maximal 
added erythropoietin only, was analysed. The mean number of erythroid colonies 
(BFUe & CFUe) and myeloid colonies (GM-CFU) was calculated and the results of 
this calculation are portrayed in Figure 2[3].
Figure 2[3]: The mean number of erythroid and myeloid colonies & the 
erythroid : myeloid ratio from 80 assays (33 PV, 37 IE & 10 normals)
(IxloVm l mononuclear cells derived from peripheral blood were put into semi-solid 
medium with erythropoietin 2iu/ml, erythroid [BFUe & CFUe] and myeloid [GM- 
CFU] colonies were counted at Day 14 and mean values by diagnosis [PV = 
polycythaemia vera, IE = idiopathic erythrocytosis, N = normals] are shown here 
together with the erythroid : myeloid ratio)
Erythroid & myeloid colonies





This data shows that significantly more erythroid colonies were formed from the PV 
and IE patients than the normal subjects but that there was no difference in 
erythroid:myeloid colony ratio between these groups. This confirms that whilst 
erythroid colony formation is increased in the PV and IE groups, it is not an excess of 
erythroid progenitors in PV that induces the formation of the EECs seen in this 
disease.
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3.1.3 V6I7F JAK2 screening
Screening for V617F JAK2 was performed as described in 2.4.6 by PCR of 
neutrophil-derived DNA using a mismatched primer which introduced a cutting site 
into wild type JAK2 for the restriction enzyme Afl III. Products were resolved by 
agarose gel electrophoresis and representative samples are shown in Figure 3[3]. Of 
the 27 patients with PV, 25/27 (93%) expressed V617F JAK2 with 5 (20%) showing 
homozygous expression of the mutant form. All of the 35 patients with IE or SP & the 
14 control subjects were wild type for Jak 2. Patients expressing V617F JAK2 are 
designated as ‘Myeloproliferative disease’ as the mutation is not specific for PV.
Figure 3[3]: PCR products for wild type and V617F mutant Jak 2
(homozygous / heterozygous mutant = V617F JAK2, normal = wild type JAK2)
Mutant Jak 2 ^  
Normal Jak 2 ►
Homozygous Heterozygous Normal
Myeloproliferative disease Idiopathic erythrocytosis Secondary polycythaemia 
Pseudopolycythaemia
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3.1.4 PRVI mRNA expression
Detection of upregulated PRVl mRNA expression was assessed semi-quantitatively 
by reverse transcription of neutrophil-derived RNA followed by simultaneous PCR of 
PRY 1 and GAPDH as described in 2.4.4. Results were categorized into 3 groups with 
marked, mild or no upregulation of PRVl as shown in the examples of Figure 4[3].
Of the 27 patients with PV 24/27 (89%) had marked upregulation of PRY 1 mRNA. 
Of the 3 remaining patients with PV, 2 had mild upregulation of PRY 1 and 1 patient 
was not assessed for PRVl expression. None of the 35 patients with IE or SP had 
marked upregulation of PRVl expression but 6  had mild upregulation .Of the 14 
control subjects, only 1 had mild upregulation of PRVl.
Figure 4[3]: Semi-quantitative evaluation of PRVl mRNA upregulation
(upper band corresponds to PRY 1 product, lower band to GAPDH product, increased 




3.1.5 Screening for Chuvash Polycythaemia
Sixty seven patient samples including 26 patients with PV were screened for the 
Arg200Trp VHL mutation described in hereditary Chuvash Polycythaemia. Screening 
for the mutation was performed as described in 2.4.5 by PCR of neutrophil-derived 
DNA. Use of the BSRBl restriction enzyme with this methodology resulted in 
digestion of the wild type but not the mutant. Agarose electrophoresis of 
representative products is shown in Figure 5[3]. One of these 67 samples, derived 
from a patient with unmutated V617F JAK2 and polycythaemia secondary to 
carcinoma of the larynx, showed heterozygosity for the Chuvash mutation which was 
confirmed by sequencing as shown in Figure 6[3]. A further sample from a patient 
with new onset PV screened positive for the mutation but sequencing of the VHL 
gene showed that this was a false positive.
Figure 5[3]: Mutational screening for Chuvash Polycythaemia
(PCR products resolved by agarose electrophoresis, HET = heterozygous for 




Figure 6[3J: Sequencing plot from a patient heterozygous for Chuvash 
Polycythaemia
(arrow shows heterozygous expression at the mutation site due to a single point 









3.2 Liquid culture of erythroblasts
3.2.1 Optimisation of methodology
Throughout the study some patient samples had to be discarded due to technical 
sampling issues with venesection as described in 2.1.3 which led to clot formation in 
the venesection pack. This was a particular problem in patients with PV although it 
also occurred in samples from other patients. An issue specific to PV was that 
samples often had residual platelets after a single manual removal step so a 2 -step 
approach (using Ficoll & Clinimacs Buffer together with slow centrifugation) was 
ultimately adopted for all samples.
In samples from patients with PV in whom the concentration of immature circulating 
granulocytes was high, Ficoll separation on Day 0 was sometimes suboptimal. In 
these circumstances 2  approaches were adopted depending on the microscopic 
appearances: if there was excessive granulocytic contamination early on, the liquid 
culture was subject to repeat separation on a Ficoll gradient between Days 0-6. If 
there were still viable granulocytic cells at Day 6 , anti-CD 15 -  conjugated microbeads 
were introduced into the negative selection cocktail described in 2 .2 . 2  as per 
manufacturer’s instructions (130-046-601, Miltenyi Biotec).
At the start of the study methodology was adapted to optimise the cellular yield of the 
protocol but minimize contamination with non-erythroid cells. A positive selection 
strategy from the outset initially seemed more attractive. Unfortunately an early 
positive selection approach using CD34 selection ‘up front’ on patient samples 
ultimately gave low numbers of erythroblasts with up to 2 0 % contamination with 
non-erythroid myelomonocytic precursors at the end of the culture period. This was 
not a problem when large numbers of CD344- mobilized cells were used but was a 
limiting factor for therapeutic venesection products containing low numbers of 
progenitor cells. A negative selection strategy ‘up front’ likewise gave limited cellular 
yields from patient packs.
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Attempts at a delayed positive selection strategy were confounded by the poor 
specificity of any single marker for early erythroblasts: CD36 is considered a valuable 
erythroid marker but when mononuclear cells at Day 6  of culture were selected for 
CD36 there was heavy platelet contamination as this marker is also expressed on 
platelets. Most of the erythroblasts were CD36+, however, a significant number of 
erythroblasts were lost in the CD36- fraction as shown in Figure 7[3] [a & b]. 
Likewise, the transferrin receptor, CD71, is known to be strongly expressed on 
erythroblasts but positive selection for CD71 gave a similar problem with 
macrophages as shown in Figure 7[3] [c & d].
Figure 7[3]: Cytospins of CD36 and CD71 selected mononuclear culture
(CD36 positive fraction is heavily contaminated with platelets, some erythroblasts 
were lost in the CD36 negative fraction [a & b], CD71 positive fraction is heavily 
contaminated with macrophages and numerous erythroblasts were lost in the CD71 
negative fraction [c & d]
a] CD36 positive b] CD36 negative




d] CD 71 negative
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In some samples (mainly from patients with PV) there was persistent macrophage 
contamination after negative selection at Day 6  which could not be corrected by 
immediate reselection. Residual macrophages were removed in these circumstances 
by 2 methods on Day 7/8: Negative selection using anti-CD 14-conjugated microbeads 
only or adherence depletion. Adherence depletion was achieved by laying the tissue 
culture flask on its side for 1 hour and then aspirating non-adherent cells to a clean 
flask. This was then repeated as necessary.
One normal individual with an exacerbation of asthma had excessive eosinophil 
contamination at Day 9 and the sample had to be discarded. Following this, more 
careful attention was paid to take normal samples from volunteers who were 
completely well. Despite the high initial eosinophil and basophil counts in peripheral 
blood of some patients with PV, contamination of Day 9 cells with these cell types 
was <2% in PV patients.
There were intermittent problems with infected cultures in the laboratory. Samples 
which showed evidence of infective contamination were immediately discarded. No 
antibiotics were added to the primary culture systems as it was felt this might 
prejudice interpretation of results.
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3.2.2 Erythroblast morphology
All samples were morphologically assessed at Day 9 (or sooner if indicated by non­
hom ogeneity of the cellular culture on microscopy). Some patients showed dysplastic 
features in derived basophilic erythroblasts but overall there was no significant 
morphological difference between patient samples. A representative cytospin is 
show n in Figure 8[3].
Figure 8[3]: The morphological appearance of Day 9 erythroblasts after cytospin 
and staining with MGG
(M ay-Grumwald-Giemsa staining shows characteristic basophilic erythroblasts with 




3.2.3 Erythroblast immunophenotype as assessed by flow cytometry
By Day 9 the viable cellular population was >90% erythroblasts by morphology 
(>95% for microarrays & 80-90% for erythroblasts derived from CD34-t- progenitors). 
Figure 8[3] shows representative plots from one sample. The majority of erythroblasts 
were CD36-t- with low/intermediate mean fluorescence intensity. C D 71 was expressed 
in nearly all erythroblasts with high mean fluorescence intensity. CDl 17 was weakly 
expressed in a minority of erythroblasts. Glycophorin A was expressed at an 
intermediate level in approximately half of the cells. However, there was a spectrum 
of expression for this antigen.
Forty-three separate samples of day 8-10 erythroblasts were immunophenotyped. 
These 43 included 21 with PV ( 6  homozygous, 15 heterozygous V617F JAK2), 14 
with DE, & 8  normal controls. Mean percentage positivity for each marker was 
calculated and these results are shown in Figure 10[3]. Similar results were noted 
when data was assessed by mean fluorescence intensity: There was no significant 
difference in immunophenotype between erythroblasts generated from peripheral 
blood either by diagnosis or by JAK2 status.
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Figure 9[3]: Flow cytometric plots of Day 9 erythroblasts from a patient with IE 
after incubation with a] CD36-FITC + Ig-PE, b] CD71-FITC + CDl 17 PE, c] Ig- 
F1ÏC + Glycophorin A-PE











Figure 10[3J; Flow cytometric findings from 43 separate patient-derived samples 
according to diagnosis
(includes 6  patients with PV homozygous for V617F JAK2 [HOMJ, 15 patients with 
PV heterozygous for V617F JAK2 [Het], 15 patients with IE & 8  normal samples all 
wild type for JAK2, percentage positivity for GpA [Glycophorin A], CD36, CDl 17 & 
CD71 shown with calculated standard error of the mean)
8Û.









Immunophenotyping of Day 13 cells in 7 samples (2 PV, 2IE, 3 normals) also showed 
no difference between PV and controls (data not shown).
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3.2.4 Erythroid colony-forming potential of basophilic erythroblasts
In order to establish the erythroid colony-forming potential of the cultured cells, 
mononuclear cells derived from 6  normal peripheral blood samples were put into 
standard colony assays on days 0, 1, 2, 3, 4, 6 , 8 , 9 & 10 of in vitro liquid culture 
(IxloVm l pre-selection & IxlO'^/ml post Day 6  negative selection). Erythroid 
colonies were enumerated after a further 14 days of culture in semi-solid medium and 
designated as BFUe (Burst-forming unit-erythroid; single or multiple clusters 
containing >200 immature erythroid progenitors) or CFUe (Colony-forming unit- 
erythroid; 1 - 2  cell clusters of 8 - 2 0 0  mature erythroid progenitors).
Averaged results from these assays are shown in Figure 11[3]: Erythroid colonies 
were formed from assays set up on cells up to and including day 1 0  of liquid culture. 
Erythroid colonies were predominantly BFUe from assays set up on cells up to Day 4 
of liquid culture and increasingly CFUe thereafter although occasional BFUe were 
produced from assays set up from cells at Day 10 of liquid culture. Images of 
representative colonies are shown in Figure 12[3].
Figure 11[3J: The relationship between BFUe & CFUe according to the number 
of days of liquid culture
(Mean number of colonies derived from cells taken from liquid culture on the 
specified days and plated into semi-solid colony assays, BFUe = Burst forming unit 
erythroid, CFUe = Colony forming unit erythroid)










Figure 12[3J: Erythroid colonies from mononuclear cells in liquid culture
(images of colony plates after 14 days of semi-solid culture taken from liquid culture 







Anticoagulated peripheral blood from 134 samples (13 homozygous for V617F JAK2, 
38 heterozygous for V617F JAK2, 83 wild type for JAK2 including 52 from patients 
with lE/SP, 7 from patients with Pseudopolycythaemia & 24 from normal controls) 
was separated to obtain mononuclear cells as described in 2.2.2. The cellular yields 
per ml of anticoagulated blood are shown in Figure 13[3] and suggest a trend towards 
higher cell number according to V617F level. Median values x 10  ^ for cellular yields / 
ml were 0.28 (homozygous), 0.23 (heterozygous) and 0.16 (wild type).
Figure 13[3]: The number of mononuclear cells (xlO )^ per ml derived from 
anticoagulated peripheral blood by JAK2 status
(the mean number of mononuclear cells harvested per ml of venesected blood is 
shown & includes samples from individuals with PV expressing homozygous V617F 
JAK2 [HOM], heterozygous V617F JAK2 [HET] and samples from patients with 
lE/SP or normal controls expressing wild type JAK2 [WT], calculated standard error 
of the mean shown)







Overall, a higher number of erythroblasts were obtained after in vitro culture using 
samples from patients with PV compared with patients with lE/SP or from normal 
controls although there was considerable variation between individuals. Erythroblast 
counts from 81 venesection packs were available at Day 9 of in vitro culture (44 PV;
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8 Homozygous V617F JAK2, 36 Heterozygous V617F JAK2, 30 lE/SP & 7 Normal 
subjects all expressing wild type JAK2). Values have not been corrected for pack 
volume or quality. Results are shown in Figure 14[3J.
Figure 14[3]: Erythroblast yields from 81 venesection packs after 9 days of in 
vitro culture according to JAK2 status
(number in millions of erythroblasts at D9 including 44 PV with V617F JAK2 [8 
HOM = homozygous, 36 Het = heterozygous, 30 lE/SP [WT = wild type] & 7 
normals [N], calculated standard error of the mean shown]








HOM Het WT N
Jak2 status
For 59 samples there was numerical data for both the mononuclear cells harvested on 
DO and the erythroblasts derived at D9 of in vitro culture. The averaged results are 
shown in Figure 15[3] and suggest that homozygous, but possibly not heterozygous, 
expression of V617F JAK2 may confer a proliferation advantage over normal controls.
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h
<• Figure 15[3J: The proportion of mononuclear cells which went on to form 
erythroblasts
(ratio of the numbers of D9 to DO cells shown from 59 subjects including 29 with PV 
& V617F JAK2 expression [6 homozygous], 25 subjects with lE/SP & 5 normals [all 
wild type for JAK2], calculated standard error of the mean shown)















3.2.6 Resistance of PV erythroblasts to erythropoietin deprivation
It is well established that a proportion of circulating progenitor cells in patients with 
PV have potential to form erythroid colonies in the absence of erythropoietin (EECs). 
There is currently no data in the scientific literature to show whether resistance to 
factor deprivation is a feature of maturing erythroblasts in patients with PV.
Twenty four separate experiments (14 PV, [2 homozygous, 12 heterozygous V617F 
Jak 2] 8 IE & 2 normals [all wild type JAK2] were performed using Day 9 
erythroblasts. The methodology for this is described in 2.8.2. In brief, this involved 
comparison of the viable cell number of erythroblasts which had been either washed 
free of cytokines and deprived of erythropoietin or cultured in the presence of 2iu/ml 
erythropoietin overnight.
Erythroblast viable cell number was assessed colourimetrically after addition of MTS 
reagent and viable cell number ratio of erythropoietin-deprived / erythropoietin- 
replete samples was calculated. The averaged results from these experiments are 
shown in Figure 16[3].
These findings clearly illustrate that maturing erythroblasts from patients with PV are 
relatively resistant to factor deprivation and that this resistance may be greater where 
expression of V617F JAK2 is homozygous.
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Figure 16[3J: Relative erythroblast viable cell number with erythropoietin 
deprivation as assessed by MTS assay in 24 separate experiments
(the ratio of viable ceils without erythropoietin to viable cells with erythropoietin is 
shown, samples include 14 patients with PV; 2 homozygous [HOM] & 12 
heterozygous [HET] for V617F JAK2 and 10 samples from subjects expressing wild 

















3.2.7 Apoptosis as assessed by Annexin V, Propidium Iodide & FACS
Nine preliminary experiments (2 PV, 3 IE, 4 normals) were performed to assess 
resistance to apoptosis with a range of doses of erythropoietin and or SCF. The 
methodology for this is described in 2.8.3. In brief, D9 erythroblasts were washed to 
remove residual cytokines and incubated overnight with or without added 
erythropoietin and/or SCF at a range of doses. The following day cells were stained 
with Annexin V-FITC & Propidium Iodide (PI) and counted by flow cytometry after 
cellular debris had been excluded by gating. The percentage of viable cells which 
were negative for both Annexin V and PI was calculated for each sample. Both 
erythropoietin and SCF prevented apoptosis in a dose dependent fashion & their 
effects were additive. No difference was noted between PV & control samples.
In order to confirm this finding, a larger number of samples were evaluated with 
cytokine deprivation or fixed high levels of added Erythropoietin or SCF: Thirty four 
separate experiments were performed (11 V617F+ PV; 4 homozygous, 7 
heterozygous for, 14 IF & 9 normals all wild type for JAK2). There was no 
significant difference in apoptosis between PV and control cells which had been 
deprived of erythropoietin or SCF (see Figure 17[3]).
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Figure 17[3]: Mean values from 34 experiments evaluating apoptosis in 
erythroblasts
(includes 11 PV [V617F JAK2], 14 IE & 9 normals [all wild type JAK2, viable cell 
numbers for cytokine deprived, + Erythropoietin, + SCF normalised to Erythropoietin 
+ SCF, standard error of the mean shown]
Apoptosis with SCF & Epo
^  120 











When V617F JAK2 was described in PV there was wide variation from 65-97% in the 
prevalence of the mutation between studies. [Vainchenker et al, 2005] This variance 
may have been due in part to the sensitivity of the screening technique or perhaps due 
to the use of different diagnostic criteria (PVSG or WHO) in the individual studies. In 
some cases the explanation subsequently found was an alternative mutation in JAK2. 
[Scott et al, 2007] Yet another explanation is that some stored samples from 
apparently V617F negative JAK2 patients were, in fact, from patients who never 
actually had PV but who had been assigned this label in the absence of another clear 
cause for polycythaemia at the time.
The work described in this thesis provides data on a significant number (62) of 
patients with true polycythaemia including 27 with Polycythaemia Vera. This cohort 
of patients was closely assessed and investigated throughout the study period by 
myself and clinical data was regularly reviewed. As a result, several patients who had 
previously been diagnosed with PV (no other cause for erythrocytosis was apparent at 
the time) were subsequently ‘undiagnosed’, and 1 patient with previous borderline 
erythrocytosis was later diagnosed with PV. I am therefore confident that the 
scientific data reported in this study corresponds to the correct clinical diagnosis in 
these patients.
The PV patients in this cohort were broadly comparable with the general PV 
population having an average age of 61.5 years with similar clinical and laboratory 
profiles to that described in the literature: All PV patients in whom serum 
erythropoietin was tested had low/normal levels and all of the non-PV patients had 
levels in the normal or high range. High white cell count and platelet count was 
strongly associated with a diagnosis of PV. EECs were positive in 25/27 patients with 
PV. Of the 2 remaining PV patients, 1 did not have EECs performed and in the other, 
results from a single colony assay were equivocal. EECs were not positive in patients 
with lE/SP or normal controls.
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A simple and robust method of screening for V617F JAK2 was used. The level of 
detection found with this method was consistent with this being a sensitive screening 
technique. Detection levels were comparable to the ARMS technique used in the 
study with the highest reported rate of V617F JAK2 positivity in PV (97%). [Baxter 
et al, 2005] Amongst the cohort of patients assessed in this study, 25/27 PV patients 
(93%) expressed V617F JAK2. One of the 2 negative results was from the patient 
with equivocal EECs who interestingly had a strong family history of probable 
myeloproliferative disease. Of the 25 patients expressing V617F JAK2, 20% showed 
homozygous expression which is comparable with the approximately 1/3 prevalence 
noted in published data.
The PRV-1 gene, a member of the uPAR receptor superfamily, was cloned and found 
to be associated with PV in 2000. [Temerinac et al, 2000] It was subsequently 
suggested that overexpression of this gene could completely separate PV from SP 
patients. [Klippel et al, 2003] Work done since this time has shown that PRV-1 can be 
upregulated in SP and that PRV-1 is not only homologous to N B l, (a gene 
overexpressed in reactive neutrophilia) but that both are alleles of the same gene now 
known as CD177. [Caruccio et al, 2006] PRVI upregulation cannot therefore now be 
said to be absolutely specific for PV. Despite these more recent findings, it is still 
clear that PRV-1 upregulation defines a similar cohort of MPD patients to those with 
positive EECs and those expressing V617F JAK2. [Goerttler et al, 2005]
Screening for upregulation of PRV-1 using a semi-quantitative approach in this cohort 
showed that 24/27 patients with PV had marked (& 2/27 had mild) upregulation of 
PRV-1 expression. None of the 35 patients with IE had marked (though 6 had mild) 
upregulation of PRV-1. These PV patients therefore also show a high degree of 
correlation between identification of marked upregulation of PRV-1 with positive 
EECs and presence of the V617F JAK2 mutation.
In 2003, a group of patients with polycythaemia in Chuvashia, Russia were found to 
be homozygous for a 598 C>T mutation in the Von Hippel Lindau (VHL) gene 
resulting in an Arg200Trp substitution in the protein. [Ang et al, 2002] Autosomal 
dominant mutations of VHL have previously been described in association with 
cancers but this 598 C>T mutation was found to be associated with polycythaemia
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and other clinical problems, but not with cancer. The pattern of inheritance for this 
mutation was recessive with only homozygotes being clinically affected. The VHL 
protein normally mediates proteosomal degradation of the a  subunit of hypoxia 
inducible factor 1 (HIF-1) during cellular normoxia. This mutation disrupts binding of 
the VHL protein resulting in an accumulation of HIF-1 a as normally occurs in cellular 
hypoxia. Chuvash polycythaemia is therefore a congenital disorder of oxygen sensing 
resulting in secondary polycythaemia and it is associated with elevated erythropoietin 
levels.
Following the original description, sporadic cases of Chuvash polycythaemia were 
reported around the world, [Percy et al, 2003; Bento et al, 2005; Perrotta et al, 2006] 
and elegant linkage analysis traced the mutation to a single founder effect which 
occurred from 1,000-62,000 years ago. [Liu et al, 2004] One of these reports included 
a Portuguese patient with heterozygous expression of the mutation who had 
polycythaemia in association with Ataxia-Telangiectasia. Other reports have 
identified alternative mutations in the VHL gene which may co-operate with the 
598C>T mutation to cause polycythaemia. [Ang et al, 2002]
In the UCH cohort, 67 patient samples of neutrophil derived DNA, including 26 with 
PV, were screened for the Chuvash mutation using a restriction digest approach. One 
patient who screened positive was found to have heterozygous expression of the 
mutant which was confirmed by sequencing. No other mutations were detected in his 
VHL gene. This was an unexpected finding in a Caucasian British man of 52 years 
who had presented with apparent polycythaemia which was presumed to be secondary 
to the carcinoma of the larynx for which he was being treated. This patient was also a 
lifetime heavy smoker and serum erythropoietin was just above the normal range at 
25.4 iu/1. The clinical relevance of the mutation in this case is unclear.
Work that has been published on the in vitro study of human erythroblasts includes 
cells which have been derived from mononuclear cells of the bone marrow, [Silva et 
al, 1998; Panzenbock et al, 1998; Myklebust et al, 2002; Ugo et al, 2004] from cord 
blood [Panzenbock et al, 1998], from cytokine mobilized progenitors [Somervaille et 
al, 2001] or from peripheral blood. [Wickenhauser et al, 2003; Dai et al, 2005,
Arcasoy et al, 2005; Zeuner et al, 2006] In all studies, following manual separation.
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mononuclear cells were cultured in a medium which preferentially enhanced erythroid 
growth. The culture medium components varied from study to study.
Some studies undertook selection of CD34+ stem cells ‘up front’. [Ugo et al, 2004; 
Myklebust et al, 2002; Wickenhauser et al, 2003; Dai et al, 2005, Zeuner et al 2006; 
Somervaille et al, 2001, Zermati et al, 2001, Bouscary et al, 2003] Others relied on the 
differentiating medium principle originally described in a study by Sawada et al [1987] 
to generate erythroblasts within a population of mononuclear cells. Five of these 
studies used a delayed positive selection strategy, 3 initially used CD34+ selection 
followed by delayed CD36+ selection, [Ugo et al, 2004; Zermati et al, 2001, Bouscary 
et al, 2003] One study initially used CD34+ selection followed by delayed CD 714- 
selection, [Myklebust et al, 2002] and a further study used no initial selection but 
delayed Glycophorin A selection. [Silva et al, 1998] Four studies did not use 
additional delayed selection. [Wickenhauser et al, 2003; Somervaille et al, 2001; 
Arcasoy et al, 2005; Zeuner et al, 2006] One study, which built on previous work by 
members of this group, used a delayed negative selection strategy. [Dai et al, 2005]
Direct comparison of functional data between all the published studies described 
above may not be strictly appropriate since erythroblasts may functionally differ 
depending on whether they are derived from bone marrow or cord blood, cytokine 
mobilised cells or normal peripheral blood. [Van Epps et al, 1994] Direct comparison 
between studies using progenitors which have been derived from normal peripheral 
blood is probably more valid although different cell selection strategies may result in 
a subtly different cellular population. [Dai et al, 2005]
Initial experiments presented in this thesis explored delayed (to Day 6) positive 
selection of cells cultured in erythroid medium with either CD36 (thrombospondin 
receptor) or C D 71 (transferrin receptor) conjugated microbeads. Neither of these 
markers was found to be specific; Most erythroblasts were CD36 and C D 71 positive 
but some morphologically identical erythroblasts were not & contaminating cells were 
present in both the CD36 and C D 71 positive fractions.
In subsequent experiments using cells derived from venesection packs, a technique 
involving delayed negative selection of primary mononuclear cells which had been
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cultured in a medium preferentially enhancing erythroid growth was used. There were 
advantages and disadvantages with this approach: The clear advantage was that this 2- 
step procedure allowed harvest of all peripheral blood erythroblasts (including CD36 
negative cells) with >95% purity at the end of the culture period. The major 
disadvantage was a laborious technique with several manual removal steps to remove 
unwanted cells.
In experiments using mobilised CD34+ progenitors from normal subjects cultured in 
erythroid medium, further selection was not performed. This approach resulted in a 
nucleated cell population which was only 80-90% erythroid which appears to be less 
than that found in the published data outlined above. It is possible that the lower 
purity in this study compared to that reported in published data related to the batch of 
fetal calf serum which was being used at the time.
The mixture of cytokines used for erythroid culture included Erythropoietin, Stem 
Cell Factor, Insulin Growth Factor 1, Interleukin 3, Estradiol and Dexamethasone.
The roles of Epo, SCF and IL3 are illustrated in Figure 1[1] and their use for erythroid 
proliferation & controlled differentiation in vitro together with IG Fl, Estradiol & 
Dexamethasone has been previously described [Panzenbock et al, 1998, Migliaccio et 
al, 2002]. Using this system, the Day 9 erythroblasts in this study were homogeneous 
morphologically and retained colony forming potential. Dexamethasone and estradiol 
were removed from the culture medium from Day 6 to allow a period of wash out for 
these pharmacological agents but high levels of erythropoietin, SCF, IL3 and IGF-1 
were maintained. Of course, samples from all types of patients and normal controls in 
this study were treated identically, so that any artefactual changes induced by the in 
vitro culture system would apply to all diagnostic groups.
With this culture system, there was strong expression of CD71, intermediate 
expression of CD36, & Glycophorin A and weak expression of CD l 17 in Day 9 
erythroblasts. These results are comparable with published data [Arcasoy et al, 2005; 
Josefsen et al, 2000] There was no significant difference in either immunophenotype 
(CD71, CD36 & Glycophorin A) or morphology of erythroblasts between subject 
groups, having looked at 43 Day 9 erythroblast specimens including 21 with PV.
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The published literature on the differentiation status of PV erythroblasts relative to 
normal erythroblasts has not identified clear differences. W hilst one group found 
marginally increased expression of Glycophorin A in PV, [Ugo et al, 2004] other 
groups [Dai et al, 2005; Zeuner et al, 2006] have found no differences. Corroboration 
of the immunophenotype findings in this study using molecular gene expression 
profiling of our samples was obtained & these results, discussed in Chapter 6, confirm 
the FACS findings of no significant difference in erythroblast differentiation between 
PV & controls.
The colony forming potential of cultured erythroblasts was assessed by taking cells on 
each day of culture and plating them into standard colony assays. There was 
predominantly BFUe formation up to Day 4 and subsequently predominantly CFUe 
formation up to and including Day 10 of liquid culture. There was marked expansion 
of erythropoiesis by Days 4-6 which is illustrated in Figure 12 [3] and corresponds to 
published findings. [Panzenbock et al, 1998]
Polycythaemia Vera is associated with an increased white cell and mononuclear cell 
count. When compared with patients with myelofibrosis, the number of circulating 
stem cells derived from the mononuclear cell compartment is not significantly 
increased. [Passamonti et al, 2003] However, when patients with PV are compared 
with normal controls, the number of circulating CD34+ cells is increased.
[Andreasson et al, 1997] Within the group of PV subjects who express V617F JAK2 
there is a dose-response effect between the number of mutant alleles and the 
concentration of circulating CD344- progenitors. [Passamonti et al, 2006] CD34-I- stem 
cell progenitors derived from patients with PV are reduced in patients taking 
therapeutic Hydroxycarbamide. [Andreasson et al, 2000]
In this cohort of patients, an elevated white cell count was strongly associated with a 
diagnosis of PV. Presumably as a result of this, there was an increased yield of 
mononuclear cells from PV patients compared to other groups with the notable 
exception of patients taking therapeutic Hydroxycarbamide. In addition, there was a 
trend towards increased yield of mononuclear cells in PV patients with homozygous 
rather than heterozygous expression of V617F JAK2.
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Publications that have looked at proliferation in erythroblasts have found increased 
proliferation with a spectrum of added cytokines in PV. [Ugo et al, 2004; 
Wickenhauser et al, 2003; Dai et al, 2005; Zeuner et al, 2006] Comparison of 
erythroblast yield with the number of mononuclear cells initially harvested from 
peripheral blood in this study showed that the proportion of erythroblasts produced 
from PV patients with homozygous expression of V617F JAK2 was 3.5 times higher 
than normal controls.
Jamieson et al [2006] compared erythroid colony formation in CD34+ cells derived 
from patients with PV and normals including bone marrow, cord blood and peripheral 
blood specimens. They found a significant difference in the quantity and quality of 
erythroid but not myeloid colonies. Whilst it had been recognized that the ratio of 
erythroid to myeloid progenitors in the bone marrow was increased in PV, [Anger et 
al, 1989] earlier studies had not shown a significant increase in erythroid (compared 
to myeloid) committed stem cells as assessed by colony assays. [Eaves et al, 1980]
In this study, 80 colony assays were performed using peripheral blood mononuclear 
cells including 33 from patients with PV, 37 from patients with IE and 10 normal 
controls. Erythroid colonies were increased in PV relative to normal individuals, but 
not relative to IE; erythroid:myeloid colony ratios were not altered in PV compared to 
either IE or normals. These results do not suggest skewing of CD34+ cells to 
erythroid commitment in PV.
It has been suggested that apoptosis is reduced in PV erythroblasts. This observation 
principally stems from a study by Silva et al which reported increased expression of 
the anti-apoptotic protein, Bcl-xL in PV erythroblasts compared to controls. This 
study used erythroid progenitors derived from PV bone marrow with growth in 
erythroid medium and the authors also reported reduced morphological evidence of 
apoptosis with erythropoietin deprivation in representative PV samples [Silva et al, 
1998]. Bcl-xL may not, however, play a role that is limited to apoptosis (BCL-XL is 
progressively upregulated during erythropoietin and SCF induced erythroblast 
differentiation in vitro). [Myklebust et al, 2002] Garçon et a] [2006] have described 
induction of EECs from erythroid progenitors with overexpression of STAT/Bcl-xL 
which is reversed by knock down of STAT5 & Bcl-xL suggesting that Bcl-xL may
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play a role in proliferation. Sui et al [2000] specifically looked at differences in 
erythropoietin and SCF induced expression of Bcl-xL in erythroblasts and the 
relationship of this to apoptosis with Wortmannin (PI3K inhibitor) and found that 
differential Bcl-xL expression did not correlate with apoptosis but with proliferation 
and differentiation. Josefsen et al [2000] found that Bcl-xL expression increased with 
days of in vitro culture but that this did not correlate with a change in apoptosis.
Two published studies have taken day 7/8 bone marrow derived erythroblasts from 
liquid culture and shown that, in some cases, EECs can be derived from this cellular 
population. [Silva et al, 1998, Ugo et al, 2004]. In order to examine whether PV 
erythroblasts cultured in vitro retain their relative erythropoietin independence, the 
work presented in this chapter looked at samples incubated overnight with and 
without erythropoietin. MTS assays to quantify viable cell number showed that 
relative resistance to erythropoietin deprivation was a feature of V617F JAK2 
mutated erythroblasts. In addition, homozygous expression of the mutant form was 
associated with increased resistance to erythropoietin deprivation compared to 
heterozygous counterparts.
Measurement of apoptosis in erythroblasts deprived of erythropoietin or SCF using 
Annexin V-FITC staining of erythroblasts and FACS analysis showed no difference 
between PV and control cells. These findings are similar to Panzenbock et al [1998]. 
Other groups have also found no difference in functional erythroblast apoptosis in PV : 
Ugo et al [2004] found no difference between PV & controls in the apoptosis of 
erythroblasts with erythropoietin deprivation using Annexin V methodology. Dai et al 
[2005] reached similar conclusions using TUNEL assays.
Polycythaemia Vera is a disease characterised by erythroid expansion. There are 3 
principal potential explanations for this phenomenon (which are not mutually 
exclusive): The proportion of circulating stem cells committed to erythroid 
differentiation could be higher, erythroblast proliferation could be increased or 
erythroblast apoptosis could be reduced. In order to better understand the 
pathophysiology of PV, an in vitro model was developed which allowed direct 
comparison of the function of erythroid progenitors derived from patients with PV, 
Idiopathic Erythrocytosis (disease entities characterised by erythroid expansion not
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due to PV) and normal controls. Results obtained from this did not suggest erythroid 
skewing of the stem cell compartment in PV. There was significantly increased 
proliferation of PV erythroblasts in the presence of maximal concentrations of 
cytokines as well as increased viable cell number, but no alteration of apoptosis, in 
PV erythroblasts which had been cytokine-deprived.
98
CHAPTER 4 -  RESULTS 2
Signal transduction pathways in primary erythroid progenitors 
& haematopoietic tumour cell lines
4.1 Signal transduction pathways activated by SCF and Epo differ 
between haematopoietic tumour cell lines & primary human 
erythroid progenitors
Work shown in this chapter includes study of the signalling enzymes AKT, p70S6K, 
GSK3a/b, p38MAPK, RSK, ERK, JAK2, STATS & Pim-1. Activation of 
phosphoinositide 3-kinase signalling leads to subsequent phosphorylation and 
activation of the Akt and p70S6 Kinases. Active Akt can phosphorylate and inactivate 
GSK3alpha/beta. However, GSK3 can be a downstream target of the PI3K, MAPK or 
Protein Kinase C (PKC) pathways [Doble & Woodgett, 2003]. Activation of Ras 
signalling by growth factors leads to the subsequent activation of the ERK 
MAPkinase -  a downstream target for ERK is the p90RSK. Janus-associated kinases 
(JAKs) directly activate Signal Transducers and Activators of Transcription (STATs) 
of which Pim-1 oncogene (Pim-1) is a downstream target [Stout et al, 2004].
Previous work by our group identified PI3K mediated phosphorylation of GSK3 as 
being critical for erythroblast survival [Somervaille et al, 2001]. The work presented 
in this chapter initially explored the precise position of GSK3 phosphorylation via 
PI3K and other pathways in haematopoietic cell lines and then moved on to work with 
primary erythroid precursors derived from the peripheral blood of patients with 
Polycythaemia Vera and control subjects. To enable study of the contribution of 
individual pathways, small molecule inhibitors were used and a representation of their 
effects together with the position of GSK3 in the pathways studied is shown in Figure 
1 [4] & Table 1[4].
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Figure 1[4J: Simplified representation of the signalling pathways and small 
molecule inhibitors used in this chapter
(PKC = Protein Kinase C, MAPK = mi to gen-associated protein kinase, PI3K = 
phosphoinositidc-3-kinase, JAK = Janus-associated kinase, ST AT = Signal transducer 
and activator of transcription. Pirn = Pirn oncogene, GSK3 = Glycogen synthase 
kinase 3, inhibitors target the indicated pathways with Go6976 inhibiting both JAK & 
PKC and LY294002 inhibiting PI3K a & Pirn)
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Table 1[4]: Small molecule inhibitors of signalling pathways
(LY294002* also inhibits Pim-1 kinase activity)
Pathway PKC MAPK PI3K JAK
Inhibitor 1 Go6983 U0126 LY294002* Jak Inhibitor 1
Inhibitor 2 Go6976 PI103 Go6976
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4.1.1 The kinetics of individual pathway stimulation & inhibition differ
The phosphorylation of GSK3 via PI3K and MAPK was initially explored in 
haematopoietic cell lines: Figure 2[4]a shows the effects of stimulation of Mo7e cells 
with SCF together with inhibition of either or both pathways. As expected, pAKT was 
inhibited by LY294002 alone but not by U0126 alone for both short and long periods 
of stimulation (note the combination of LY294002 & U0126 showed greater 
inhibition than that seen with LY294002 alone). By contrast, phosphorylation of 
GSK3 was inhibited by LY294002 after long (but not short) periods of stimulation. 
This effect was also seen in Mo7e cells stimulated with GM-CSF, in TFl cells 
stimulated with SCF or GM-CSF & in 32D cells stimulated with mIL3 (shown in 
Figure 2[4]b).
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Figure 2[4]: The early phase of GSK3 phosphorylation is dependent on both 
PI3K & MAPK pathways in haematopoietic cell lines whereas the late phase is 
PI3K dependent only
(a. Mo7e cells were starved of cytokines overnight then incubated with or without 
LY294002 and/or U0126 followed by stimulation with SCF for 10 mins or 4 hrs, 
western blots from protein lysates probed for pAKT, pGSK3 & tubulin (not shown) b. 
32D cells starved then stimulated with IL3 +/-LY294002 or U0126 for lOmins & 4 
hrs, western blots from protein lysates probed for pAKT, pGSK3 & tubulin)
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In contrast. Western blots from erythroid progenitors showed (as our group previously 
reported), that phosphorylation of GSK3 was entirely PI3K dependent at early time 
points (10 mins of cytokine stimulation as shown in Figure 3[4]).
102
Figure 3[4]: Phosphorylation of GSK3 is immediately PI3K dependent in 
erythroid progenitors
(erythroblasts derived from peripheral blood after 9 days of in vitro culture washed 
and starved in serum free medium for 2 hours then stimulated with either Epo or SCF 
[SCF shown] for 10 mins +/- pre-incubation with LY294002)
Erythroid progenitors at lOmins
p A K T
p G S K 3
E p o / S C F  L Y
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4.1.2 Cytokine dose affects pathway activation in cell lines
A potential explanation for the partial PI3K dependency of GSK3 phosphorylation 
observed in haematopoietic cell lines relates to the supraphysiological doses of 
cytokines used in previous experiments. Subsequently Mo7e cells were stimulated 
with a range of cytokine concentrations. When low doses of SCF were used for 
stimulation GSK3 phosphorylation was mostly PI3K dependent (the combination of 
LY294002 & U0126 had greater effect on GSK3 phosphorylation than LY294002 
alone). This PI3K dependency of GSK3 phosphorylation was lost when the dose of 
SCF was increased to 5ng/ml or above. These results are presented in Figure 4[4].
Figure 4[4]: Early GSK3 phosphorylation is PI3K dependent in haematopoietic 
cell lines when low doses of cytokine stimulation are used
(a. Mo7e cells starved of cytokines then stimulated for 10 mins with SCF 20ng/ml +/- 
LY294002 [LY], western blots from protein lysates probed for pAKT and pGSK3, b. 
Mo7e cells starved of cytokines then stimulated for 10 mins with SCF Ing/ml or 
5ng/ml +/- LY294002, U0126 [U] or both, western blots from protein lysates probed 
for pAKT and pGSK3) 
a.
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4.1.3 Cytokines may show overlapping pathway activation patterns in 
erythroid progenitors
A possible explanation for the observation that high doses of cytokines induced 
pGSK3 via PI3K and MAPK in haematopoietic cell lines, but not in primary erythroid 
cells, was that Epo did not induce MAPK phosphorylation in erythroid cells. However, 
as shown in Figure 5[4], SCF or erythropoietin stimulation of erythroid progenitors 
did result in activation of MAPK. This figure also shows that phosphorylation of 
STAT5 was induced by erythropoietin (but not SCF) in erythroid progenitors.
Figure 5[4]: MAPK is phosphorylated by both Epo & SCF whilst STATS is 
independently phosphorylated by Epo but not SCF in erythroid progenitors
(western blots from primary erythroblasts starved then incubated with no inhibitor, 
LY294002 or U0126 or both, then [with the exception of the first lane] stimulated 
with SCF, erythropoietin or both cytokines for 10 mins, blots probed for the known 
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In order to further test the activity of the MAPK pathway in erythroid progenitors, 
cells were stimulated with tetradecanoyl phorbol-myristate acetate (TPA) which can 
potently activate MAPK signalling via direct activation of protein kinase C. Under 
these conditions, phosphorylation of GSK3 was predominantly MAPK dependent as 
shown in Figure 6[4] a&b. It is therefore apparent that the MAPK pathway can be 
stimulated to induce pGSK3 in erythroid progenitors but that this mechanism is not 
usually engaged by SCF or Epo.
Figure 6[4]: TPA can induce phosphorylation of GSK3 in primary erythroblasts 
via the MAPK pathway
(western blots of protein lysates from erythroid progenitors which had been starved, 
stimulated with tetradecanoyl phorbol-myristate acetate [TPA] for 10 mins, incubated 
with the MAPK inhibitor U0126 or treated with both TPA and U0126. Blots for 
pGSK3 and Tubulin are shown in a), scanning densitometry results relative to tubulin 
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4.1.4 There may be cross-talk between signalling pathways revealed by 
inhibitor studies
In several experiments using Mo7e cells stimulated with SCF, GM-CSF, Epo & 
Thrombopoietin , there was apparent cross-talk between the PI3K & MAPK pathways: 
Whilst LY294002 blocked pAKT & U0126 blocked pERK as expected, there was a 
paradoxical increase in pAKT when cytokine stimulated cells were pre-incubated with 
U0126 alone (data not shown). Limited experiments in erythroid progenitors were 
inconclusive on this issue (see representative study in Figure 5[4]).
In Mo7e cells it was also observed that although tyrosine phosphorylation of STAT5 
was overwhelmingly PI3K & MAPK independent at early time points, with longer 
periods of stimulation, a weak pSTAT5 signal showed evidence of cross talk with the 
PI3K pathway as shown in Figure 7[4]. There was insufficient time to pursue this 
issue specifically in erythroid progenitors.
Figure 7[4]: Pbospborylation of STATS can be PI3K dependent
(Mo7e cells were starved and stimulated with GM-CSF +/- pre-incubation with 
LY294002 [LY], U0126 [U] or both for 10 minutes, 1 hour or 5 hours, western blots 
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4.2 Basal & stimulated primary erythroid progenitor signalling
As discussed previously, evidence published in the scientific literature pointed 
towards abnormalities in signal transduction in Polycythaemia Vera as being key to 
the pathophysiology of the disease. This work therefore set out to define these 
abnormalities in individual pathways using erythroid progenitors derived from 
patients with PV comparing them with control subjects. Primary erythroid progenitors 
were derived from peripheral blood venesection packs and from normal buffy coat 
residues supplied by the National Blood Service as described in 2.2.1-5. After a 
period of in vitro culture with a negative selection step, mononuclear cells were 
assessed morphologically and by immunophenotype and samples with >90% 
erythroblasts were processed further.
Basal (unstimulated) activity and cytokine stimulated activitation of signalling 
pathways was investigated with an emphasis on comparisons over time as this issue 
had been relevant in our previous work. Western blot exposure times were selected 
for non-saturating signals allowing comparison between unstimulated & stimulated 
lanes referenced against the total loading protein control.
In order to study signalling, a reproducible model of erythroid development was 
established which would allow ready comparison between groups (4.2.1). Having 
developed this model, experiments were carried out under the following conditions 
which allowed comparison between diagnostic groups under different conditions of 
cytokine stimulation:
• Stimulation with SCF plus Epo in a small group of subjects (4.2.2).
• Basal and stimulated (with SCF plus Epo) activity over time (but less than 6 
hours) comparing diagnostic groups (4.2.3).
• Basal and stimulated (with Epo alone) activity over time comparing diagnostic 
groups (4.2.4)
Using data from the the total set of experiments a comparison in basal signalling 
between PV and control groups was made (4.2.5). Finally, differences between 
diagnostic groups with prolonged (>6 hour) stimulation times were investigated 
(4JL6y
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4.2.1 Establishing a basis for investigating erythroblast signalling
In a first series of experiments, the effect of the number of days of in vitro culture (in 
standard growth factor replete conditions) on signal transduction in the PI3K, MAPK 
& STAT pathways was examined. BCLxL expression, as being both a potential 
STAT5 target and an erythroid differentiation marker, was measured in parallel. A 
representative study using erythroblasts from a patient with IE is shown in Figure 8[4].
Figure 8[4]; Assessing activity of the PI3K, MAPK & STAT pathways in 
erythroid progenitors by day of in vitro culture
(2x10^ cells taken direct from culture on days 8, 10, 13 & 15, protein lysates from 
western blots incubated with antibodies to pAKT, pERK & pSTAT5 & BCLxL 
followed by Total STAT & AKT [a], densitometric assessment of phospho-enzymes 
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These experiments confirmed that, in order to make accurate comparison between 
erythroblasts by diagnostic group, it would be optimal to select a specific day of 
culture and stick with it throughout experiments. Day 9 was chosen for all future work 
as this would allow assessment of each of the 3 signalling pathways that were the 
focus of this work to be studied and because this day coincided with an optimal 
number of erythroblasts available.
Subsequent methodology is described in 2.6.1-2 but in brief: erythroblasts were 
washed free of cytokines and suspended in serum free medium for 2-3 hours at 37°C 
& 5% CO2 . Cells were then aliquoted into the desired number of experimental 
samples with 0.5-1 x 10  ^cells per point each suspended in 1ml medium. Where 
appropriate, inhibitors were then added followed by further incubation at 37°C for 30- 
60 minutes. Cytokines were then added to selected samples at concentrations of 
liu/ml for Epo and lOng/ml for SCF (previous experiments showed that 
phosphorylation was saturated with these doses of cytokines) followed by further 
incubation at 37°C. If this incubation step was >1 hour, cells were maintained at 5% 
CO2. At the selected time point following cytokine stimulation, (10 minutes to 
overnight) cells were rapidly chilled and protein lysates made.
Protein lysates were then assessed as per 2.6.4 -  2.6.7 by standard western blotting. 
Nitrocellulose membranes were incubated sequentially with a range of Phospho- 
antibodies followed by an appropriate protein loading control. Bands of the correct 
size & visual appearance were scanned from Hyperfilm with an Epson Stylus Photo 
RX620 Scanner. Densitometry was performed using NTH Image! software. A ratio of 
protein expression was derived by dividing the densitometric value for the phospho- 
band by that of a total protein band (Tubulin, ERK2 or STAT5b) for the selected lane 
on western blot. In experiments with cytokine stimulation > 4 hours, this protein 
expression ratio was further analysed by dividing the value for the basal sample by 
that of the cytokine stimulated sample at the same time point.
Results were assessed according to the diagnostic group of the patient from whom 
they had been harvested. Mean values by diagnostic group were calculated and are 
presented in graph form with standard error of the mean plotted. Representative 
western blot results from one patient are shown in Figure 9 [4].
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Figure 9[4]: Illustrative western blot results from erythroblasts derived from a 
patient with Polycythaemia Vera starved and stimulated over a time course
(Day 9 erythroblasts were washed and starved for 2 hours in serum free medium at 
1x10^ per ml, half of the 1 ml aliquots were stimulated with Epo plus SCF, starved & 
stimulated [*] aliquots were lysed in parallel after 10, 60, 120, 240 & 480 minutes, 
western blots were made and the membrane incubated sequentially with phospho- 
antibodies prior to assessment of total protein)
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4.2.2 Protein phosphorylation patterns in erythroblasts stimulated over a short
time course
Initial experiments compared activity in 6 samples of erythroid progenitors including 
2 from patients with PV. Analysis of the PI3K, STAT & MAPK pathways is shown in 
Figure 10[4]. Results for pp38MAPK are derived from only 4 experiments (3 IE, 1 
PV) but are shown to provide comparison with pERK.
Figure 10[4]: Quantification of signal pathway activation in stimulated erythroid 
progenitors
(erythroid progenitors from 6 samples including 4 IE and 2 PV were starved and 
stimulated with SCF & Epo for 10,30 60 & 120 minutes then lysed, western blots 
were probed for pAKT, pGSK3, pSTAT5, pERK, pp38MAPK [3 IE & 1 PV only] & 
total protein, expression of phosphorylated relative to total protein plotted in 5 
separate graphs)
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These preliminary results from a small group of patients established a working 
platform and suggested that there may be some differences between PV and IE in both 
the basal and stimulated signalling pathways of erythroblasts.
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4.2.3 Protein phosphorylation patterns in erythroblasts both starved and
stimulated for a short time (<lhour) with erythropoietin and SCF
In order to separate out the alterations in signalling between basal and short-term 
cytokine stimulated responses a larger cohort of 17 experiments using erythroid 
progenitors from patients with PV & controls was carried out. Average results 
according to diagnostic group are shown in Figure 11 [4] & 12[4].
Figure 11 [4]: Comparing basal & stimulated pAKT, pERK & pGSK3 between 
PV & controls
(mean values from 8 patients with IE, 7 patients with PV & 2 normals shown, protein 
band expressed relative to total protein loading control for basal [B] & stimulated [S = 
SCF-i-Epo] samples with the ratio of basal/stimulated [B/S] in the 3'^ column, standard 
error of the mean plotted)











This pattern suggested that there was increased basal and stimulated phosphorylation 
of AKT & ERK in the PV subjects compared to IE. Results from the normal samples 
were probably similar to the IE patients but could not be accurately placed due to the 
low number of samples available. Interestingly GSK3 phosphorylation was not simply 
aligning with AKT phosphorylation.
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For some of these patients results were available for pSTATS, pRSK and pp38 MAPK 
and these are shown in Figure 12[4]. Whilst results for RSK and p38MAPK could fit 
with the ERK phosphorylation pattern, the pattern for STAT5 was different in this 
smaller group: basal phosphorylation was not significantly increased and STAT5 was 
not excessively stimulated in the PV subjects.
Figure 12[4]: Comparing basal & stimulated pSTATS, pRSK and pp38 MAPK 
between PV & controls
(mean values from diagnostic groups shown, protein band expressed relative to total 
protein for basal [B] & stimulated [S = SCF+Epo] samples with the ratio of 
basal/stimulated [B/S] in the 3'"^  column, standard error of the mean plotted, includes 
the same group of experiments as for Figure 11 [4] but results available for fewer 
patients -  pSTAT5 = 13 [7 IE, 4 PV, 2 normals], pRSK = 5 [2 IE, 3 PV] & 
pp38MAPK = 8 [5 IE, 3 PV])
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4.2.4 Protein phosphorylation patterns in erythroblasts both starved and
stimulated for a short time (<lhour) with erythropoietin alone
In order to assess whether the differences by diagnostic group were due to Epo- 
dependent abnormalities, as Epo signals via Jak and SCF characteristically does not, 
further experiments from 16 subjects including 9 with PV in which cytokine 
stimulation was with Epo alone were done. This increased number of samples could 
potentially have drawn out small differences in signalling by assessing a larger cohort 
of patients with PV. Average results by diagnostic group are shown in Figure 13 [4]. 
There was no difference between the PV samples heterozygous & homozygous for 
V617F JAK2.
Figure 13[4]: Relative phosphorylation in erythroblasts starved or stimulated 
with erythropoietin for <lhour
(Averaged results from 16 experiments shown in 3 separate graphs of pAKT, 
pSTATS and pERK, includes 7 samples from patients with EE [all wild type for JAK2] 
and 9 samples from patients with PV [2 homozygous, 7 heterozygous for V617F 
JAK2], expression of phospho-antibodies relative to total protein for basal [B] & 
stimulated [S] samples shown with basal/stimulated ratio [B/S], standard error of the 
mean plotted)
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These findings confirmed that basal and stimulated (for <lhour) expression of pAKT 
and pERK were higher in PV. The larger cohort of samples also brought out the slight 
increase in basal and stimulated pSTAT5 in PV. Interestingly the ratios of expression 
between basal and stimulated samples were somewhat different when Epo was used 
alone for stimulation: The ratios for pAKT and pERK were normal and only the ratio 
for pSTATS was increased. This may indicate that signalling abnormalities in PV are 
not entirely JAK2 dependent.
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Since the basal signal in all the preceding experiments was derived from cells under 
the same conditions (erythroblasts washed and starved in serum free medium for 2-3 
hours) all this data was merged showing that basal pAKT, pERK and pSTAT5 were 
significantly higher in PV than in control subjects but that there was variation 
between individuals as shown in Figure 14[4].
Figure 14[4]: Basal signalling of PV erythroid progenitors is increased in all 
pathways
(a. western blots from 18 patients with PV [V617F JAK2] & 21 controls [wild type 
WT JAK2] showing the erythroblast signal after 2-3 hours of starvation in serum free 
medium for pAKT, pERK & pSTAT5 relative to total protein, standard error of the 
mean shown, b. representative blots from 2 patients with IE and 3 with PV showing 
starved & stimulated phospho-enzymes relative to total protein, c. all values for basal 
signal relative to total protein shown with mean of all portrayed [pSTAT5 values 
multiplied by 5 & maximum value adjusted from 6.4 to 3.1 for representation]) 
a.
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4.2.5 Protein phosphorylation patterns in erythroblasts both starved and 
stimulated for longer periods (4 hrs, 8hrs & overnight) with 
erythropoietin and SCF
Results in 4.2.2 had suggested that there may be differences in signalling between PV 
& controls with >2 hours cytokine stimulation. Twenty four samples which had been 
starved or stimulated for longer periods with Epo +/- SCF (4 hours, 8 hours & 
overnight) were therefore assessed to consider this issue. In order to control for 
proliferative differences over this longer time period, basal activity relative to total 
protein was expressed as a ratio of stimulated activity at each time point. Results are 
shown in Figure 15 [4].
Figure 15[4]: Quantitative evaluation of the signalling activity of erythroid 
progenitors over a protracted time course
(erythroid progenitors were starved for 2 hrs, incubated plus/minus cytokines and 
paired basal & stimulated samples lysed after a further 4hrs, Shrs & overnight 
incubation. Western blots were probed for pAKT, pGSK3, pFRK & pSTAT5 and 
expression quantitated relative to total protein. The basal / stimulated ratio was 
calculated for each time point & average results by diagnosis shown from a total of 24 
experiments including 14 PV, 8 IF & 2 normals from signals at 4hrs[n=10], 8hrs [n= 
6] & overnight [ON, n= 8], standard error of the mean shown)
































As these results have been expressed as a ratio in order to control for proliferative 
effects, it is not possible to say whether there was individual variation in basal or 
stimulated signalling between PV & controls. In addition these experiments include a 
mixture of those stimulated with Epo alone and those stimulated with Epo + SCF; 
unfortunately the sample size was not sufficient to allow separate analysis of these 
groups. Despite these limitations this evidence suggests that the elevated PI3K 
activity seen in PV is increased for sustained periods in erythroid progenitors derived 
from patients with PV. This sustained effect was not apparent for the MAPK or STAT 
pathways.
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4.3 The effects of P13K inhibition on aberrant signalling in PV
erythroblasts
Having established differences in erythroid signalling in PV, further work went on to 
assess whether specific pathway inhibitors might have differential effects on PV 
erythroid progenitors.
4.3.1 Assessing the effects of PI3K inhibition with LY294002 in PV
Initial data had shown that inhibition of PI3K in erythroid progenitors reduced the 
phosphorylation of AKT and p70S6K but not of ERK or STAT5 (see Figure 5[4]). In 
order to investigate the effects of PI3K inhibition in potentially aberrant PV signalling, 
further experiments were done with 13 samples including 6 from patients with PV. 
Results are shown in Figure 16[4].
Figure 16[4]: The effects of PI3K Inhibition on aberrant PV signalling
(western blots were made from 13 samples of erythroblasts (6 PV, 7 IE) starved -/+ 
stimulated with Epo (n=6) +/- SCF (n=7) -/+ pre-incubation with LY294002, blots 
were probed for for pAKT, pERK, pSTAT5 & total protein and relative quantitation 
is shown with standard error of the mean)
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These results confirmed that LY294002 inhibits phosphorylation of AKT but not 
ERK or ST AT5 in erythroid progenitors derived from patients with idiopathic 
erythrocytosis as is seen in normal samples.
A different pattern emerged for samples from patients with Polycythaemia Vera: 
LY294002 reduced stimulated phosphorylation of AKT, ERK and ST AT5 and, in the 
case of AKT and ERK, additionally reduced the increased basal activity noted in PV. 
In also appeared that LY294002 may have more profound effects on signalling in PV 
than in IE as, whilst the stimulated signal was significantly higher in PV, the inhibited 
signal was not. This was particularly evident for STAT5 phosphorylation.
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4.3.2 The effects of novel PI3K inhibitors on signalling
f
Work from several groups has raised doubts about the selectivity of LY294002 and 
shown inhibitory effects on Pim-1 & protein kinase CK2 as well as PI3K signalling. 
Therefore, more recently developed novel PI3K inhibitors were evaluated. These 
experiments were unfortunately limited in number due to time constraints. TFl cells 
(expressing wild type JAK2) were starved overnight then incubated with either 
LY294002 or PI103, a highly selective Class I PI3K inhibitor, [Raynaud et al, 2007] 
prior to stimulation with GM-CSF. The results are shown in Figure 17[4]. Similar 
effects were seen in Mo7e cells with PI 103 inhibiting GM-CSF induced AKT 
phosphorylation at a concentration of 250nM.
Figure 17[4]: Comparing the effects of LY294002 with the Class 1 PI3K inhibitor, 
PI 103 in tumour cells
(western blots from protein lysates of TFl cells starved then incubated for 1 hour at 
37°C with LY294002 [ly] at 25 or 50uM or PI 103 [pi 103] at 0.01, 0.1 or luM then 




t t  ^ t f t +
nil + ly ly pi103 pi1G3 pi103
25 50 0,01 0.1 luM
These results indicated that PI103 at a dose of luM  inhibited PI3K but not MAPK in 
TFl cells. Further studies were done to evaluate if PI 103 would additionally affect the 
MAPK & STAT pathways in PV samples, as LY294002 had done. 3 experiments 
using erythroblasts from 1 normal CD34+ derived sample, 1 IE and 1 patient with PV 
were done. Findings in the 2 control subjects were as for those in the TFl cells (the
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IMAPK & STAT pathways were unaffected). Results from the patient with PV are 
shown in Figure 18 [4].
Figure 18[4]: Comparing the effects of PI3K inhibitors in PV erythroblasts
(erythroblasts starved and stimulated with erythropoietin -/+ pre-incubation with 
either LY294002 [LY] or PI 103, western blots probed for PI3K effects; pAKT & 








0 Epo LY PI103
.1 . '
In this patient pAKT was reduced with both LY294002 and PI 103, there was a 
possible mild effect of both inhibitors on pERK but no effect on pSTAT5 expression. 
These findings should be explored in a larger group of samples.
The effects of inhibitors of specific isoforms of PI3K were also looked at and it was 
found that inhibition of a single PI3K isoform did not impact on erythroid signalling 
in any pathway. These findings are shown in 5.2.4.
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4.4 The effects of specific inhibitors of JAK2 on signalling
Since data was published on the high degree of association between V617F JAK2 and 
a diagnosis of PV, there has been considerable interest in the therapeutic potential of 
JAK2 inhibitors in this and other myeloproliferative disorders. This study explores the 
effects of 2 such inhibitors in haematopoietic cell lines expressing V617F and wild 
type JAK2 and then goes on to explore potential differential effects in primary PV 
erythroblasts.
4.4.1 JAK2 inhibitors & signalling in haematopoietic cell lines expressing wild 
type& V617FJAK2
Initially the effect of Go6976 (JAK2 & PKC inhibitor), Jak Inhibitor 1 and Go6983 (a 
PKC inhibitor) in the TFl (wild type JAK2) and HEL (V617F JAK2) cell lines was 
studied. Protein lysates & western blots were made from T F l cells (in the presence of 
GM-CSF or erythropoietin) and HEL cells which had been incubated with a range of 
doses of the 3 inhibitors separately. For both TF l and HEL cells, there was dose- 
dependent reduction in expression of pSTAT5, pAKT, pGSK3, pERK and PIM-1 
with Go6976 & Jak Inhibitor 1 but not with Go6983. A representative experiment 
using HEL cells is shown in Figure 19[4].
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ïFigure 19[4]: The effect of the JAK2 inhibitors Go6976 and Jak Inhibitor 1 on 
signal transduction in haematopoietic cell lines
(representative western blots from protein lysates of HEL cells incubated with 
Go6976 [Gl=50nM, G2=250nM, G3=500nM, G4=luM , G5=2.5uM] & Jak Inhibitor 
1 [Jl=10nM, J2=100nM, J3=250nM, J4=0.5uM, J5=luM ], increased pJAK2 due to 
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There was increased signal for pJAK2 with the JAK2 inhibitors. Our group previously 
reported this finding which is due to the mode of action of these and other Jak 
inhibitors in binding & stabilising phosphorylated JAK2. Under these conditions 
pJAK2 accumulates but is unable to activate downstream signalling. [Grandage et al, 
2006] This finding illustrates that probing western blots for pJAK2 may not be a 
useful method in screening for potential JAK2 inhibitors.
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4.4.2 The effects of specific inhibitors of JAK2 on erythroid signalling
The effects of JAK2 inhibition on erythroid progenitors were investigated in 10 
experiments including 5 samples from patients with PV & V617F JAK2, Mean results 
by JAK2 status from these experiments are shown in Figure 20[4]. These results show 
that JAK2 inhibition markedly reduces stimulated pSTAT5 in PV and control cells 
but also reduces stimulated pAKT and pERK in PV.
Figure 20[4]: The effects of JAK2 inhibition in PV & control erythroid cells
(erythroid progenitors from 5 patients with PV [V617F JAK2] & 5 controls [wild type 
= WT JAK2] were washed & starved, lysates were made from a basal sample [nil], an 
Epo-stimulated sample [E] and an Epo-stimulated sample which had been pre­
incubated with Go6976 [E-kG] or Jak Inhibitor 1 [E+J], western blots were probed for 
pAKT, pERK, pSTAT5 & tubulin & results were quantitated, a. representative plots 
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Increased basai signalling was not apparent in all PV cases. Where there was an 
increase this was eliminated by Jak2 inhibition. This can be seen in Figure 20[4] and 
also in Figure 21 [4]. This suggests that the increased constitutive signalling seen in 
PV is Jak2 dependent.
Figure 21 [4]: Basal and stimulated pSTATS are reduced with JAK2 inhibition
(Day 9 erythroblasts were washed and separated into 2 test groups for 10 mins or 1 
hour epo stimulation time points; nil [0], epo [E], nil + Jak Inhibitor 1 [0/J], epo + Jak 
Inhibitor 1 [E/J]. Western blots were made, probed for pSTATS and Tubulin and 
scanned as shown below)
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In section 6.2.2 PIMl gene expression in erythroblasts is discussed as the microarray 
and real-time quantitative per data showed increased expression of PlM l in PV 
erythroblasts relative to controls. Subsequently in 6.3.1 it is shown that PIMl mRNA 
expression was reduced by inhibitors of JAK2. PIM-1 protein expression with JAK2 
inhibition was therefore specifically assessed by western blotting and results are 
shown in Figure 22[4]. They illustrate that, like pSTAT5, PIM-1 is expressed at low 
levels in starved erythroblasts but that expression can be induced by Epo in a JAK2 
dependent manner. It is additionally apparent that PIM-1 is basally upregulated in PV 
and that this upregulation is also reduced with JAK2 inhibition.
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Figure 22[4]: JAK2 inhibition blocks Epo-induced Pim-1 expression in ali 
erythroid progenitors and also basal upregulation in PV progenitors
(a.western blots were made from 5 samples of erythroblasts (2 PV [heterozygous 
V617F JAK2, 2 IE & 1 normal [wild type JAK2]) starved [0] -/+ stimulated with Epo 
[E] -/+ pre-incubation with Go6976 [G], blots were probed for for pSTATS, Pim-1 & 
total protein and relative quantitation is shown with standard error of the mean. b. 
western blot from PV derived erythroblasts showing that both basal and stimulated 
PIM-1 are inhibited at 3 time points)
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Intracellular signal transduction is a highly complex dynamic process with 
individualized operating systems for each cell type which are adapted to the 
functional requirements of the cell. Our group initially studied erythoid progenitors 
derived from G-CSF mobilized stem cell collections & showed both that 
phosphorylation of signalling protein kinases was cytokine dependent in normal 
erythroid cells and also that PI3K signalling via GSK3 was critical to erythroid 
survival. [Somervaille et al, 2001]. Subsequent work by our group reported 
constitutive activation of PI3K, MAPK & Jak/STAT pathways in primary acute 
myeloid leukaemia blast cells which was reduced with specific inhibitors of PI3K and 
JAK2 [Grandage et al, 2005;2006]. The work presented in this study focuses on 
aberrant signal transduction in Polycythaemia Vera, a disease characterised by 
erythroid expansion with the potential for leukaemic transformation.
Evidence published by other groups has shown roles for the PI3K, MAPK & 
Jak/STAT pathways in normal erythroid signalling. Activation of the PI3K pathway 
via phosphorylation of AKT was shown to be critical to erythroid proliferation, 
differentiation & survival by Haseyama et al in 1999. The MAPK pathway which 
includes pRSK & pERK was also shown to synergise with the PI3K pathway to 
support erythropoiesis by Sui et al in 1998. Negative regulation of the Jak/STAT 
pathway by Suppressor of Cytokine Signalling 3 (SOCS-3) was shown to suppress 
erythropoietin induced proliferation by Sasaki et al in 2000.
Several cytokines have been shown to contribute to erythroid proliferation and 
survival but the 2 critical cytokines are Epo and SCF which act via their cognate 
receptors EpoR & c-Kit. Epo & SCF synergise to support erythropoiesis but activate 
signalling by different routes: EpoR lacks intrinsic protein tyrosine kinase activity & 
uses intracellular JAK2 for signal transduction. Epo signalling is therefore JAK2 
dependent. By contrast, when SCF binds to c-KIT, which has intrinsic tyrosine kinase 
activity, the complex signals by creating binding sites for a variety of Src homology 2 
domain-containing enzymes and adaptor proteins such as the p85 subunit of PI3K.
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SCF signalling is therefore not directly JAK2 dependent [Munugalavadla & Kapur, 
2005].
Epo, but not SCF, directly induces phosphorylation of STAT5 via JAK2 in erythroid 
progenitors. Epo also transiently induces phosphorylation of ERK in normal erythroid 
cells. SCF is the major contributor to phosphorylation of AKT (although Epo has 
some independent effect) in early erythroid progenitors but also sustains 
phosphorylation of ERK in these cells. [Arcasoy & Jiang, 2005]
This work initially focussed on the detailed position of GSK3 in haematopoietic cell 
lines and in primary erythroid progenitors comparing and contrasting findings. Firstly, 
SCF induced phosphorylation of GSK3 in Mo7e tumour cells was assessed. As 
expected, pAKT was reduced by the PI3K inhibitor, LY294002, but not by the MAPK 
inhibitor, U0126 (in fact U0126 increased pAKT). Phosphorylated ERK was reduced 
by U0126 but not by LY294002. Surprisingly, GSK3 phosphorylation did not directly 
mirror pAKT, but showed delayed kinetics with no effect of LY294002 apparent at a 
10 minute stimulation time point but complete inhibition at a 4 hour time point. A 
similar pattern was observed in Mo7e cells, TFl cells and 32 D cells. Where GSK3 
phosphorylation was not inhibited by LY294002 alone, it was abrogated by the 
addition of U0126 to LY294002.The concentration of SCF used for stimulation in 
Mo7e cells was then reduced to more physiological levels & it was found that 
phosphorylation of GSK3 was PI3K dependent under these conditions. This 
observation contrasts with the immediate PI3K dependency of GSK3 apparent in 
stimulated erythroid progenitor cells at supraphysiological doses of cytokine 
stimulation.
One possible explanation for these findings was that the predominant PI3K 
dependency of GSK3 in erythroid progenitors might result from an inability of SCF to 
activate the MAPK axis in these cells. In order to address this, experiments were 
performed using erythroid progenitors & it was found that either Epo or SCF 
stimulation could induce MAPK phosphorylation. In addition, Tetradecanoyl phorbol- 
myristate acetate (TPA) has been shown to act via protein kinase C (PKC) to 
stimulate phosphorylation of ERK & GSK3 in neuronal cells [Medina et al, 2005]. In 
this study Mo7e cells and erythroid cells were stimulated with TP A and it was found
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that GSK3 was also phosphorylated in these cells in a MAPK dependent fashion. 
These findings show that although GSK3 can be phosphorylated through the MAPK 
pathway in erythroid cells, SCF or Epo utilize PI3K for this purpose in these cells, 
despite activating MAPK.
In erythroid progenitors stimulated with Epo or SCF, it was confirmed that STAT5 
phosphorylation was induced by Epo but not SCF and was PI3K and MAPK 
independent with short periods of stimulation. Using Mo7e cells this period of 
cytokine stimulation was extended and it was found that, whilst STATS activation 
was overwhelmingly PI3K & MAPK independent for short periods of stimulation, 
there was evidence of cross-talk between pathways with more protracted stimulation. 
This analysis was not pursued in erythroid progenitors.
The published literature on signalling regulation in Polycythaemia Vera erythroblasts 
is limited. Ugo et al [2004] introduced PI3K, JAK/STAT & ERK/MAPK inhibitors 
into liquid cultures of bone marrow derived erythroblasts and noted reduced Epo 
dependent terminal differentiation with all 3 inhibitors & reduction of Epo 
independent differentiation with 2/3 inhibitors (not MAPK). Zeuner et al [2006] 
observed that, in the presence of saturating levels of Epo, there was no difference 
between the PV and control signal for pAKT or pERK in peripheral blood derived 
erythroblasts. By contrast, they observed that when Epo was reduced or withdrawn, 
pAKT and pERK were maintained in PV erythroblasts but not in normal controls. Dai 
et al [2005] did not detect any constitutive activation of pAKT in PV but did note that 
Epo and SCF induction of PV erythroblasts resulted in increased pAKT expression 
which was sustained in 4/5 PV but not in controls. This group also looked at pGSK3 
and reported that effects were similar to those seen with pAKT although their data 
shows that the kinetics of pGSK3 may be different to pAKT in PV.
This study set out to clearly establish signalling abnormalities in primary PV 
erythroid progenitors looking at each of the PI3K, MAPK & ST AT pathways. All of 
the PV samples used in these experiments expressed V617F JAK2 and all of the 
controls expressed wild type JAK2. The optimal erythroid culture conditions were 
first established by building on the work of others. The signal in each pathway by day 
of in vitro culture was then looked at to assess pathway activity and Day 9 was
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selected for further study. After 9 days of in vitro culture there was a homogeneous 
population of basophilic erythroblasts in sufficient number to study protein effects 
and each of the PI3K, MAPK & ST AT pathways were active. All further experiments 
were performed on Day 9 erythroblasts to facilitate comparison between subject 
groups.
The effects on signal transduction of stimulation with SCF & Epo were initially 
assessed over a period of up to 2 hours in a small group of samples including 4 from 
patients with IE and 2 from patients with PV & homozygous expression of V617F. 
There was a suggestion of increased signalling with stimulation in all pathways in the 
PV samples.
The next step was to look at a larger group of 17 samples including 8 IE, 7 PV (3 
homozygous, 4 heterozygous for V617F JAK2) & 2 normal controls. In these 
experiments the basal and short term (<lhr) stimulated effects with Epo & SCF were 
assessed. A ratio of these values was then derived in order to assess whether the 
maximal achievable signal might be greater than that simply induced by an increase in 
basal activity. Using this method there were clear differences between PV & IE in the 
basal, stimulated and basal / stimulated signal for the PI3K & MAPK pathways. In 
this group of studies pSTAT5 was only assessed in 4 of the PV patients and there was 
no overall difference between PV & controls in this small group.
In the knowledge that Epo transduction is Jak dependent & that SCF transduction is 
Jak independent, results from the previous group of experiments were contrasted with 
a further cohort of 16 samples including 7 with IE and 9 with PV (2 homozygous, 7 
heterozygous for V617F JAK2) using Epo alone for stimulation. With this approach it 
was again apparent that there was increased basal & stimulated signal in the PI3K & 
MAPK pathways with no excess in the basal / stimulated signal for these pathways. In 
contrast to the previous results, when studying this larger group of PV subjects, there 
were clear increases in basal, stimulated and basal / stimulated signal for STATS 
(which is, as has been shown, SCF independent).
Overall, when the basal signal of pAKT, pERK & pSTATS between 18 patients with 
PV (& V617F JAK2) and 21 control subjects (all wild type JAK2) was compared.
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there were highly significant increases for PV in all 3 pathways. The conclusion is 
therefore that, not only is there constitutive activation affecting each of the PI3K, 
MAPK & Jak/STAT pathways in PV but that the cytokine hypersensitivity of PV 
erythroblasts observed by other authors is in addition to, and not just as a result of, 
this constitutive basal activation.
Having noted an excess in the basal signal expressed as a proportion of the maximal 
signal for pAKT & pERK (Epo + SCF) & pSTAT5 (Epo) for stimulation periods of 
<1 hour in PV samples, further work went on to see if this effect was sustained for 
longer periods of stimulation. It was found that increased signalling in PV was 
sustained up to 4 hours for pSTAT5 and up to 24 hours for pAKT. Together these 
findings point to a critical role for PI3K signalling in PV.
Blockade of individual signalling pathways has been shown to affect erythroid 
progenitor function. LY294002 is a PI3K inhibitor which has been shown to reduce 
phosphorylation of AKT and reduce Epo & SCF supported proliferation and 
maturation of erythroblasts. U0126 has been shown to reduce phosphorylation of 
ERK and Epo-dependent viability in erythroblasts. [Myklebust et al, 2002] Absence 
of STAT5 in mice has been shown to reduce erythroblast survival & differentiation. 
[Sokolovsky et al, 2001].
Having identified this crucial role of PI3K in aberrant PV signalling, the effects of 
LY294002 on erythroblasts from 6 patients with PV and 7 patients with IE were 
compared. LY294002 reduced expression of stimulated pAKT in both subject groups 
as expected but it also reduced the increased basal phosphorylation of AKT in PV 
erythroblasts. In addition, LY294002 decreased pERK and pSTAT5 in PV 
erythroblasts, but had no effect in IE erythroblasts. As it became clear that LY294002 
also had inhibitory effects on the Jak/STAT target PIM-1 and on CK2, further work 
moved to use of the pan-PI3K inhibitor PI 103 rather than LY294002. Results showed 
that PI 103 effects were similar to LY294002 in cell lines and in primary erythroid 
progenitors; however there was not sufficient time to test PI 103 in more than 1 PV 
sample. Further work was done to test the effects of inhibitors of individual PI3K 
isoforms but it was found that these did not exert independent effects in cell lines or in 
primary erythroid cells.
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Whether V617F JAK2 has a primary or secondary role in PV pathophysiology, use of 
a JAK2 inhibitor may have therapeutic potential. This study used 2 specific JAK2 
inhibitors, Go6976 & Jak Inhibitor 1, to explore the effects of JAK2 inhibition on 
erythroid signal transduction. The effects of Go6976 & Jak Inhibitor 1 in cells 
expressing wild type JAK2 (TFl cells) and V617F JAK2 (HEL cells) were first 
assessed. These effects were compared with those of the inhibitor Go6983 to control 
for the PKC inhibitory element of Go6976. Both of the JAK2 inhibitors induced dose 
dependent reduction of signal in the PI3K, MAPK & ST AT pathways of both wild 
type & mutant JAK2 cells. Go6983 had no effect.
Eleven experiments were performed where JAK2 inhibitors were incubated with 
primary erythroblasts in the presence of Epo including 6 patients with PV 
(heterozygous V617F JAK2), 4 patients with IE & 1 normal sample from CD34+ 
mobilized erythroid progenitors (all wild type for JAK2). As expected, stimulated 
pSTAT5 was reduced in PV and control subjects with JAK2 inhibition. JAK2 
inhibition also reduced stimulated pERK and pAKT in PV. PIM-1 expression was 
also assessed in some erythroblasts including 2 samples from patients with PV and 
effects were comparable to that seen with pSTAT5 in keeping with the recognized 
status of PIM-1 as a Jak/STAT target. In a number of these studies in PV it was 
apparent that basal activation of pSTAT5 & PIM-1 seen in PV was suppressed by 
inhibitors of JAK2.
In summary, work presented in this chapter shows that signalling in the PI3K, MAPK 
& ST AT pathways is both constitutively upregulated and hypersensitive over and 
above this basal activity in PV. PI3K dysregulation has been shown to be aberrantly 
sustained in PV erythroblasts and a key role for PI3K inhibition in controlling basal 
signalling abnormalities has been identified. In addition it is shown that JAK2 
inhibition of erythroid progenitors derived from patients with PV expressing V617F 
JAK2 can suppress aberrant signal transduction in all pathways.
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CHAPTER 5 -  RESULTS 3
The effects o f  small molecule inhibitors on erythropoiesis
5.1 The effects of JAK2 inhibition on erythroid colony formation 
& erythroblast viable cell number
5.1.1 The effects of JAK2 inhibition on standard colony assays
Standard colony assays were set up using mononuclear cells derived from peripheral 
blood. Simultaneous colony assays were set up with either of the JAK2 inhibitors, 
Go6976 or Jak Inhibitor 1 as described in 2.3.3. Colonies were counted at Day 14 and 
the number of colonies in the absence of inhibitor was compared with the number in 
the presence of inhibitor.
Two initial experiments, using mononuclear cells from normal individuals, were 
performed to compare the effect on colony formation of Go6976 (a JAK2 & protein 
kinase C [PKC] inhibitor) with Go6983 (a PKC inhibitor) at concentrations between 
lOOnM and 5uM. Go6976 reduced erythroid (BFUe/CFUe) & myelomonocytic (GM- 
CFU) colony formation, whereas Go6983 had no effect as shown in Figure 1[5].
Figure 1[5]: JAK2 inhibition with Go6976 reduces erythroid & myelomonocytic 
colony formation
(results from 2 experiments comparing the effects on erythroid [BFUe] & 
myelomonocytic [GM-CFU] colony formation between JAK2 + PKC inhibition 
[Go6976] with PKC inhibition alone [Go6983]
The effect of Go6976 & Go6983 on colony 
formation
Inhibitor dose
BFUe + Go6976 
BFUe + Go6983 
GM-CFU + Go6976 
GM-CFU + Go6983
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A further 4 experiments were performed to determine comparable effective inhibitory 
doses of Go6976 and Jak Inhibitor 1 on erythroid colony formation. The mean of 
normalised values including material from 2 normal individuals, 1 with secondary 
polycythaemia and 1 with Polycythaemia Vera is shown in Figure 2[5].
Figure 2[5]: Comparing the effects of Go6976 and Jak Inhibitor 1 on erythroid 
colonies from 4 individuals
(erythroid colony numbers shown normalised to colonies in the absence of inhibitor, 
values shown for increasing doses of the JAK2 inhibitors Go6976 or Jak Inhibitor 1 
[JIl], mean of 3 control samples shown with single PV sample, differences are not 
statistically significant)
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Having established the dose responsiveness of standard colonies to JAK2 inhibitors, 
the effects of JAK2 inhibitors according to JAK2 status were assessed on a larger 
subject group. Forty colony assays with added Go6976 / Jak Inhibitor 1 were 
performed. Averaged results are shown in Figure 3[5]. A further single experiment 
putting Day 7 PV erythroblasts from liquid culture into colony assays resulted in an 
erythroid colony ratio (inhibitormo inhibitor) of 0.46 with added Go6976 at luM 
suggesting that JAK2 inhibitory effects are not limited to early erythroblasts.
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Figure 3[5J: Results from 40 colony assays with added inhibitors of JAK2 
according to JAK2 status
(mean erythroid colony numbers with either added Go6976 or Jak Inhibitor 1 [JIl] 
shown as a percentage of total erythroid colonies without inhibitors by JAK2 status 
[n=number of JAK2 inhibited samples]; PV with homozygous V6I7F [HOM, n=4], 
PV with heterozygous V617F [Het, n=20], controls with wild type JAK2 [includes IE, 
n=10. Normal, n=6], calculated standard error of the mean shown)
Effect of Jak inhibitors on erythroid colonies
HOM Het IE Normal
Diagnosis
PV Control
These results show that JAK2 inhibition reduces erythroid colony formation in PV 
and control subjects similarly overall. Although the numbers are small there is a 
suggestion that PV samples expressing homozygous V617F JAK2 may be less 
sensitive to JAK2 inhibition.
At the same time the effects of JAK2 inhibition on GM-CFU formation were assessed. 
In 22 assays Go6976 reduced GM-CFU to 0.80 +/- 0.11 & Jak Inhibitor 1 reduced 
GM-CFU to 0.25 -t-/- 0.07. There was no significant difference between PV patients 
and controls.
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n5.1.2 JAK2 inhibition of erythropoietin independent colonies
In 8 patients with PV and heterozygous expression of V617F JAK2, Go6976 or Jak 
Inhibitor 1 was introduced into EECs. Go6976 2.5uM reduced mean EECs to 0.07 
(ratio to no inhibitor control) overall (n=5, PVl-5). Go6976 luM reduced EECs to 
0.31 (n=3, PV5-8*). Jak Inhibitor I at luM reduced mean EEC formation to 0.02. 
These results are shown in Figure 4[5] and confirm that JAK2 inhibition dramatically 
reduces the erythropoietin-independent colonies which are the hallmark of PV.
Figure 4[5]: EECs from 8 patients with PV in the absence or presence of Go6976 
or Jak Inhibitor I
(individual results from 8 patients with PV and heterozygous expression of V617F 
JAK2 shown, number of colonies normalised to no inhibitor control [nil], PV 1-5 
treated with 2.5uM Go6976 & luM Jak inhibitor 1 [JIl], PV5*-8* treated with luM 
Go6976& luM Jll)








5.1.3 The effects of JAK2 inhibition on cell number in haematopoietic cell lines 
and primary erythroblasts
Go6976 and Jak Inhibitor 1 were introduced into 5 MTS assays using eells expressing 
mutant JAK2 (HEL) and 3 assays using cells expressing wild type JAK2 (Mo7e & 
TFl with added cytokines). A elear dose response effect was apparent for both 
inhibitors and averaged results are shown in Figure 5[5] below.
Figure 5[5]: Results from 8 experiments assessing the viable cell number of 
tumour cells expressing V617F or wild type JAK2 in the presence of Go6976 or 
Jak Inhibitor 1
(averaged results from MTS assays where Go6976 or Jak Inhibitor 1 at concentrations 
of 50nM-2.5uM and lOnM to luM respeetively were added at variable doses to HFL 
eells expressing V617F JAK2 [n=5] & Mo7e/TFl cells with added GM-CSF 
expressing wild type JAK2 [WT, n=3]












Similar experiments were then performed using primary erythroblasts from 20 
patients including 10 patients with PV adding JAK2 inhibitors in the presence of Fpo. 
The first key point to note is that JAK2 inhibition reduced the increased basal viable 
cell number seen in V617F mutant erythroblasts. Dose responsiveness was apparent 
for 2 distinct inhibitors. The dose response effects of inhibitors were equivalent 
between subject groups at lower doses but separation was apparent at the highest dose 
of both inhibitors as shown in Figure 6[5]a. At this higher dose there was a suggestion 
that homozygotes for V617F JAK2 may be less sensitive to JAK2 inhibition although 
numbers were small (Figure 6[5]b).
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Figure 6[5]: Results from 40 experiments assessing the viable cell number of 
primary erythroid cells expressing V617F or wild type JAK2 in the presence of 
Go6976 or Jak Inhibitor 1
(a. Day 9 erythroblasts from 10 PV patients expressing V617F JAK2, 5 IE patients & 
5 normals [all expressing wild type JAK2 = WT], cells were starved of cytokines [nil] 
or stimulated with erythropoietin -/+ increasing doses of 2 inhibitors of JAK2,
Go6976 & Jak inhibitor 1 [JIl], mean values normalised to the erythropoietin only 
control are shown with calculated standard error of the mean, b. results separated by 
JAK2 expression for the highest dose of JAK2 inhibitors and expressed as a 
percentage of uninhibited viable cell number, HOM = homozygous V617F [n=4], Het 







5.2 The effects of PI3 kinase pathway blockade on erythroid colony 
formation & erythroblast viable cell number
Work presented in the previous chapter showed that The PI3K pathway is activated in 
Polycythaemia Vera. This upregulation was found to be JAK2 dependent and further 
work therefore went on to look at whether PI3K blockade might be an alternative 
strategy for PV by assessing the effects of PI3K inhibition on erythroblast viable cell 
number and erythroid colony growth.
In order to explore the effects of PI3K inhibition 3 distinct inhibitors were initially 
used: LY294002 is a pan-PI3K inhibitor which is now known to inhibit PIM-1 and 
other serine/threonine kinases. PI 103 is a highly selective Class IP I3K  inhibitor 
which also inhibits mTOR, a downstream target of PI3K. Rapamycin is an mTOR 
inhibitor.
5.2.1 Comparing PI3K and JAK2 inhibition of erythroblasts
The effects of PI3 kinase inhibition with JAK2 inhibition were first contrasted in a 
V617F JAK2 expressing cell line; LY294002 at 50uM was added to HEL cells in an 
MTS assay in parallel with Go6976 2.5uM and Jak Inhibitor 1 luM  for 48 hours. 
Viable cell number was reduced to 0.10 (LY294002) compared with 0.37 (Go6976) & 
0.42 (Jak Inhibitor 1).
Next, 6 experiments were performed using primary erythroblasts from 3 subjects with 
PV expressing V617F JAK2 and 3 samples which were wild type for JAK2. It was 
found that PI3K inhibition was comparable to JAK2 inhibition in reduction of 
erythroblast viable cell number. There was no significant difference between PV 
subjects and controls. Mean values of normalised results are shown in Figure 7[5].
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Figure 7[5]: Results from 6 experiments comparing the effects of PI3 kinase & 
JAK2 inhibition on erythroblast viable cell number using MTS assays 
(samples include 3 from patients with PV expressing V617F JAK2, 2 IE & 1 normal 
all expressing wild type JAK2 [WT], mean erythroblast viable cell number as 
assessed by MTS assay after overnight incubation with or without the inhibitors 
LY294002, Go6976 & Jak Inhibitor 1 [JIl] shown, mean va]ues normalised to no 
inhibitor Epo-replete wells shown, standard error of the mean plotted)
Comparing erythroblast viable cell number 












In order to confirm that this effect was due to PI3K (and not just Pim-1) inhibition, 
the effects of PI3K inhibition with LY294002 or PI 103 were contrasted with JAK2 
inhibition with Go6976 or Jak Inhibitor 1. Normal erythroblasts were incubated with 
PI3K or JAK2 inhibitors in the presence of erythropoietin. The results are shown in 
Figure 8[5] and illustrate the comparable effects of PI3K and JAK2 inhibition on 
erythroblast survival. A combination of PI3K & JAK2 inhibition was not tested as 
each inhibitor on its own critically reduced viable cell number.
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Figure 8[5J: Comparing the effects of PI3K inhibition with JAK2 inhibition on 
normal erythroblasts in liquid culture
(erythroblasts were washed and incubated in serum free medium overnight with no 
added cytokine [0] or erythropoietin and increasing doses of inhibitors [1-5], doses 
were 3/6/12/25/50um for LY294002, 10/100/250/500/lOOOnM for PI 103, 
50/250/500/1000/2500nM for Go6976 & 10/100/250/500/lOOOnM for Jak Inhibitor 1 






Erythroblast viable cell number with increasing 
doses of P13K & Jak2 inhibitors





A further experiment went on to confirm this effect in erythroblasts derived from a 
patient with PV. On this occasion PI 103 or PI3K inhibition was used together with the 
mTOR inhibitor, Rapamycin, and the effects of inhibition with the ABL & KIT kinase 
inhibitor, Imatinib were tested. The results are shown in Figure 9[5].
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Figure 9[5J: MTS assay comparing PI3K and JAK2 inhibition in erythroblasts
(results from a single experiment using erythroblasts from a patient with PV and 
increasing doses of 5 inhibitors [maximum doses were 2.5uM Go6976, luM Jak 





















Having confirmed that PI3K inhibition reduced erythroblast viability similarly to 
JAK2 inhibition, PI3K inhibition was then assessed in a larger group of samples.
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5.2.2 The effects of PI3 kinase inhibitors on erythroblast ceil number in liquid 
culture
The dose response effect of the PI3 kinase inhibitor, PI103, was first tested on HEL 
cells at concentrations of 62nM -  luM for 48 hours. There was dose dependent 
reduction in viable cell number in 2 separate experiments with mean reduction in 
(PI103 treated cells / inhibitor free cells) ratio to 0.41 at luM. This effect was then 
tested in 7 experiments using primary erythroblasts (5 PV, 1 IE, 1 normal) giving an 
average reduction of 0.30 with luM PI103. Results are shown in Eigure I0[5], 
differences were not significant.
Figure 10[5]: Results of 7 experiments exploring the effect of PI103 on the viable 
cell number of primary erythroblasts
(includes 5 patients with PV expressing V617F JAK2 and 2 subjects with wild type 
JAK2 [WT], normalised mean values are shown, differences between the subject 
groups were not significant)




Rapamycin was introduced into 2 MTS assays using primary erythroblasts from 
patients with PV expressing V617E JAK2. Rapamycin 20nM reduced viable cell 
number relative to the no inhibitor control to 0.75 & 0.59 in the presence of 
erythropoietin. Viable cell number was reduced from 0.56 to 0.31 for erythroblasts 
incubated in the absence of erythropoietin.
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5.2.3 The effects of PI 103 & Rapamycin on standard colony assays and EECs
PI 103 luM was introduced into erythropoietin independent colonies (EECs) from a 
patient with PV in parallel with Go6976 2.5uM and Jak Inhibitor 1 luM. EECs were 
completely abolished with PI103, Go6976 & Jak Inhibitor 1.
Rapamycin was introduced at 20nM into standard colony assays in 8 patients (4 PV & 
4 IE) and the effects were compared with luM Go6976 luM and 500nM Jak Inhibitor 
1 and an inhibitor free control. Mean values from these experiments are shown in 
Figure 11[5J suggesting that Rapamycin has comparable inhibitory effects with JAK2 
inhibitors. In an experiment in which Rapamycin was introduced into colony assays 
from Day 7 erythroblasts the erythroid colony ratio was 0.36. If this was reproducible 
it may suggest that the effects of Rapamycin are greater in less mature erythroblasts.
Figure 11 [5]: Comparing erythroid colonies between 4 patients with PV (& 
V617F JAK2) and 4 with IE (& wild type JAK2)
(inhibitors added to standard colony assays, JIl = Jak Inhibitor 1, standard error of the 
mean shown)












lÉ J L ià j






5.2.4 Exploring the effects of inhibitors of PI3 kinase isoforms
Having first established that the PI 10a, (3 and ô isoforms of PI3K were expressed in 
TFl, HEL and other cell lines, expression of these isoforms were then confirmed in 
erythroblasts. These results are shown in Figure 12[5].
Figure 12[5]: Expression of the alpha (a), beta (P), gamma (y) and delta (y) 
isoforms in erythroblasts
(western blot of erythroblast protein lysates which were probed separately for each of 
the 4 PI3K isoforms and then for total protein)
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In order to assess the differential contribution of PI3K isoforms to erythroblast PI3K 
signalling and survival, some novel inhibitors with predominant effects on specific 
PI3K isoforms were tested; PI387 (alpha inhibitor) [Knight et al, 2006], TGX221 
(beta inhibitor) [Jackson et al, 2005] and D030 (delta inhibitor) [Sujobert et al, 2005]. 
These inhibitors were first tested in TFl cells where no reduction in phosphorylation 
of AKT was noted despite reduction with both LY294002 and PI103. Further work 
then went on to assess affects in primary erythroblasts from 1 patient with PV, 1 with 
IE and 1 normal control. Once again there was no effect on pAKT with inhibition of 
the individual isoforms and representative results are shown in Figure 13 [5].
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Figure 13[5]: Pan-PI3K inhibitors reduce stimulated phosphorylation of AKT in 
erythroblasts but specific inhibitors of individual PI3K isoforms do not
(western blot shown depicting phosphorylated AKT and Tubulin expression in 
erythroblasts starved [nil] or stimulated [+] having been pre-incubated with a range of 
PI3K inhibitors -  LY294002 [LY] & PI 103 [pan-PI3K inhibitors], PI387 [a inhibitor], 
TGX-221 [P inhibitor] and D030 [Ô inhibitor])
pAKT
Tubulin
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In each of these 3 experiments there was a clear reduction in phosphorylation of AKT 
with LY294002 and PI 103 but not with any of the PI3K isoform inhibitors 
individually. None of the inhibitors affected the MAPK and ST AT axes in these 
experiments.
Next, erythroblast survival with these inhibitors was studied. Viable cell number was 
assessed by MTS assay in 4 experiments using erythroblasts (2 PV, 2 IE) in the 
presence of erythropoietin [Epo, n = 4], stem cell factor [SCF, n = 1 (IE)] or insu]in 
growth factor-1 [IGF-1, n = 1 (IE)]. IGF-1 alone did not sustain adequate cellular 
viable cell number to allow assessment of inhibitor effect. The effects of inhibitors on 
erythropoietin stimulated cells are shown in Figure 14[5]. The relative effects of Epo 
and SCF stimulated cells in 1 individual are shown in Figure 15[5]. These findings 
suggest that the reduced cytokine-dependent survival of erythroblasts seen with PI3 
kinase inhibition is dependent on blockade of all isoforms simultaneously.
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Figure 14[5]: 4 experiments assessing the effect of specific PI3 kinase inhibitors 
on erythroblast viable cell number
(mean normalised results from MTS assays in 4 individuals; 2 with IE expressing 
wild type JAK2 and 2 with PV expressing V617F JAK2, standard error of the mean 
shown)
Inhibition of P13K isoforms
Inhibitor
IE I  
PV^
Figure 15[5]: The comparative effects of PI3K isoform inhibitors on 
erytbroblasts stimulated with erythropoietin (Epo) or stem cell factor (SCF)
(both cytokines tested in parallel on D9 erythroblasts derived from a patient with IE 
and wild type JAK2, actual variations in viable cell number shown)
□ SCF
in h ib it o r
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5.3 Discussion
It is now well established that a specific point mutation in JAK2 (V617F) is highly 
correlated with a diagnosis of Polycythaemia Vera. [James et al, 2005; Kralovics et al, 
2005; Levine et al, 2005; Baxter et al, 2005; Zhao et al, 2005; Jones et al, 2005] Initial 
and subsequent research has gone on to look at how this mutation might be implicated 
in the pathophysiology of PV and whether specific inhibitors of JAK2 might have 
therapeutic potential in PV and other myeloproliferative disorders.
In this study, the effects on colony formation of the JAK2 inhibitor, Go6976 (also an 
inhibitor of PKC) were initially compared with a known PKC inhibitor, Go6983. 
Go6976 reduced erythroid and myeloid colony formation whereas Go6983 did not 
confirming that the effects of Go6976 on colony formation were PKC independent. 
The dose responsiveness of colonies to Go6976 in parallel with another JAK2 
inhibitor, Jak Inhibitor 1 (also an inhibitor of Tyk2, Jakl & Jak3) was then tested and 
both were found to be similarly effective.
Iniitial work explored whether there was a difference in effect on erythroid colony 
formation of the JAK2 inhibitors between patients with PV expressing V617F JAK2 
and wild type JAK2 control subjects. Forty colony assays including 24 from samples 
expressing V617F JAK2 were performed and comparison by JAK2 status showed no 
significant difference in the number of erythroid colonies for either Go6976 or Jak 
Inhibitor 1 overall. However, when the 3 samples which were homozygous for V617F 
JAK2 were compared to the rest, it was apparent that these samples were significantly 
less affected by Go6976. In the same group of experiments GM-CFU were reduced by 
both JAK2 inhibitors indicating that these inhibitors did not specifically target 
erythroid colony formation.
The effects of Go6976 and Jak Inhibitor 1 on erythropoietin independent colonies 
from 8 patients with PV and heterozygous expression of V617F JAK2 were assessed. 
Both inhibitors markedly reduced the EEC formation that is characteristic of PV.
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Evaluation of semi-solid colony assays is somewhat subjective in that colonies are 
counted manually. It is also difficult to precisely control cell density in a viscous 
medium. Previous experiments had shown that Day 9 erythroblasts retained functional 
differences between PV and controls and that these cells were still sensitive to JAK2 
inhibition. Further experiments were therefore performed assessing the effects of 
JAK2 inhibitors on erythropoiesis by comparing the viable cell number of 
erythroblasts between V617F JAK2 and wild type control samples using MTS assays.
The principle was first tested in 8 experiments using haematopoietic cell lines 
expressing either V617F or wild type JAK2 in liquid culture. Dose-responsiveness in 
viable cell number with use of both Go6976 and Jak Inhibitor 1 was found. There was 
a trend to reduced sensitivity of cells expressing mutant JAK2 which did not reach 
significance.
A further 40 experiments were then performed using primary erythroblasts. Cells 
were washed free of residual cytokines and then incubated with no added cytokine or 
with added erythropoietin -/+ Go6976 or Jak Inhibitor 1 at a range of doses. There 
was a trend to reduced susceptibility of V617F erythroblasts to JAK2 inhibition which 
reached significance at higher inhibitor doses. Analysis of the small proportion of 
samples from patients expressing homozygous V617F (n=4) again suggested that 
these patients may be less sensitive to JAK2 inhibition than controls.
In 4.4.2 data was presented illustrating that increased basal signalling was seen in PV 
and that this was abolished with JAK2 inhibition. The experiments represented in
5.1.3 and discussed above showed that viable cell number in the absence of 
erythropoietin was increased in PV and that this increased basal viable cell number 
was suppressed with JAK2 inhibition. The implication is therefore that it is the JAK2 
signal which accounts for the increased survival signalling seen in PV erythroid 
progenitors.
The data presented in this study showed that JAK2 inhibitors do reduce erythroid 
colony formation and erythroblast viable cell number but that they also affect myeloid 
colony formation. Using these 2 inhibitors primary erythroid cell survival is 
significantly reduced in V617F and wild type JAK2 samples although the inhibitory
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effect may be lower in mutant cells. Ideally a JAK2 inhibitor with therapeutic 
potential might preferentially affect V617F JAK2 expressing erythroid progenitors.
The role of PI3K signalling in survival of diverse normal and malignant cells is now 
well established. Work done by our and other groups which is discussed in Chapter 4 
showed that PI3K signalling is upregulated in PV erythroblasts and that this signal 
could be reduced with PI3K inhibitors as well as with JAK2 inhibitors. Further 
experiments were performed to assess whether this alteration in signalling with PI3K 
inhibitors was associated with a differential effect on PV erythroid progenitor 
viability.
Our group and others have used the Pan-PI3K inhibitor, LY294002, to explore the 
effects of PI3K signalling. Latterly it has become clear that LY294002 has broad 
effects on serine/threonine kinases including inhibition of the Jak/STAT target Pim l. 
[Jacobs et al, 2005] In view of the particular relevance of aberrant Jak/STAT 
signalling and its potential impact on erythroblast survival in PV, the highly selective 
Class IPI3K  inhibitor PI 103 (which also inhibits mTOR, a downstream target of 
PI3K) and the mTOR inhibitor, Rapamycin, were used in these experiments as well as 
LY294002.
The effects on primary erythroblast viable cell number of LY294002 were compared 
with Go6976 and Jak Inhibitor 1 in 6 primary samples, including 3 from patients with 
PV. Whilst the JAK2 inhibitors did not show different effects on the PV and control 
groups, there was a suggestion that LY294002 might be more effective in PV. This 
may relate to the additional inhibitory effects of LY294002 on Pim-1 as further 
experiments showed that PI 103 and Rapamycin did not have greater effects on 
erythroblast viable cell number than JAK2 inhibitors in subsequent experiments.
PI3K inhibition was then looked at in a larger group. Firstly a dose dependent 
reduction in viable cell number of the V617F JAK2 expressing HEL cells with PI 103 
was observed. It was then found that the effect of PI3K inhibition with LY294002 
was comparable to the effect of JAK2 inhibition in these cells. The effect of PI 103 on 
primary erythroblast viable cell number was then assessed in 7 experiments including 
5 from patients with PV. It was found that primary cells, including those from patients
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with PV, showed dose-dependent reduction in viable cell number with PI103. It was 
additionally found that Rapamycin reduced PV erythroblast viable cell number in the 
presence or absence of erythropoietin.
Colony assays were performed using mononuclear cells derived from peripheral blood 
and it was found that PI 103 could reduce erythroid colony formation and abolish 
EECs in PV. Colony formation in the presence of PI3K inhibitors was then contrasted 
between 4 patients with PV and 4 control subjects using Rapamycin and it was found 
that Rapamycin reduced erythroid colonies by approximately 50%. There was no 
significant difference in effect between PV and controls.
Having established that each of the a, p and ô isoforms of PI3K were expressed in 
primary erythroblasts, the effects of the novel PI3K isoform inhibitors, PI387, 
TGX221 & D030 were then assessed individually in these cells in comparison with 
LY294002 & PI 103. It was found that inhibition of a single isoform had no effect on 
phosphorylation of AKT in contrast to the pan-PI3K blockade seen with LY294002 or 
PI 103. Erythroblast survival was then assessed in 4 experiments using erythroblasts 
from 2 patients with PV and 2 control subjects. Whilst both LY294002 & PI 103 
reduced erythropoietin and SCF dependent viable cell number, the individual PI3K 
isoform inhibitors did not. The implication of these findings is that PI3K dependent 
survival in erythroblasts is not dependent on inhibition of a single isoform but on 
inhibition of all isoforms simultaneously.
The conclusion from these findings is that PI3K inhibition, or blockade of its 
downstream target, mTOR, reduces erythroid colony formation & primary 
erythroblast viable cell number in both PV and control subjects to levels comparable 
with JAK2 inhibitors. PI3K inhibitors might offer an alternative therapeutic approach 
in PV but inhibitors may need to block all PI3K isoforms simultaneously. An 
additional approach may be to explore the therapeutic potential of Rapamycin in PV.
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CHAPTER 6 -  RESULTS 4
The m olecular im print o f  Polycythaem ia Vera
6.1 Affymetrix GeneChip expression profiling of erythroblasts 
From patients with PV and control groups
6.1.1 Quality control
In order to derive sufficient high quality erythroblast RNA suitable for microarray 
analysis, over 30 separate primary patient venesection packs were processed in an 
identical fashion. The 14 that were selected (6 PV [2 homozygous, 4 heterozygous for 
V617F JAK2], 4 IE & 4 normals) were chosen on the basis that enough erythroblasts 
(>0.4 million) with >95% purity had been produced to yield sufficient (>5ug) high 
quality RNA (A260/280 = 1.9-2.1) following Qiagen extraction as described in 2.7.1. 
Biotinylated fragmented RNA was derived from this primary RNA using the rigorous 
approach outlined in 2.7.2-3 applied identically to all samples.
Quality control procedures carried out on the fragmented cRNA using the Agilent 
Bioanalyser showed samples were of good quality. These samples were then 
hybridised onto U133a GeneChips as discussed in 2.7.4. U133a GeneChips offer a 
broad expression profile including that of 14,500 well characterised human genes. 
Hybridisation of the biotinylated erythroblast RNA onto these arrays gave consistent 
GeneChip exposures as shown in Figure 1[6].
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Figure 1[6]: Boxplots showing consistent chip exposure in the 14 microarrays
(PV = Polycythaemia Vera, EE = Idiopathic Erythrocytosis, N = Normals)
<0
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6.1.2 Statistical analysis of microarrays
Data analysis of the microarrays was carried out using the R statistical environment 
and programming language [Venables & Ripley, 2002] and Bioconductor packages 
[Gentleman et al, 2004]. The 'affy' package written to handle Affymetrix data, and 
specifically the 'rma' algorithm for pre-processing, normalizing and calculation of 
expression values was used [Irrizary et al, 2003]. Heatmaps were created using the 
Cluster and Tree view software packages [Bisen et al, 1998, Mootha et al, 2003].
Classical multidimensional scaling (or principle coordinates method) was used to 
show the relation between patient samples. This transformed the high dimensional 
expression signature differences between samples into an optimum 2-dimensional 
descriptive figure with the minimum of distortion.
The gene enrichment analysis used a resampling method (n= 10000), to calculate the 
whether the ‘Jak/STAT’ and ‘differentiation’ genesets were significantly modulated 
above the null distribution. Ten thousand randomly extracted genesets were extracted 
from the data, and the sum of t-values recorded for each. The significance (p) value 
was then the fraction of t-value sums which exceed the t-value sum of the Jak/STAT 
or differentiation set.
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6.1.3 Segregation of microarray signature by subject group
Analysis of the microarray data showed that there was clear separation between the 
PV, IE and normal groups. Classical multidimensional scaling (as described in 2.7.5) 
was used to illustrate the relation between patient samples and this additionally 
showed separation of the PV subjects homozygous & heterozygous for V617F JAK2 
(Figure 2[6]). One of the samples, from a patient with PV who was heterozygous for 
V617F JAK2, was an outlier for some of the differentiating genes but segregated with 
the PV patients for other differentiating genes. This patient did not show any 
significant differences from other PV patients in clinical phenotype, however, there 
was evidence of mild myelofibrosis on her bone marrow trephine.
Figure 2[6]: Multidimensional scaling analysis of tbe microarray data shows 
separation of the subject groups
(analysis of 14 GeneChips including 4 PV patients with homozygous [PV-homo] & 2 
with heterozygous [PV-het] V617F JAK2, 4 patients with Idiopathic erythrocytosis 







































Comparison was made between samples from patients with PV and the 2 control 
groups and genes showing the most significant dysregulation are listed in Table 1[6]. 
Downregulation of genes was more frequently observed in PV than upregulation. A 
heatmap of the 96 most differentially expressed genes comparing the 3 subject groups 
is shown in Figure 3 [6]. This and subsequent heatmaps are depicted with increasing 
intensity of red reflecting gene overexpression & increasing intensity of green 
reflecting gene underexpression relative to the group as a whole.
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Table 1[6]: Genes with altered expression on U133a microarrays in PV
Genes showing marked differentiation between PV & control groups Fold change 
U|)fer|ul<Ttioii
interferon ind uced  tran sm em b ran e protein 1 i^-27) 3 ,5 3
interferon ind uced  tran sm em b ran e protein 1 ^'27) 2  9 6
insulin receptor su b stra te  2  1 7 3
KIAA0676 proleim 1 ,4 3
pim-1 o n c o g e n e  1 6 9
gen om ic  large h tston e  fam ily c lu ster  1 4 3
h i s t o n e l . H t c  1 4 3
hypothetical protein LO C I5 1 1 6 2  1 37
Dowiiiegiiiation
BUB1 budding uninhibited by b en z im id a z o les  1 h om olog  (y e a s t)  0 .3 4
guanine n u cleotid e  binding protein ( 6  protein), alpha 13  0  36
protein tyrosin e  p h o sp h a ta s e , receptor ty p e . O 0  37
bu tyrale-indu ced transcript 1 0 ,4 3
ribonucleotide r ed u c ta se  M l po lyp ep tide 0 .4 6
cyclin  A 2 0  51
cell division c y c le  2 7  0  5 2
protein p h o sp h a ta se  2 (formerly 2A ), regulatory subunit A  (P R  6 5 ) ,  b e ta  isoform  0 ,5 4
cA M P resp o n siv e  e lem e n t binding protein 1 0  5 5
ad en o sy lm eth io n in e  d e c a rb o x y la se  1 0 ,5 6
TPX2, m icro tu b u le -a sso c ia ted  protein h om olog  Ç<enopus laevis) 0 .5 7
m icro tu b u le -a sso c ia ted  protein 7 0  5 8
protein p h o sp h a ta se  2  (formerly 2A ). regulatory subunit A  (P R  6 5 ), b e ta  isoform  0 ,5 9
m icro tu b u le -a sso c ia ted  protein 7  0  6 0
cell division c y c le  27  0 .6 0
dihydrolipoam ide S -a ce ty itra n sfer a se  (E 2 com p on en t o f pyruvate d e h y d ro g e n a se  com plex) 0  6 0
LanC lantibiotic s y n th e ta s e  com p on en t C-like 1 (bacterial) 0  6 0
acid  p h o sp h a ta se  1 . so lu b le  0  61
C 0 P 9  s ig n a lo so m e  subunit 8  0 ,6 2
ribonucleotide red u c ta se  M2 polyp ep tide 0 .6 3
alpha th a la ssem ia /m en ta l retardation syn d rom e X-linked (R A 0 5 4  h o m o lo g . S  cerevrsiae) 0 .7 7
ch ro m o so m e 14 op en  reading fram e 1 3 6  0 .7 8
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Figure 3[6J: Heatmap showing 96 of the most discriminatory genes
(includes 6 PV, 4 IE and 4 normal control samples [N])
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CCR4-N0T transcrlDtion comclex. subunit 3
Solute carrier fzmily 12 (potassium/chloride tramsporters), member 6 
216926 s at 
212634 at
Solute carrier familv 7 (cationic amino acid tramsoorter. v+ svstem). member 1 
Protein ohosohatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform 
Acid DhosDhatase 1. soluble
Nuclear transoort factor 2-like exoort factor 2 
Coatoaer urotein comolex. subunit aloha 
CAMP resoonsive element bindina orotein 1
TPX2. microtubule-associated orotein homoloa (Xenoous laevis)
C0P9 constitutive ohotomorohoaenic homolog subunit 8 (Arabidopsis) 
Microtubule-associated protein 7 
211600 at
Zinc finoer protein 43 (HTF6)
Cvclin D2
Chromosome 19 ooen readina frame 6
Aloha thalassesiia/mental retardation syndrome X-linked (RAD54 hcmolog, S. cerevisiae) 
ATPase. Ca++ transporting, plasma membrane 4 
211150 s at
Nucleoohosmin (nucleolar ohosohoorotein B23, numatrin)
Adenosylmethionine decarboxylase 1
Protein ohosohatase 2 (formerly 2A> . reoulatorv subunit A (PR 65), beta isoform
Membrane comoonent. chromosome 11. surface marker 1
Membrane ccHsoonent. chromosome 11. surface marker 1
L2mC lantibiotic synthetase comoonent C-like 1 (bacterial)
Chaoeronin containino TCPl. subunit 2 (beta)
Microtubule-associated protein 7 
Cell division cycle 27
Translocated promoter region (to activated MET oncogene)
219679 s at 
Cyclin A2
Cell division cycle 27 
Ribonucleotide reductase Ml oolyoeptide 
RABllB. member RAS oncoaene family
Neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) 
Metastasis suooressor 1
Neuroblastoma RAS viral (v-rasl oncogene homolog 
GRB2-associated bindina orotein 1 
Glucocorticoid receotor DHA bindina factor 1
Erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked)
217399 s at 
217189 s at
Heat shock transcriotion factor 1 
S-adenos-ylhomocysteine hydrolase-like 1 
Ataxin 2-like
Phosohatidylcholine transfer orotein 
Ankvrin reoeat domain 27 (VPS9 dcmiain)
Byoothetical orotein FLJ20489
RABll family interactina orotein 1 (class I)
TBCl dMsain familv. member 5
Glycine C-acetvItransferase (2-amino-3-ketobutyrate coenzyme A  ligase)
CCR4-N0T transcriotion complex, subunit 3 
Bromodomain containina 4
Serine/threonine kinase 11 (Peutz-Jeghers syndrome)
Chromosome 16 ooen reading frame 35 
Myelin basic orotein 
Byoothetical orotein FLJ22028
Interferon induced transmembrane protein 1 (9-27)
Leotin receotor
Core-binding factor, runt dMsain, alpha subunit 2; translocated to, 3 
209184 3 at
RAB. member of RAS oncoaene familv-like 4 
Transmembrane 7 suoerfëuaily member 3 
Solicina factor, arainine/serine-rich 7. 35kDa 
Cell division cycle 2-like 6 (CDKB-like)
MAX bindina orotein 
Byoothetical orotein FLJ20489
Interferon induced transmembrane orotein 1 (9-271 
Ubiouitin associated and SB3 demain containina. A 
TCF3 (E2A1 fusion partner (in childhood Leukemia)
215071 s at 
Pim-1 oncoaene
Caooina orotein (actin filament1 muscle Z-line, beta 
Tetratricooeotide reoeat domain 3 




Fasciculation and elonaation protein zeta 2 (zygin II)
Bromodomain containina 2 
Tetratricooeotide reoeat dcxmain 3 
Dicerl. Dcr-1 homoloa (Drosoohilal 
Seven transmembrcme demain orphan receptor 
Transcriotion factor 4 
KIAA1033 orotein
Chromosome 20 ooen readina frame 67
(Alanine nucleotide binding protein (G protein) , alpha 13 
Aoootosis inhibitor 5
Reolication factor C (activator 11 5, 36.5kDa 
Secretory carrier membrane orotein 1 
Butyrate-induced transcriot 1 
Ribonucleotide reductase M2 oolvoeotide 
CAMP resoonsive element binding protein 1 
Primase. oolvoeotide 1. 49kDa
5,10-methylenetetrahydrofolate reductase (NADPH)
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6.1.4 Erythroid differentiation assessed by microarray analysis
Sets of genes known to be associated with erythroid differentiation were identified 
from the scientific literature and are shown in Table 2[6]. The expression pattern of 
these genes was analysed using the gene enrichment method described in 2.7.5 to 
assess whether expression of the erythroid differentiation set was modulated 
significantly from the null distribution for the sample set.
Table 2[6]: Genes known to be associated with erythroid differentiation
CD34 CD34 molecule
CD36 Thrombospondin receptor
KIT Stem cell receptor (GDI 17)
GYPA Glycophorin A
HBB Hemoglobin beta
H B Al Hemoglobin alpha
CDHl E-Cadherin precursor
EPOR Erythropoietin receptor
GATAI GATA-binding protein 1
TFRC Transferrin receptor (CD71)
EBP41 Protein 4.1
Comparison of all groups (PV, IE & normals) showed a significant difference in 
erythroid differentiation (p=0.0005). However, as can be seen in Figure 4[6], these 
differences were due to increased expression in the IE group with PV & normal 
groups showing similar expression patterns. This overall pattern was consistent with 
the flow cytometric (FACS) assessment of immunophenotype: FACS data showed 
that IF versus non IF subjects were 56% +/-7% vs. 48% +/-3% Glycophorin A 
positive (mean fluorescence intensity 26 vs. 24 +/-3) and 84% +/-4% vs. 81% +/-2% 
CD36 positive (mean fluorescence intensity 29 vs. 18 +/-3).
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Figure 4[6]: Heatmap showing gene expression by erythroid differentiation 
marker in subject groups
(includes data from 4 normal subjects, 4 IE and 6 PV [PV-het & PV-homo denotes 
PV subjects heterozygous and homozygous for V617F JAK2], red = increased 
expression, green = decreased expression)






























6.1.5 Janus-associated kinase (JAK2) gene expression
With the knowledge of the association between V617F JAK2 and Polycythaemia 
Vera, JAK2 gene expression was specifically assessed to see whether any differences 
were apparent. There were 2 probes for JAK2 on the U133a GeneChips. Whilst there 
was an indication that IF had a marginally higher level of JAK2 expression than 
normal samples (mean IF:N= 8.39:7.54, p=0.03), an F-test comparison of all 3 groups 
was not significant (mean IF:PV:N= 8.39:7.64:7.54, p=0.10). The conclusion is 
therefore that the V617F JAK2 mutation is not associated with an altered level of 
JAK2 gene expression in erythroblasts.
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6.1.6 Candidate targets of Jak-STAT activation
It seemed important to consider carefully whether the differences noted in the 
microarray data might represent a simple Jak/STAT imprint. In order to explore this, 
an extensive search was performed to identify genes which had been clearly identified 
as Jak-STAT targets in published literature and these genes are shown in Table 3 [6].
Table 3[6]: Published Jak-STAT targets
BCL2L1 BCL-2 related protein (BCLXL included)
MCLl M yeloid cell leukaemia 1





TP53 Tumor protein p53
VEGF Vascular endothelial growth factor
HIFIA Hypoxia-inducible factor 1, alpha subunit
PIMl Oncogene PIM 1
PIM2 Oncogene PIM2
CISH Cytokine-inducible SH2-containing protein
SOCSl Suppressor o f cytokine signaling 1
S0C S2 Suppressor o f cytokine signaling 2
SOCS3 Suppressor o f cytokine signaling 3
SOCS4 Suppressor o f cytokine signaling 4
S0C S5 Suppressor of cytokine signaling 5
SOCS6 Suppressor of cytokine signaling 6
SOCS7 Suppressor o f cytokine signaling 7
OSM Oncostatin M
IRFl Interferon regulatory factor 1
CDKNIA Cyclin-dependent kinase inhibitor lA  (p21)
IFITl Interferon-induced protein with tetratricopeptide repeats I
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2
IFI27 Interferon-alpha-inducible protein 27
IFI16 Interferon-gamma-inducible protein 16
IFITMl Interferon-induced transmembrane protein 1
IFITM2 Interferon-induced transmembrane protein 2
IFITM3 Interferon-induced transmembrane protein 3
ARNT Hypoxia-inducible factor 1, beta subunit
GRBIO Growth factor receptor-bound protein 10
CEBPA CCAAT/Enhancer-binding protein, alpha
ETSl Oncogene E T S1
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Using the gene enrichment test to compare these genes with other randomly selected 
genes it was clear that these Jak-STAT targets were significantly modulated against 
the null distribution overall for PV samples compared to both control groups 
(p=0.0183). However, within the group of Jak/STAT targets there was a spectrum of 
modulation with some genes showing no significant differences in expression as 
illustrated in Figure 5 [6].
Figure 5[6]: Heatmap showing gene expression of known Jak-STAT targets
(includes evaluation of the published Jak-STAT targets listed in Table 3[6] by subject 
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6.2 PCR validation of basal erythroblast gene expression
Planning validation of the microarray dataset was difficult for two reasons. Firstly, the 
differences in gene expression detected by the microarray analysis were relatively 
small fold changes predominantly involving gene downregulation in PV. Secondly, 
there was a limited quantity of residual high purity primary erythroblast RNA. As it 
would be difficult to be confident of results with low polymerase chain reaction (PCR) 
copy number due to reduced expression, genes which were up-regulated in PV were 
selected for validation. Wherever possible (and unless stated otherwise) the same 
primary material as had been used for the microarray analysis was used for validation.
A SYBR-green conjugated Taqman approach as outlined in 2.4.7 was used for 
validation. Selected genes were Pim-1 oncogene (PEMl), Interferon-induced 
transmembrane protein 1 (IFITMl) Core binding factor, alpha subunit 2, translocated 
to,3 (CBFA2T3) and Leptin receptor (LEPR). These 4 genes were chosen to include 2 
which were believed to be Jak-STAT targets (PIM l, IFITM l), and 2 which were not 
(LEPR & CBFA2T3). After some initial experiments. Oncogene ABL (ABL) was 
selected as a single ‘housekeeping gene’.
6.2.1 Quality control of real-time quantitative PCR (RQ-PCR) analysis
Taqman primers for PIM l and ABL were taken from published data [Kim et al, 2005; 
Beillard et al, 2003] and primers for IFITM l, LEPR and CBFA2T3 were designed ‘in 
house’ as there were no suitable published alternatives. RNA from leukaemic cells 
was used to derive cDNA as per 2.4.3. This cDNA was diluted 1:2, 1:4, 1:8, 1:16 and 
RQ-PCR performed in triplicate on at least 2 occasions as per 2.4.7. Standard curves 
were constructed, trendlines applied and R^ values calculated as shown in Figure 6[6] 
confirming a parallel relationship between the selected and housekeeping gene within 
the mean threshold cycle (Ct) range appropriate to subsequent experiments.
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Figure 6[6]: Standard curves for Taqman analysis
(RNA from leukaemic cells reverse transcribed to cDNA, cDNA diluted 1:2, 1:4, 1:8, 
1:16 and RQ-PCR performed in triplicate for a) IFITM l, PIMl & ABL b) CBFA2T3, 
LEPR & ABL on at least 2 occasions using a SYBR-green Taqman approach, mean 
threshold cycle [Ct] plotted against log cDNA dilution)
a)
Standard Curves for IFITMl, PIM1 & ABL
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6.2.2 Pim-1 oncogene (PIMl)
Fresh cDNA was prepared from the erythroblast stock RNA on each occasion with 
cDNA amplified in duplicate for real-time quantitative PCR using SYBR-Green as 
described in 6.2.1. Sixteen samples were available including 13/14 used in the 
microarray analysis and 3 further samples of comparable quality (1 IE, 2 Normals). 
Six/16 samples were processed on 3 separate occasions, 5/16 on 2 separate occasions 
and 5/16 only once. Mean Ct was calculated for PIMl & ABL and relative expression 
was calculated using the formula ABL - mean ctPiMi) ^ significant
difference between PV patients and the control groups as shown in Figure 7[6].
Figure 7[6]: PIMl expression by diagnostic group
(PIM 1 expression relative to ABL shown, includes averaged results from 6 PV, 5 IE 
& 5 normal subjects with standard error of the mean shown)




6.2.3 Interferon-induced transmembrane protein 1 (IFITMl)
Fresh cDNA was prepared from the erythroblast stock RNA on each occasion with 
cDNA amplified in duplicate for real-time quantitative PCR using SYBR-Green as 
described in 6.2.1. Sixteen samples were available including 13/14 used in the 
microarray analysis and 3 further samples of comparable quality (1 IE, 2 Normals). 
Eleven/16 samples were processed on 2 separate occasions and 5/16 on 1 occasion. 
Relative expression was calculated as in the previous section. There was a significant 
difference between PV patients and the control groups as shown in Figure 8 [6].
Figure 8[6]: IFITMl expression by diagnostic group
(IFITMl expression relative to ABL shown, includes averaged results from 6 PV, 5 
IE & 5 normal subjects with standard error of the mean shown)









As IFITMl was so strongly over-expressed in the PV subjects a simple semi- 
quantitative approach was developed to corroborate these findings using different 
primers. The same erythroblast template RNA was used as in the preceding 
experiments and cDNA was produced in an identical fashion. cDNA was amplified 
simultaneously for EFITM1 and GAPDH as described in 2.2.4. Findings confirmed 
overexpression of IFITMl in PV as shown in Figure 9[6].
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Figure 9[6]: Semi-quantitative analysis of IFITMl / GAPDH expression
(simultaneous amplification of IFITMl & GAPDH was performed using the same 
samples of template RNA as in Figure 8[6], resolved products were quantified by 
densitometry & the ratio of IFITM1 to GAPDH is shown with standard error of the 
mean plotted)



















6.2.4 Core binding factor, runt domain, a subunit 2, trans. to 3 (CBFA2Ï3)
CBFA2T3 expression was evaluated by RQ-PCR in duplicate using freshly made 
cDNA from 15 subjects. Template erythroblast RNA from these 13 subjects included 
13/14 microarray samples and 2 further samples of similar quality from normal 
subjects. There was a significant difference between PV patients and the control 
groups as shown in Figures 10[6].
Figure 10[6]: CBFA2T3 expression by diagnostic group
(CBFA2T3 expression relative to ABL shown, includes averaged results from 6 PV, 4 
IE & 5 normal subjects with standard error of the mean shown)




6.2.5 Leptin receptor (LEPR)
LEPR expression was evaluated by RQ-PCR using the same samples and methods 
described in 6.2.4. Using this technique, homozygosity for V617F JAK2 was the 
factor which resulted in the significant increase in LEPR expression found in PV as 
shown in Figure 11 [6]. This finding was not apparent in the microarray analysis 
where expression was portrayed relative to the whole sample set (samples 
homozygous for V617F JAK2 in lanes 3 & 5 of the heatmap shown in Figure 3[6]).
Figure 11[6]: LEPR expression by diagnostic group & V617F JAK2 status
(LEPR expression relative to ABL shown, includes averaged results from 6 PV [2 
HOM = homozygous, 4 FIET = heterozygous for V617F JAK2, 4 IE & 5 normal 
subjects with standard error of the mean shown)








6.3 PCR analysis of the modulatory effects on gene expression of 
inhibitors of JAK2 in haematopoietic cell lines and primary 
erythroblasts
Having confirmed the upregulation of PIM 1, IFITM 1, CBFA2T3 & LEPR in 
erythroblasts, further work was done to explore whether this increased expression was 
the result of overactive JAK signalling. Experiments on haematopoietic cell lines 
were performed using HEL cells (cytokine independent, homozygous expression of 
V617F JAK2) and TFl cells (cytokine dependent, expressing wild type Jak 2). 
Experiments on primary cells were performed using CD34+ derived erythroblasts 
from normal individuals and Day 9 erythroblasts derived from the peripheral blood of 
patients with PV & IE. Cytokine dependent cells were washed and starved, then pre­
incubated with either Go6976 or Jak Inhibitor 1 followed by stimulation with 
erythropoietin as described in 2.6.1.
RNA was extracted using the chloroform technique described in 2.4.2 with reverse 
transcription as in 2.4.3. Semi-quantitative evaluation was performed with GAPDH as 
per 2.4.4. Real-time quantitative PCR (RQ-PCR) was performed as per 2.4.7. Relative 
gene expression was calculated as in 6.2.2 and results were normalised (to no 
inhibitor for HEL cells and to cytokine alone for cytokine dependent cells). Mean 
values relative to the normaliser are expressed below.
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6.3.1 PIMl
Five separate experiments were performed where HEL cells were exposed to the 
JAK2 inhibitor, Go6796. The effects of this inhibitor were evaluated semi- 
quantitatively initially but differences were subtle and difficult to quantitate, so an 
RQ-PCR approach was adopted. Results are shown in Figure 12[6] and suggest that 
PIMl expression in HEL cells may be JAK2 dependent. This effect was also apparent 
at a protein level as shown in Figure 19[4].
Figure 12[6]: The effect of JAK2 inhibition on PIMl expression in HEL cells
(mean normalised results from 5 experiments where HEL cells were incubated with 
no inhibitor or Go6976 for 6 hours, standard error of the mean shown)
PIM1 expression with Jak2 inhibition in HEL cells




In 4 experiments TFl cells were starved and then stimulated with erythropoietin for 1 
hour +/- pre-incubation with Go6976 or Jak Inhibitor 1. PIMl expression was 
evaluated by RQ-PCR and the results are presented in Figure 13[6] showing that 
PIMl expression is erythropoietin inducible in a JAK2 dependent manner in these 
cells. This pattern was also noted with Go6976 pre-incubation & GM-CSF 
stimulation.
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Figure 13[6]: The effect of erythropoietin & JAK2 inhibition on PIMl expression 
in TFl cells
(mean normalised PIMl expression relative to ABL from 4 experiments where TFl 
cells were starved and then stimulated with erythropoietin -/+ Go6976 or Jak Inhibitor 
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Five experiments were performed using CD34+ derived erythroblasts which had been 
washed and starved for 2 hours and then stimulated for 1 hour with erythropoietin +/- 
pre-incubation with Go6976 or Jak Inhibitor 1. Results from these experiments are 
shown in Figure 14[6] and confirm that PIMl expression is erythropoietin induced 
and JAK2 dependent in normal erythroblasts. This pattern persisted at a 4 hour 
stimulation time point.
Figure 14[6]: The effect of erythropoietin & JAK2 inhibition on PIMl expression 
in normal CD34+ derived erythroblasts
(mean normalised PIMl expression relative to ABL from 5 experiments where 
erythroblasts were starved & then stimulated with erythropoietin -/4- Go6976 or Jak 
Inhibitor 1[JI1], standard error of the mean shown)
Normalised PIM1 expression in CD34+ derived 
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Four experiments were performed using erythroblasts derived from the peripheral 
blood of patients with PV (Ihomozyous, 3 heterozygous for V617F JAK2). RNA was 
extracted from cells which had been washed and starved for 2 hours and then 
stimulated with erythropoietin +/- pre-incubation with Jak Inhibitor 1 (n=3) or 
Go6976 (n=l). As previously, fresh derived cDNA was amplified in duplicate.
Three/4 primary samples were analysed on 3 occasions, 1/4 on 2 occasions. Mean 
results from these experiments are shown in Figure 19[6] and confirm that PIMl 
expression is erythropoietin induced and JAK2 dependent in PV erythroblasts. It can 
also be seen that there is a trend to reduction of PIMl levels to below basal expression 
with JAK2 inhibition as was seen in protein analysis in primary erythroid cells shown 
in Figure 22 [4].
Figure 15[6]: The effect of erythropoietin & JAK2 inhibition on PIMl expression 
in erythroblasts derived from the peripheral blood of patients with 
Polycythaemia Vera
(mean PIMI expression relative to ABL from experiments in 4 patients shown ( 1 
homozygous [red], 3 heterozygous for V617F JAK2), erythroblasts were starved [Nil] 
and then stimulated with erythropoietin [Epo] -!+ pre-incubation with Jak Inhibitor 
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Initial experiments were performed using HEL cell derived RNA following exposure 
to the Jak 2 inhibitors Go6976 and Jak Inhibitor 1 followed by semi-quantitative 
evaluation of IFITMl with GAPDH. Good products were obtained but repeat 
experiments showed no significant effect of JAK2 inhibition visually or by 
densitometry and an example of this is shown in Figure 16 [6].
Figure 16[6]: Semi-quantitative analysis of IFITMl with GAPDH using RNA 
extracted from HEL cells exposed to JAK2 inhibitors
(RNA was extracted from HEL cells exposed to either Go6976 or Jak Inhibitor 1 [JIl], 
cDNA was amplified for IFITMl & GAPDH simultaneously and products resolved 
on an agarose gel)
IFITMl
GAPDH
Î Î Î t Î Î
Nil Go6976 JIl Nil
6hrs 6h rs 6h rs 36h rs
Go6976 JIl 
3 6 h rs 36h rs
As IFITMl is an interferon response gene known to be induced by Jak/STAT 
signalling, this lack of response to JAK2 inhibitors seemed surprising and so the 
effect of these inhibitors was further assessed by RQ-PCR. These experiments were 
performed simultaneously with the same primary samples and subsequent analysis 
described in the previous section for PIM l (results shown in Figures 12[6] -  15[6]). 
The derived results are shown below in Figures 17[6] = 20[6] and confirm that 
IFITMl expression is not JAK2 dependent in HEL cells and is not erythropoietin- 
induced in a JAK2 dependent manner in TFl cells, normal or PV erythroblasts.
Figure 17[6]; The effect of JAK2 inhibitors on IFITMl expression in HEL cells
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(mean normalised IFITMl expression relative to ABL from 5 experiments where 
HEL cells were incubated with no inhibitor or either Go6976 or Jak Inhibitor 1 [JIl] 
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Figure 18[6J: The effect of erythropoietin & JAK2 inhibition on IFITMl 
expression in TFl cells
(mean normalised IFITMl expression relative to ABL from 4 experiments where TFl 
cells were starved and then stimulated with erythropoietin -/+ Go6976 or Jak Inhibitor 
1 [JIl], standard error of the mean shown)
Normalised IFITM1 expression in TFl cells
<D 0.4




Figure 19[6J: The effect of erythropoietin & JAK2 inhibition on IFITMl 
expression in normal CD34+ derived erythroblasts
(mean normalised IFITMl expression relative to ABL from 5 experiments where 
erythroblasts were starved and then stimulated with erythropoietin -/+ Go6976 or Jak 
Inhibitor 1[JI1], standard error of the mean shown)
Normalised IFITM1 expression in CD34+ derived 
erythroblasts with Jak2 inhibitors
Nil Epo Epo + Go6976
Cell conditions
Epo + JI1
Figure 20[6]: The effect of erythropoietin & JAK2 inhibition on IFITMl 
expression in erythroblasts derived from the peripheral blood of patients with 
Polycythaemia Vera
(mean IFITM1 expression relative to ABL from experiments in 4 patients shown as 
per Figure 15 [6])
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Whilst investigating IFITMl expression in TFl cells it was shown that IFITMl 
expression was interferon-inducible in these cells. Further experiments were 
performed to assess the effects of interferon stimulation +/- JAK2 inhibition using 
CD34+ derived erythroblasts and it was found that interferon stimulation of IFITM 1 
was Jak dependent in these cells as shown in Figure 21 [6].
Figure 21 [6]: Induction of IFITMl by Interferon in a Jak dependent manner
(mean normalised IFITM 1 expression relative to ABL from 4 experiments using 2 
separate samples of CD34+ derived erythroblasts which had been washed, starved and 
then stimulated with Interferon alpha -/+ pre-incubation with Go6976 or Jak Inhibitor 
1 [JIl], standard error of the mean shown)
Normalised IFITM1 expression in erythroblasts 
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The preceding data suggests that IFITMl is a target of JAK activation in the context 
of interferon but not erythropoietin stimulation. This is likely to be a consequence of 
the specific STATs involved in interferon signalling. Furthermore, Epo can inhibit the 
interferon induced upregulation of IFITMl as shown by the following experiments. 
CD34+ derived erythroblasts were stimulated with Interferon alpha in the absence or 
presence of erythropoietin and RQ-PCR was performed on derived products from 2 
separate experiments. Mean values from 3 amplification runs of the 2 experiments are 
shown in Figure 22[6].
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Figure 22[6J: The inhibitory effect of erythropoietin on IFITMl expression in 
CD34+ derived erythroblasts
(mean values from 3 amplification runs of 2 experiments using CD34+ derived 
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Two experiments were performed where HEL cells were exposed to Go6976 and Jak 
Inhibitor 1 for 4 hours. Go6976 reduced expression of CBFA2T3 (x 0.73 & x 0.40 
whilst Jak Inhibitor 1 had variable effects (x 2.17 & x 0.56). In 2 experiments TFl 
cells were starved and then stimulated with erythropoietin with or without pre­
incubation with Go6976 or Jak Inhibitor 1. Erythropoietin expression variably 
affected CBFA2T3 (x 1.01 & x 6.43). Go6976 & Jak Inhibitor 1 did not decrease 
CBFA2T3 expression in the presence of erythropoietin (x 1.44 & x 1.29 and x 3.67 
and X 1.15 respectively).
In 2 experiments CD34-I- derived erythroblasts were washed and starved then 
stimulated with erythropoietin +/- pre-incubation with Go6976 and Jak Inhibitor 1. 
Erythropoietin stimulation did not increase CBFA2T3 expression (x 0.05 & x 0.86). 
Go6976 & Jak Inhibitor 1 did not consistently decrease CBFA2T3 expression in the 
presence of erythropoietin (x 0.04 & x 0.57 and x 0.02 & x 1.18 respectively).
The experimental material from PV erythroblasts used in 6.1.3 & 6.2.3 and portrayed 
in Figures 15 [6] and 20[26] was also tested in parallel with LEPR for CBFA2T3 
expression. Fresh cDNA was amplified in duplicate on 2 separate occasions. There 
was no clear relationship with erythropoietin stimulation or JAK2 inhibition as shown 
in Figure 23[6] for 3/4 patients. Mean values from normalised results are shown in 
Figure 24[6] and confirm this overall impression. These results are inconclusive, but 
suggest that CBFA2T3 is not dependent on the erythropoietin -  Jak/STAT axis.
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Figure 23[6]; Results from 4 separate experiments using erythroblasts from 
patients with PV exploring the effect of JAK2 inhibition on CBFA2T3 expression
(mean CBFA2T3 expression relative to ABL in 4 experiments using peripheral blood 
derived erythroblasts from patients with PV which were stimulated with Epo -/+ pre­
incubation with Go6976 or Jak Inhibitor 1 [III])
CBFA2T3 expression in erythroblasts
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Figure 24[6J: Mean normalised CBFA2T3 expression in erythroblasts with 
erythropoietin stimulation and JAK2 inhibition
(normalised mean results from Figure 23[6], standard error of the mean shown)
Normalised CBFA2T3 expression in erythroblasts
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6.3.4 LEPR
Two experiments were performed where HEL cells were exposed to Go6976 and Jak 
Inhibitor 1. Neither Go6976 nor Jak Inhibitor 1 consistently reduced LEPR expression 
(x 2.5 & X 2.9 and x 1.42 & x 0.57 respectively). In 2 experiments TFl cells were 
starved and then stimulated with erythropoietin with or without pre-incubation with 
Go6976 or Jak Inhibitor 1. Erythropoietin induced LEPR expression in 1/2 
experiments (x 1.29 and x 0.27). Go6976 & Jak Inhibitor 1 reduced expression in 3/4 
experiments (x 0.40 & x 0.44 and x 1.82 & x 0.43 respectively).
In 2 experiments CD34+ derived erythroblasts were washed and starved for 2 hours 
then stimulated with erythropoietin 4-/- pre-incubation with Go6976 2.5uM or Jak 
Inhibitor 1. Erythropoietin did not induce LEPR expression (x 0.02 & 0.33). Go6976 
& Jak Inhibitor 1 reduced LEPR expression (x 0.02 & x 0.35 for Go6976 and x 0.01 
& X 0.18 respectively).
The experimental material from PV erythroblasts used in the previous section was 
also tested in parallel with CBFA2T3 for LEPR expression with fresh cDNA 
amplified in duplicate on 2 separate occasions. LEPR expression was increased with 
erythropoietin stimulation and was reduced with JAK2 inhibition in each case. The 
single patient homozygous for V617F JAK2 had markedly higher levels of LEPR 
expression as had been noted previously by RQ-PCR of the microarray template 
erythroblast RNA. The results are shown in Figure 25 [6] with normalised mean 
values in Figure 26[6] and confirm the erythropoietin -  Jak/STAT dependency of 
LEPR expression in PV erythroblasts.
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Figure 25[6]: Results from 4 separate experiments using erythroblasts from 
patients with PV exploring the effect of JAK2 inhibition on LEPR expression
(LEPR expression relative to ABL in 4 experiments using peripheral blood derived 
erythroblasts from patients with PV which were stimulated with Epo -/+ pre­






Figure 26[6]: Mean normalised LEPR expression in erythroblasts with 
erythropoietin stimulation and JAK2 inhibition
(normalised mean results from Figure 25[6], standard error of the mean shown)
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6.4 Semi-quantitative analysis of gene expression using RNA 
derived from neutrophils
Since neutrophils are easier to collect than erythroblasts it might have been useful to 
identify changes in neutrophil gene expression for further investigative work. Four 
genes were selected and assessed using semi-quantitative amplication of cDNA made 
from the neutrophil-derived RNA of patients with PV, EE and normal controls using 
the same methods as that employed for FRY 1. These 4 genes included 2 which were 
upregulated on the microarrays (PIM 1 & IFITM 1 ) and 2 which were downregulated 
(Nucleophosmin [NPl] & Protein phosphatase 2 regulatory subunit alpha [PPP2R2A]. 
GAPDH was used as a ‘housekeeping’ gene, amplified products were resolved with 
agarose electrophoresis and band density relative to GAPDH was calculated.
6.4.1 Pim-1 oncogene (PIMl)
Minimal or no product was obtained following RT-PCR of PIM l using neutrophil 
derived RNA.
6.4.2 Interferon induced transmembrane protein 1 (IFITMl)
Expression was assessed in 8 patients with PV, 5 patients with IE and 7 normal 
individuals. Mean densitometric ratios for IFITM l / GAPDH were 1.08 (PV, 0.63- 
2.28), 0.69 (IE, 0.39-1.00) & 1.11 (Normals, 0.74-1.38). This expression pattern was 
different to that seen in the erythroblast-derived material from the same subjects.
6.4.3 Nucleophosmin (NPl)
Neutrophil derived material was assessed in 6 patients with PV, 4 patients with IE & 4 
normal individuals. The PGR product with the initial primer design gave a double 
band. Subsequently 4 different sets of primers were developed but in each case a 
double band was produced. Semi-quantitative densitometric analysis of these bands 
relative to GAPDH gave values of 0.76 (PV), 0.45 (IE) & 1.27 (normals). This pattern 
of relative expression differs from that noted in the erythroblast microarrays.
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6.4.4 Protein phosphatase 2 regulatory subunit alpha (PPP2R2A)
Neutrophil derived material was assessed in 6 patients with PV, 4 patients with IE & 4 
normal individuals. Semi-quantitative densitometric analysis relative to GAPDH gave 
values of 0.19 for PV, & 0.53 for IE. The faint products for PPP2R2A formed from 
normal samples were not suitable for densitometric analysis. These neutrophil-derived 
results are not, therefore, comparable with the expression pattern in erythroblasts in 
that normals had lower expression than PV.
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6.5 The contribution of Interferons & Leptin to erythroblast 
proliferation & survival
6.5.1 Interferons
IFITM 1 is a known interferon response gene. In the knowledge that this was 
upregulated in PV, further work was done to assess the affects of Interferon in 
primary cells. Interferon Alpha (IFN-A) or Gamma (IFN-G) was introduced into 
colony assays to assess their effects on erythroid proliferation. Averaged results from 
7 (IFN-A) & 8 (IFN-G) experiments gave non-significant reductions in BFUe 
formation relative to controls of 12% & 22%. EECs were reduced with both agents in 
a single experiment.
Interferon Gamma was introduced into 5 MTS assays using Day 9 erythroblasts (3 PV, 
2 IE) and produced a slight increase in erythroblast viable cell number with some 
differences between PV & IE as shown in Figure 27[6]. One experiment was 
performed where the effects of IFN-A, B & G were evaluated in parallel by MTS 
assay and with Annexin V (AV = Annexin V negative cells) staining & FACS 
analysis. The ratio of viable cells to the erythropoietin only controls were 1.1 (AV = 
0.9) for IFN-A, 1.5 (AV = 1.3) for IFN-B & 1.9 (AV=1.6) for IFN-G. These results 
confirm the complex effects of interferons on erythroblast viable cell number with 
anti-proliferative and anti-apoptotic impact.
Figure 27[6]: Average results from 5 experiments assessing the effects of 
Interferon-G (IFN-G) on erythroblast viable cell number
Interferon G & erythroblast viable cell number
IE
PV
Nil E po IFN-G + Epo
c o n d i t io n s  & d ia g n o s is
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6.5.2 Leptin
Once upregulation of LEPR was ascertained in PV it was felt that some preliminary 
work assessing the effects of Leptin on primary cells would be relevant. Recombinant 
human Leptin was introduced into colony assays to assess its effect on erythroid 
proliferation. Averaged results from 7 experiments showed a non-significant increase 
of 14% in colony formation relative to controls. In order to explore the effect of 
Leptin at more physiological concentrations of erythropoietin, Epo was restricted to 
0.03iu/ml in 5 colony assays with or without Leptin. The results shown in Figure 28[6] 
suggest that Leptin makes little contribution to erythroblast proliferation.
Figure 28[6]: Results from 5 experiments where Leptin was added to erythroid 
colonies with low level erythropoietin
(colony assays from 3 patients with PV & 2 with IE with Epo 0.03iu/ml +/- Leptin 
200ng/ml)
Effect of Leptin on erythroid colonies with Epo 
0.03iu/mi
20
Epo Epo + Leptin
The effect of Leptin on erythroblast viable cell number was assessed by MTS assay 
using D9 erythroblasts from 3 patients. In the absence of Epo Leptin increased 
erythroblast viable cell number by a mean factor of 1.2. There was no effect on viable 
cell number when Leptin was added in the presence of erythropoietin 2iu/ml.
These results show that Leptin may exert a slight pro-survival effect on erythroblasts 
but that this effect is overwhelmed with higher concentrations of added erythropoietin.
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6.6 Discussion
Whilst there is some literature on the gene expression profile of neutrophils and 
CD34+ cells from patients with PV, there is no published data on erythroid progenitor 
gene expression in this disease. The work presented in this chapter was designed to 
compare erythroid gene expression between patients with clonal (PV) and non-clonal 
(IE) erythroid expansion as well as normal controls. This gave insight into the 
changes in gene expression which simply result from erythroid expansion and those 
which provide clues to an underlying myeloproliferative disorder.
Template RNA was extracted from highly purified erythroblasts derived from the 
peripheral blood of 14 individuals including 6 with PV (2 homozygous, 4 
heterozygous for V617F JAK2) 4 with IE & 4 normal subjects (all wild type for 
JAK2). Fragmented biotinylated RNA derived from this template material was 
hybridised onto U133A microarrays with evidence of good quality control. 
Affymetrix U133A GeneChips were produced following publication of the draft 
Human Genome data and offer a broad gene expression profile including that of 
14,500 well characterised human genes.
As other investigators had found, there was segregation of the PV expression 
signature from the control signatures. Intriguingly, there was also clustering of each 
individual diagnostic category (PV [homozygous & heterozygous for V617F JAK2], 
IE and normals). Only 1 of the 6 patients with PV grouped with the IE samples. As an 
outlier overall, this PV patient helped to narrow down targeted analysis of the group 
of genes which might have pathophysiological consequence in PV.
The altered expression profile found in PV was broad but subtle in keeping with the 
slow pace of this disease relative to acute leukaemia in vivo. Comparing PV to the 
control subjects, the most upregulated gene was IFITM l with a 3.59 fold increase. 
Gene downregulation was more frequently observed in PV but was less marked, with 
the significant fold decreases reaching a minimum of 0.34 for BUBl.
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It is recognized that the gene expression pattern of erythroblasts varies with the 
number of days of in vitro culture as progenitors differentiate. [Scicchitano et al, 2003] 
For this reason, all the samples in this study were analysed after the same period of in 
vitro erythroblast culture. A possible explanation for the altered expression profile 
observed in PV observed in this study was primary differences in PV erythroblast 
differentiation. The published data on this issue is inconclusive. One group of 
investigators observed earlier and increased expression of Glycophorin A in CD34+ 
derived liquid cultures from the bone marrow of patients with PV. [Ugo et al, 2004]
By contrast, other groups which used CD34+ cells derived from peripheral blood did 
not find altered differentiation in PV erythroblasts [Dai et al, 2005; Zeuner et al,
2006].
Work presented in Chapter 3 did not show altered erythroid differentiation in 
peripheral blood -  derived PV erythroblasts by standard immunophenotyping and 
FACS analysis. Erythroid differentiation was again assessed using the microarray 
dataset and confirmed these findings. It was however noteworthy, (as had been the 
case with the immunophenotyping data) that the IB samples showed small but 
statistically significant differentiation differences from the PV and normal groups. 
There is no immediate explanation for these findings.
A key issue in analysis of these microarrays was whether the altered gene expression 
profiles seen in PV represented a V617F JAK2 imprint. Levels of JAK2 mRNA 
expression were initially assessed as one group of investigators had found increased 
levels of JAK2 mRNA derived from neutrophils in PV and IE compared to normal 
controls. [Lippert et al, 2006] There was no increased JAK2 expression in PV 
erythroblasts in this study.
An extensive literature search was performed to identify genes which had previously 
been implicated as Jak/STAT targets. Identified Jak/STAT targets broadly incuded 
suppressors of cytokine signalling (SOCS), interferon-inducible genes, known 
oncogenes such as E T Sl, TP53, BCL-2 & Pim-1, hypoxia inducible genes such as 
ARNT, H IFIA  & VEGF, anti-apoptotic targets such as M CLl, BIRC5 & BCL2L1 & 
D-Cyclins [Clarkson et al, 2006; Hartman et al, 2005 ; Nelson et al, 2004; Bromberg
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et al, 2000 ;Der et al, 1998 ; Zeng et al, 2006 ; Klampfer et al, 2003 ; Geiss et al,
2003 ; Xu et al, 2005 ; Stout et al, 2005 & Numata et al, 2005].
The dataset was then interrogated for significant alteration in expression of these 
genes compared to other randomly selected genes using the gene enrichment method. 
The Jak/STAT target genes overall were significantly modulated in PV (p=0.0183), 
however, there was a spectrum of modulation with some genes known to be 
Jak/STAT targets showing no altered expression in PV. It is possible that the 
supraphysiological levels of erythropoietin used in the culture system employed in 
this study may have ‘smoothed out’ the effects of an aberrant V617F Jak/STAT 
imprint. However, this ‘smoothing’ effect may also have given a selection advantage 
for differential expression of genes which are independent of Jak/STAT and this 
dataset may therefore give new insight into the pathophysiology of PV beyond V617F 
JAK2 expression.
The microarray data was validated by performing real-time quantitative PCR 
amplification of 4 genes which were upregulated in the PV microarrays using 
predominantly the same template erythroblast RNA as had been used in the 
microarray experiments. Four genes were selected to include 2 genes believed to be 
Jak/STAT targets (PIM l & IFITM l) and 2 genes which were not (CBFA2T3 &
LEPR) so that further work could be done to assess the JAK2 dependency of these 
genes by use of JAK2 inhibitors. As had been the case in the microarray analysis, 
whilst there was individual sample variation, overexpression of these 4 genes in PV 
erythroblasts was confirmed. Markedly increased expression of LEPR in the PV 
patients homozygous for V617F JAK2 was also observed. Having identified 
dysregulation of key genes in PV erythroid progenitors the JAK2 dependency of these 
4 genes was then explored with use of specific JAK2 inhibitors.
Oncogene PIM l is located at 6p21.1 and encodes for a serine/threonine protein kinase. 
Dysregulation or mutation of PIM 1 has been described in several human cancers 
including leukaemias, lymphomas and solid tumours. PIM l is well recognized as a 
STAT target. [Matikainen et al, 1999] Overexpression of PIM 1 has a]so been shown 
to independently contribute to tumour development by induction of genomic
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instability [Roh et al, 2003] and to induce cytokine independence in haematopoietic 
cell lines. [Nosaka et al, 2002]
In 1993 it was reported that PIM l deficient mice exhibited erythrocyte microcytosis 
and that overexpression of PIM l in mice induced erythrocyte macrocytosis on the 
background of an otherwise normal phenotype. [Laird et al, 1993] The precise 
mechanism for the role of Pim -1 in erythropoiesis is unknown, however the recent 
finding of a functional association between Pim-1 and ribosomal protein S19 
(implicated in the ineffective erythroid progenitor maturation observed in Diamond- 
Blackfan anaemia) may pave the way for an improved understanding of this process. 
[Orru et al, 2006].
The microarray data and RQ-PCR findings presented in this chapter showed aberrant 
overexpression of PIM l in PV erythroid progenitors. Using specific inhibitors of 
JAK2, analysis showed that PIM l was Jak/STAT dependent in tumour cells 
expressing wild type or V617F JAK2. It was then found that PIM l was erythropoietin 
inducible in a JAK2 dependent fashion in primary erythroblasts from normal 
individuals expressing wild type JAK2 and from patients with PV expressing V617F 
JAK2. It therefore seems likely that upregulated PIM l in PV erythroblasts represents 
a V617F JAK2 imprint. The subsequent lack of a PIM l PCR product from the PV 
neutrophil RNA was unsurprising since PIM 1 is expressed at low levels in circulating 
adult neutrophils.
Interferon induced transmembrane protein 1 (IFITM l) is located on chromosome 11 
& is an interferon-inducible gene whose expression is known to correlate with the 
sensitivity of cell lines to growth suppression by interferon. Interferon response genes 
were identified as Jak/STAT targets in 1994. [Darnell et al, 1994] The role of IFITMl 
in haemopoiesis was unclear but latterly its’ relevance to the migration and 
differentiation of primordial germ cells has been elucidated. [Tanaka et al, 2005] 
IFITMl upregulation has been noted in the CD34+ cells of Myelodysplastic 
Syndrome (MDS) [Pellagatti et al, 2006] and also in the buffy coat of low risk 
patients with CML [Aykerli et al, 2005]. Increased IFITMl expression in MDS & 
CML cannot, however, be regarded as an aberrant V617F imprint since this mutation
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is an infrequent finding in these diseases. [Steensma et al, 2005; Kronenwett et al, 
2006]
IFITMl was significantly upregulated in PV erythroblasts by microarray analysis and 
RQ-PCR. Use of specific inhibitors of JAK2 showed that IFITMl was not directly 
JAK2 dependent in HEL cells expressing V617F JAK2 or in TFl cells induced by 
erythropoietin. This effect was also noted in primary and PV erythroblasts which had 
been stimulated with erythropoietin.
Further work confirmed that IFITM l was interferon-inducible in a Jak dependent 
fashion in tumour cells and normal erythroblasts as expected. It was subsequently 
observed that both starved and interferon-stimulated expression of IFITMl in 
erythroblasts was reduced in the presence of erythropoietin. The conclusion is 
therefore that whilst IFITM l is an interferon-inducible gene in erythroid progenitors, 
increased expression of IFITM l in PV is not the direct result of a V617F JAK2 
imprint.
IFITMl associates with various molecules including CD 19, CD21 & CD81 in 
primary B-lymphocytes and ligation with an antibody imparts an inhibitory signal 
[Bradbuy et al, 1992]. Therefore, it is perhaps surprising that IFITM l should be 
overexpressed in a variety of tumours, including haematological malignancies and 
colorectal carcinoma. However, the data in germ cells show that IFITMl has 
interferon-independent functions and its precise role may vary according to cell 
context.
Core binding factor, alpha subunit 2, translocated to, 3 (CBFA2T3) is located at 
16q24. CBFA2T3 was identified through its association with the t( 16,21) 
translocation found in some patients with acute myeloid leukaemia. [Gamou et al, 
1998] Loss of heterozygosity of 16q is a frequent finding in breast cancer and 
variation of expression of CBFA2T3 in these cells has led to the suggestion that 
CBFA2T3 is a tumour suppressor gene. [Powell et al, 2002] There is no evidence to 
suggest that CBFA2T3 is Jak/STAT dependent.
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Overexpression of CBFA2T3 in primary PV erythroblasts was shown in this chapter 
by microarray analysis and confirmed by RQ-PCR. After some investigative work in 
tumour cells and primary erythroblasts, further study showed that CBFA2T3 was not 
Jak/STAT dependent in PV erythroblasts and that therefore its increased expression in 
PV was unlikely to represent a V617F JAK2 imprint.
Leptin was originally described as a hormone that regulated adipose-tissue mass 
through hypothalamic effects on satiety and energy expenditure. Leptin acts through 
the leptin receptor (LEPR, encoded at lp31), a member of the cytokine receptor 
family. LEPR was initially found to be expressed on haematopoietic progenitor cells 
[Gainsford et al, 1996]. LEPR expression was later detected on blast cells from 
patients with AML, ALL and CML and it was shown that leptin could enhance blast 
proliferation. [Nakao et al, 1998; Konoplova et al, 1999] Most recently, increased 
LEPR expression has been described in association with chronic phase CML. [Diaz- 
Blanco et al, 2007]. Whilst LEPR had not been described as a Jak/STAT target it is 
known that leptin signals via Jak/STAT activation. [Darnell et al, 1994]
Increased expression of LEPR in PV erythroblasts with marked increase in the 2 
individuals with homozygous expression of V617F JAK2 was observed in this study. 
Experiments using JAK2 inhibitors in cell lines were inconclusive but suggested 
JAK2 dependency of LEPR. Work in normal and PV erythroblasts confirmed that 
LEPR expression was erythropoietin inducible in a JAK2 dependent manner in these 
cells. It therefore seems likely that the increased LEPR expression in PV erythroblasts 
is an effect of aberrant V617F JAK2 signalling with some suggestion of a dosage 
effect for mutant JAK2. As had been shown by others, work in this study showed a 
slight enhancement of erythroid proliferation with recombinant human leptin and it is 
possible that overexpression of LEPR may be one of the mechanisms by which 
V617F JAK2 increases erythroid proliferation.
A novel gene which showed consistent dysregulation in PV might offer an additional 
diagnostic tool. It would clearly not be practical to derive erythroblasts from patients 
for diagnostic purposes so this study also looked at whether the altered expression 
noted in erythoblasts might be reflected in neutrophils. Neutrophils are plentiful in
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peripheral blood and so there was ample neutrophil RNA which allowed exploration 
of 2 genes which were downregulated in PV; Nucleophosmin (NPl) and Protein 
phosphatase 2 regulatory subunit alpha (PPP2R2A) as well as PIM l and IFITMl. 
Nucleophosmin and PP2R2A were selected as N Pl has already been implicated in 
the pathophysiology of myeloid disease [Naoe et al, 2006; Grisendi et al, 2006] and 
phosphatase activity is known to be altered in myeloproliferative disease [Xu et al, 
2003]. Preliminary data suggested that findings in neutrophil derived RNA did not 
correlate with findings in erythroblast derived RNA, so this approach was not pursued.
In summary, this chapter provides unique data on the basic gene expression profile of 
erythroblasts in Polycythaemia Vera compared with IE and normal subjects. Further 
analysis of gene expression in the presence of specific inhibitors of JAK2 suggests 
that this profile is not simply due to a V617F JAK2 imprint since, whilst PIMl & 
LEPR over-expression were identified as JAK2 dependent, IFITM l & CBFA2T3 
were found to be JAK2 independent.
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CHAPTER 7 -  CONCLUSIONS
Polycythaemia Vera is a primary proliferative disorder with leukaemia potential 
resulting from clonal change in haematopoietic stem cells. In 2005 seminal work was 
published establishing a link between PV and a specific point mutation in the JAK2 
gene. This mutation is not the only clonal change seen in PV although it is the most 
common. The pathophysiological mechanisms underlying these clonal changes are 
not well understood. This thesis contributes to understanding of PV by exploring the 
functional and molecular changes observed in primary erythroid progenitors which 
result in the increased red cell population which defines PV. It goes on to explore the 
potential role for small molecule inhibitors as disease modifying agents.
A cohort of patients with true polycythaemia including 27 with PV were characterised 
clinically and pathologically by EEC formation, V617F JAK2 expression and other 
parameters. Mononuclear cells were derived from the peripheral blood of patients 
with PV, Idiopathic Erythrocytosis and normal controls. In standard semi-solid 
cultures there was no increase in erythroid colonies between PV and IE, although both 
were increased relative to normals. When these mononuclear cells were established in 
liquid culture which preferentially selected for erythroid differentiation and growth, 
qualitatively similar progenitors were derived as defined by morphological and 
immunophenotypic criteria. However, the quantity of progenitors derived in PV liquid 
cultures was higher than that seen in control subjects.
When erythroid progenitors were deprived of erythropoietin overnight, PV cells 
showed relatively sustained viability compared to controls. This feature showed an 
allele dose response effect in that PV progenitors homozygous for V617F were more 
sustainable with erythropoietin deprivation than their heterozygous counterparts. This 
effect was subtle and only became apparent after a large cohort of patients had been 
studied.
Study of intracellular signal transduction in erythroid progenitors by western blotting 
showed that there was subtle upregulation of the PI3K, MAPK & Jak/STAT pathways 
in PV. This effect was apparent with both cytokine deprivation and cytokine
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stimulation and, in the case of the PI3K pathway, was sustained over long 
experimental periods. Increased signal for the Jak/STAT target, PIM-1, was also 
apparent in PV. Introduction of small molecule inhibitors of PI3K or JAK2 effectively 
downregulated this increased signalling activity.
When the JAK2 inhibitors, Go6976 & Jak Inhibitor 1, were introduced into colony 
assays it became apparent that erythropoietin independent colonies could be abolished 
by JAK2 inhibition. The effects of JAK2 inhibitors were not specific to V617F JAK2 
mutant cells as erythroid colony formation was reduced in PV and control cells. In 
fact there was a trend to reduced susceptibility to inhibitors in the PV subjects 
homozygous for V617F JAK2. Additionally, using Go6976 & Jak Inhibitor 1 there 
was reduction in myeloid colony formation in PV and controls. In order to accurately 
quantify these effects, erythroblast viability in the presence of inhibitor was assessed. 
Viable cell number was found to be increased in PV samples. This, once again, 
suggests that mutant progenitors may be less susceptible to JAK2 inhibition than their 
wild type counterparts and that this reduced susceptibility may be more significant for 
mutant progenitors exhibiting homozygous expression of V617F.
The PI3K inhibitor, LY294002 (also a PIM-1 inhibitor), reduced erythroblast survival 
in erythroid progenitors with greater effect in PV than controls but this difference was 
not apparent with the PI3K inhibitor, PI 103. Erythroid progenitor viability with PI 103 
was affected in a dose dependent manner similar to that seen with JAK2 inhibition for 
both PV and controls. PI 103 was also found to reduce erythroid colony formation and 
EECs in PV. When specific a, p and 8 isoform inhibitors of PI3K were introduced 
into similar systems it became apparent that pan-PI3K inhibition was necessary to 
produce effects on signalling and survival in erythroid progenitors. Inhibition studies 
using Rapamycin identified the mTOR pathway as an alternative therapeutic target.
Whilst there is some literature on the gene expression profile of neutrophils and 
CD34+ cells from patients with PV there has been no published data on erythroid 
progenitor gene expression in this disease. The gene expression profile of erythroid 
progenitors derived from patients with PV, IE and normal controls is compared and 
contrasted in this thesis. This approach gives insight into the changes in gene
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expression which simply result from erythroid expansion and those which provide 
clues to an underlying myeloproliferative disorder.
Erythroid progenitor gene expression was analysed using U 133a Affymetrix 
GeneChips and by real-time quantitative PCR. There was segregation of the PV 
expression signature with clustering between subject groups and separation between 
the subjects heterozygous and homozygous for V617F JAK2. The differences 
between the groups could not be accounted for by altered differentiation as PV cells 
showed similar modulation of differentiation genes to normal controls.
The microarray data was validated by RT-PCR amplification of 4 genes which had 
been found to be upregulated in PV; PIM l, IFITM l, CBFA2T3 & LFPR. These 
genes were further analysed in erythroid progenitors in the presence of the JAK2 
inhibitors described previously. PIM 1 was found to be erythropoietin inducible in a 
JAK2 dependent manner in both PV and controls. IFITM l, whilst clearly an 
interferon-inducible gene in erythroid progenitors was not JAK2 dependent on 
erythropoietin stimulation. CBFA2T3 was not JAK2 dependent but LFPR was. It was 
therefore apparent that upregulation of PIM l & LFPR could be explained by a V617F 
JAK2 imprint but that upregulation of IFITM l & CBFA2T3 could not.
In summary the work presented in this thesis has delineated subtle differences in the 
functional and molecular processes in primary erythroid progenitors derived from 
patients with Polycythaemia Vera. The therapeutic potential of PI3K or JAK2 
inhibitors in PV is shown in primary cells as distinct from the models described in 
other published work. A gene expression profile is identified in PV progenitors which 
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